ID   TP53B_HUMAN             Reviewed;        1972 AA.
AC   Q12888; F8VY86; Q2M1Z7; Q4LE46; Q5FWZ3; Q7Z3U4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   24-JAN-2024, entry version 235.
DE   RecName: Full=TP53-binding protein 1 {ECO:0000305};
DE            Short=53BP1 {ECO:0000303|PubMed:9748285};
DE            Short=p53-binding protein 1 {ECO:0000303|PubMed:9748285};
DE            Short=p53BP1;
GN   Name=TP53BP1 {ECO:0000312|HGNC:HGNC:11999};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RC   TISSUE=Skeletal muscle;
RX   PubMed=9748285; DOI=10.1074/jbc.273.40.26061;
RA   Iwabuchi K., Li B., Massa H.F., Trask B.J., Date T., Fields S.;
RT   "Stimulation of p53-mediated transcriptional activation by the p53-binding
RT   proteins, 53BP1 and 53BP2.";
RL   J. Biol. Chem. 273:26061-26068(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Myeloid leukemia cell;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R.,
RA   Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long cDNAs
RT   encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS GLU-353;
RP   SER-412 AND GLN-1136.
RC   TISSUE=Cervix;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-353; SER-412; VAL-648;
RP   ARG-699; GLY-1014; ALA-1026; GLN-1136; GLY-1170 AND VAL-1174.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 946-1972.
RX   PubMed=8016121; DOI=10.1073/pnas.91.13.6098;
RA   Iwabuchi K., Bartel P.L., Li B., Marraccino R., Fields S.;
RT   "Two cellular proteins that bind to wild-type but not mutant p53.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6098-6102(1994).
RN   [8]
RP   PHOSPHORYLATION.
RX   PubMed=11042216; DOI=10.1074/jbc.m007665200;
RA   Xia Z., Morales J.C., Dunphy W.G., Carpenter P.B.;
RT   "Negative cell cycle regulation and DNA-damage inducible phosphorylation of
RT   the BRCT protein 53BP1.";
RL   J. Biol. Chem. 276:2708-2718(2001).
RN   [9]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=11331310; DOI=10.1083/jcb.153.3.613;
RA   Rappold I., Iwabuchi K., Date T., Chen J.;
RT   "Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-
RT   signaling pathways.";
RL   J. Cell Biol. 153:613-620(2001).
RN   [10]
RP   FUNCTION IN DNA DAMAGE CHECKPOINT, AND INTERACTION WITH CHEK2.
RX   PubMed=12364621; DOI=10.1126/science.1076182;
RA   Wang B., Matsuoka S., Carpenter P.B., Elledge S.J.;
RT   "53BP1, a mediator of the DNA damage checkpoint.";
RL   Science 298:1435-1438(2002).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12824158; DOI=10.1074/jbc.m304066200;
RA   Iwabuchi K., Basu B.P., Kysela B., Kurihara T., Shibata M., Guan D.,
RA   Cao Y., Hamada T., Imamura K., Jeggo P.A., Date T., Doherty A.J.;
RT   "Potential role for 53BP1 in DNA end-joining repair through direct
RT   interaction with DNA.";
RL   J. Biol. Chem. 278:36487-36495(2003).
RN   [12]
RP   INTERACTION WITH H2AX.
RX   PubMed=12607005; DOI=10.1038/nature01446;
RA   Stewart G.S., Wang B., Bignell C.R., Taylor A.M.R., Elledge S.J.;
RT   "MDC1 is a mediator of the mammalian DNA damage checkpoint.";
RL   Nature 421:961-966(2003).
RN   [13]
RP   CHROMOSOMAL TRANSLOCATION WITH PDGFRB.
RX   PubMed=15492236; DOI=10.1158/0008-5472.can-04-2005;
RA   Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G., Thaler J.,
RA   Chase A.J., Cross N.C.;
RT   "p53-Binding protein 1 is fused to the platelet-derived growth factor
RT   receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-
RT   responsive eosinophilic myeloproliferative disorder.";
RL   Cancer Res. 64:7216-7219(2004).
RN   [14]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15574327; DOI=10.1016/j.molcel.2004.10.029;
RA   Riballo E., Kuehne M., Rief N., Doherty A., Smith G.C.M., Recio M.-J.,
RA   Reis C., Dahm K., Fricke A., Krempler A., Parker A.R., Jackson S.P.,
RA   Gennery A., Jeggo P.A., Loebrich M.;
RT   "A pathway of double-strand break rejoining dependent upon ATM, Artemis,
RT   and proteins locating to gamma-H2AX foci.";
RL   Mol. Cell 16:715-724(2004).
RN   [15]
RP   METHYLATION, MUTAGENESIS OF ARG-1396; ARG-1398; ARG-1400; ARG-1401 AND
RP   ARG-1403, SUBCELLULAR LOCATION, AND DNA-BINDING.
RX   PubMed=16294045; DOI=10.4161/cc.4.12.2250;
RA   Boisvert F.-M., Rhie A., Richard S., Doherty A.J.;
RT   "The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary
RT   for 53BP1 DNA binding activity.";
RL   Cell Cycle 4:1834-1841(2005).
RN   [16]
RP   METHYLATION, MUTAGENESIS OF ARG-1396; ARG-1398; ARG-1400; ARG-1401 AND
RP   ARG-1403, SUBUNIT, SUBCELLULAR LOCATION, AND DNA-BINDING.
RX   PubMed=16294047; DOI=10.4161/cc.4.12.2282;
RA   Adams M.M., Wang B., Xia Z., Morales J.C., Lu X., Donehower L.A.,
RA   Bochar D.A., Elledge S.J., Carpenter P.B.;
RT   "53BP1 oligomerization is independent of its methylation by PRMT1.";
RL   Cell Cycle 4:1854-1861(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222; SER-294; SER-500;
RP   SER-635; SER-639; SER-640; SER-1094; SER-1219; SER-1362 AND SER-1678, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-834 AND SER-1426, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [19]
RP   PHOSPHORYLATION AT SER-166; SER-176; SER-178; SER-294; THR-302; SER-380;
RP   SER-452; SER-523; SER-552; SER-831; SER-1028; SER-1086; SER-1114 AND
RP   SER-1219, AND MUTAGENESIS OF 176-SER--SER-178.
RX   PubMed=17553757; DOI=10.1016/j.dnarep.2007.04.011;
RA   Jowsey P., Morrice N.A., Hastie C.J., McLauchlan H., Toth R., Rouse J.;
RT   "Characterisation of the sites of DNA damage-induced 53BP1 phosphorylation
RT   catalysed by ATM and ATR.";
RL   DNA Repair 6:1536-1544(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-105; THR-302; SER-523;
RP   THR-543; THR-548; SER-552; SER-831; THR-855; THR-1214; SER-1216 AND
RP   SER-1219, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222; SER-265; SER-395;
RP   SER-398; SER-500; SER-523; SER-525; SER-552; SER-809; SER-831; SER-1028;
RP   SER-1094; SER-1216; SER-1219; SER-1368; THR-1372; SER-1426; SER-1430;
RP   SER-1462; THR-1609; SER-1701 AND SER-1759, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [24]
RP   PHOSPHORYLATION AT SER-25 AND SER-1778, DEPHOSPHORYLATION AT SER-25 AND
RP   SER-1778 BY PPP5C, AND SUBCELLULAR LOCATION.
RX   PubMed=19176521; DOI=10.1074/jbc.m809272200;
RA   Kang Y., Lee J.H., Hoan N.N., Sohn H.M., Chang I.Y., You H.J.;
RT   "Protein phosphatase 5 regulates the function of 53BP1 after
RT   neocarzinostatin-induced DNA damage.";
RL   J. Biol. Chem. 284:9845-9853(2009).
RN   [25]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS BZLF1 PROTEIN (MICROBIAL INFECTION).
RX   PubMed=19656881; DOI=10.1128/jvi.00512-09;
RA   Bailey S.G., Verrall E., Schelcher C., Rhie A., Doherty A.J.,
RA   Sinclair A.J.;
RT   "Functional interaction between Epstein-Barr virus replication protein Zta
RT   and host DNA damage response protein 53BP1.";
RL   J. Virol. 83:11116-11122(2009).
RN   [26]
RP   INTERACTION WITH MSL1.
RX   PubMed=19650074; DOI=10.1002/jcp.21889;
RA   Gironella M., Malicet C., Cano C., Sandi M.J., Hamidi T., Tauil R.M.,
RA   Baston M., Valaco P., Moreno S., Lopez F., Neira J.L., Dagorn J.C.,
RA   Iovanna J.L.;
RT   "p8/nupr1 regulates DNA-repair activity after double-strand gamma
RT   irradiation-induced DNA damage.";
RL   J. Cell. Physiol. 221:594-602(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294; SER-366; SER-380;
RP   SER-500; SER-523; SER-525; THR-543; SER-552; SER-834; SER-1028; SER-1114;
RP   SER-1426; SER-1430; SER-1460; SER-1462 AND SER-1474, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [28]
RP   INTERACTION WITH PWWP3A.
RX   PubMed=20347427; DOI=10.1016/j.molcel.2009.12.040;
RA   Huen M.S., Huang J., Leung J.W., Sy S.M., Leung K.M., Ching Y.P.,
RA   Tsao S.W., Chen J.;
RT   "Regulation of chromatin architecture by the PWWP domain-containing DNA
RT   damage-responsive factor EXPAND1/MUM1.";
RL   Mol. Cell 37:854-864(2010).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-294; SER-500;
RP   SER-525; SER-552; SER-566; SER-580; SER-639; SER-640; SER-809; THR-922;
RP   SER-970; SER-975; SER-1028; SER-1068; SER-1114; SER-1362; SER-1426;
RP   SER-1430; THR-1609; SER-1618 AND SER-1678, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   FUNCTION IN DNA DAMAGE RESPONSE, PHOSPHORYLATION AT SER-1778, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005;
RA   Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y.,
RA   You H.J.;
RT   "Protein phosphatase 5 is necessary for ATR-mediated DNA repair.";
RL   Biochem. Biophys. Res. Commun. 404:476-481(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222; SER-294; SER-500;
RP   SER-525; SER-552; SER-809; SER-1028; SER-1101; SER-1114; SER-1362;
RP   SER-1430; SER-1618 AND SER-1678, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   FUNCTION.
RX   PubMed=22553214; DOI=10.1242/jcs.105353;
RA   Chapman J.R., Sossick A.J., Boulton S.J., Jackson S.P.;
RT   "BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies
RT   temporal control of DNA repair.";
RL   J. Cell Sci. 125:3529-3534(2012).
RN   [34]
RP   FUNCTION, PHOSPHORYLATION, INTERACTION WITH RIF1 AND PAXIP1, AND
RP   MUTAGENESIS OF SER-6; SER-13; SER-25; SER-29; SER-105; SER-166; SER-176 AND
RP   SER-178.
RX   PubMed=23727112; DOI=10.1016/j.cell.2013.05.023;
RA   Callen E., Di Virgilio M., Kruhlak M.J., Nieto-Soler M., Wong N.,
RA   Chen H.T., Faryabi R.B., Polato F., Santos M., Starnes L.M., Wesemann D.R.,
RA   Lee J.E., Tubbs A., Sleckman B.P., Daniel J.A., Ge K., Alt F.W.,
RA   Fernandez-Capetillo O., Nussenzweig M.C., Nussenzweig A.;
RT   "53BP1 mediates productive and mutagenic DNA repair through distinct
RT   phosphoprotein interactions.";
RL   Cell 153:1266-1280(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-63; SER-124; SER-222;
RP   SER-265; SER-294; SER-366; SER-380; SER-398; SER-500; SER-507; SER-518;
RP   SER-523; SER-525; SER-552; SER-580; SER-771; SER-809; SER-834; THR-922;
RP   SER-1028; THR-1056; SER-1068; SER-1094; SER-1114; SER-1148; SER-1216;
RP   SER-1219; SER-1317; SER-1342; SER-1362; SER-1426; SER-1430; SER-1462;
RP   THR-1609; SER-1618; SER-1635; THR-1638; THR-1648; SER-1656; SER-1673;
RP   SER-1678 AND SER-1701, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RIF1, PHOSPHORYLATION, AND
RP   MUTAGENESIS OF SER-6; SER-13; SER-25; SER-29; SER-105; SER-166; SER-176;
RP   SER-178; THR-302; SER-437; SER-452; SER-523; THR-543; SER-580; SER-625;
RP   SER-674; THR-696; SER-698; SER-784; SER-831; THR-855; SER-892; SER-1068;
RP   SER-1086; SER-1104; SER-1148; THR-1171 AND SER-1219.
RX   PubMed=23333306; DOI=10.1016/j.molcel.2013.01.001;
RA   Escribano-Diaz C., Orthwein A., Fradet-Turcotte A., Xing M., Young J.T.,
RA   Tkac J., Cook M.A., Rosebrock A.P., Munro M., Canny M.D., Xu D.,
RA   Durocher D.;
RT   "A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and
RT   BRCA1-CtIP controls DNA repair pathway choice.";
RL   Mol. Cell 49:872-883(2013).
RN   [37]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, DOMAIN, AND MUTAGENESIS OF
RP   ASP-1521; LYS-1613; ASP-1616; ILE-1617; LEU-1619; ASN-1621; LEU-1622;
RP   GLU-1624 AND ARG-1627.
RX   PubMed=23760478; DOI=10.1038/nature12318;
RA   Fradet-Turcotte A., Canny M.D., Escribano-Diaz C., Orthwein A., Leung C.C.,
RA   Huang H., Landry M.C., Kitevski-LeBlanc J., Noordermeer S.M., Sicheri F.,
RA   Durocher D.;
RT   "53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark.";
RL   Nature 499:50-54(2013).
RN   [38]
RP   FUNCTION, SUBUNIT, AND MUTAGENESIS OF SER-6; SER-13; SER-25; SER-29;
RP   SER-105; SER-166; SER-176; SER-178; THR-302; SER-437; SER-452; SER-523;
RP   THR-543; SER-580; SER-625; SER-674; THR-696; SER-698; SER-784; SER-831;
RP   THR-855; SER-892; SER-1068; SER-1086; SER-1104; SER-1148; THR-1171;
RP   SER-1219; 1398-ARG--ARG-1401 AND ASP-1521.
RX   PubMed=23345425; DOI=10.1073/pnas.1222617110;
RA   Lottersberger F., Bothmer A., Robbiani D.F., Nussenzweig M.C., de Lange T.;
RT   "Role of 53BP1 oligomerization in regulating double-strand break repair.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:2146-2151(2013).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294; SER-500; SER-552;
RP   SER-630; SER-692; SER-727; SER-1114; SER-1216 AND SER-1362, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-1609 AND SER-1618, DOMAIN, AND
RP   MUTAGENESIS OF THR-1609 AND SER-1618.
RX   PubMed=24703952; DOI=10.1016/j.molcel.2014.03.020;
RA   Lee D.H., Acharya S.S., Kwon M., Drane P., Guan Y., Adelmant G., Kalev P.,
RA   Shah J., Pellman D., Marto J.A., Chowdhury D.;
RT   "Dephosphorylation enables the recruitment of 53BP1 to double-strand DNA
RT   breaks.";
RL   Mol. Cell 54:512-525(2014).
RN   [41]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-930 AND LYS-1563, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [42]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-217; LYS-868; LYS-1434 AND
RP   LYS-1563, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [43]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-930, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [44]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1563, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [45]
RP   FUNCTION.
RX   PubMed=27153538; DOI=10.1016/j.molcel.2016.03.031;
RA   Jacquet K., Fradet-Turcotte A., Avvakumov N., Lambert J.P., Roques C.,
RA   Pandita R.K., Paquet E., Herst P., Gingras A.C., Pandita T.K., Legube G.,
RA   Doyon Y., Durocher D., Cote J.;
RT   "The TIP60 complex regulates bivalent chromatin recognition by 53BP1
RT   through direct H4K20me binding and H2AK15 acetylation.";
RL   Mol. Cell 62:409-421(2016).
RN   [46]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-217; LYS-868; LYS-930; LYS-984;
RP   LYS-1365; LYS-1434 AND LYS-1563, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [47]
RP   FUNCTION, INTERACTION WITH NUDT16L1 AND RIF1, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION, AND MUTAGENESIS OF TRP-1495; ASP-1521; THR-1609 AND
RP   SER-1618.
RX   PubMed=28241136; DOI=10.1038/nature21358;
RA   Drane P., Brault M.E., Cui G., Meghani K., Chaubey S., Detappe A.,
RA   Parnandi N., He Y., Zheng X.F., Botuyan M.V., Kalousi A., Yewdell W.T.,
RA   Muench C., Harper J.W., Chaudhuri J., Soutoglou E., Mer G., Chowdhury D.;
RT   "TIRR regulates 53BP1 by masking its histone methyl-lysine binding
RT   function.";
RL   Nature 543:211-216(2017).
RN   [48]
RP   INTERACTION WITH SHLD2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=29789392; DOI=10.15252/embj.201899543;
RA   Tomida J., Takata K.I., Bhetawal S., Person M.D., Chao H.P., Tang D.G.,
RA   Wood R.D.;
RT   "FAM35A associates with REV7 and modulates DNA damage responses of normal
RT   and BRCA1-defective cells.";
RL   EMBO J. 37:0-0(2018).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1722-1971 IN COMPLEX WITH TP53.
RX   PubMed=12110597; DOI=10.1093/emboj/cdf383;
RA   Derbyshire D.J., Basu B.P., Serpell L.C., Joo W.S., Date T., Iwabuchi K.,
RA   Doherty A.J.;
RT   "Crystal structure of human 53BP1 BRCT domains bound to p53 tumour
RT   suppressor.";
RL   EMBO J. 21:3863-3872(2002).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1714-1972 IN COMPLEX WITH TP53.
RX   PubMed=11877378; DOI=10.1101/gad.959202;
RA   Joo W.S., Jeffrey P.D., Cantor S.B., Finnin M.S., Livingston D.M.,
RA   Pavletich N.P.;
RT   "Structure of the 53BP1 BRCT region bound to p53 and its comparison to the
RT   Brca1 BRCT structure.";
RL   Genes Dev. 16:583-593(2002).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1485-1602, INTERACTION WITH
RP   METHYLATED HISTONE H3 AND HISTONE H4, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF TRP-1495; TYR-1502 AND ASP-1521.
RX   PubMed=15525939; DOI=10.1038/nature03114;
RA   Huyen Y., Zgheib O., Ditullio R.A. Jr., Gorgoulis V.G., Zacharatos P.,
RA   Petty T.J., Sheston E.A., Mellert H.S., Stavridi E.S., Halazonetis T.D.;
RT   "Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand
RT   breaks.";
RL   Nature 432:406-411(2004).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1484-1603 IN COMPLEX WITH HISTONE
RP   H4, SUBUNIT, FUNCTION, MUTAGENESIS OF TRP-1495; TYR-1500; TYR-1502;
RP   ASP-1521 AND TYR-1523, AND SUBCELLULAR LOCATION.
RX   PubMed=17190600; DOI=10.1016/j.cell.2006.10.043;
RA   Botuyan M.V., Lee J., Ward I.M., Kim J.-E., Thompson J.R., Chen J., Mer G.;
RT   "Structural basis for the methylation state-specific recognition of histone
RT   H4-K20 by 53BP1 and Crb2 in DNA repair.";
RL   Cell 127:1361-1373(2006).
RN   [53] {ECO:0007744|PDB:6RML, ECO:0007744|PDB:6RMM}
RP   X-RAY CRYSTALLOGRAPHY (2.81 ANGSTROMS) OF 663-677 IN COMPLEX WITH TOPBP1,
RP   FUNCTION, INTERACTION WITH TOPBP1, PHOSPHORYLATION AT SER-366 AND THR-670,
RP   AND MUTAGENESIS OF SER-366 AND THR-670.
RX   PubMed=31135337; DOI=10.7554/elife.44353;
RA   Bigot N., Day M., Baldock R.A., Watts F.Z., Oliver A.W., Pearl L.H.;
RT   "Phosphorylation-mediated interactions with TOPBP1 couple 53BP1 and 9-1-1
RT   to control the G1 DNA damage checkpoint.";
RL   Elife 8:e44353-e44353(2019).
CC   -!- FUNCTION: Double-strand break (DSB) repair protein involved in response
CC       to DNA damage, telomere dynamics and class-switch recombination (CSR)
CC       during antibody genesis (PubMed:12364621, PubMed:22553214,
CC       PubMed:23333306, PubMed:17190600, PubMed:21144835, PubMed:27153538,
CC       PubMed:28241136, PubMed:31135337). Plays a key role in the repair of
CC       double-strand DNA breaks (DSBs) in response to DNA damage by promoting
CC       non-homologous end joining (NHEJ)-mediated repair of DSBs and
CC       specifically counteracting the function of the homologous recombination
CC       (HR) repair protein BRCA1 (PubMed:22553214, PubMed:23727112,
CC       PubMed:23333306, PubMed:27153538, PubMed:31135337). In response to
CC       DSBs, phosphorylation by ATM promotes interaction with RIF1 and
CC       dissociation from NUDT16L1/TIRR, leading to recruitment to DSBs sites
CC       (PubMed:28241136). Recruited to DSBs sites by recognizing and binding
CC       histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and histone H4
CC       dimethylated at 'Lys-20' (H4K20me2), two histone marks that are present
CC       at DSBs sites (PubMed:23760478, PubMed:27153538, PubMed:28241136,
CC       PubMed:17190600). Required for immunoglobulin class-switch
CC       recombination (CSR) during antibody genesis, a process that involves
CC       the generation of DNA DSBs (PubMed:23345425). Participates in the
CC       repair and the orientation of the broken DNA ends during CSR (By
CC       similarity). In contrast, it is not required for classic NHEJ and V(D)J
CC       recombination (By similarity). Promotes NHEJ of dysfunctional telomeres
CC       via interaction with PAXIP1 (PubMed:23727112).
CC       {ECO:0000250|UniProtKB:P70399, ECO:0000269|PubMed:12364621,
CC       ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:21144835,
CC       ECO:0000269|PubMed:22553214, ECO:0000269|PubMed:23333306,
CC       ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112,
CC       ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:27153538,
CC       ECO:0000269|PubMed:28241136, ECO:0000269|PubMed:31135337}.
CC   -!- SUBUNIT: Homoligomer (PubMed:16294047, PubMed:23760478,
CC       PubMed:23345425). Interacts with p53/TP53 (via the central domain)
CC       (PubMed:12110597, PubMed:11877378). Interacts with DCLRE1C
CC       (PubMed:15574327). Interacts with histone H2AX and this requires
CC       phosphorylation of H2AX on 'Ser-139' (PubMed:12607005). Interacts with
CC       histone H4 that has been dimethylated at 'Lys-20' (H4K20me2)
CC       (PubMed:17190600). Has low affinity for histone H4 containing
CC       monomethylated 'Lys-20' (H4K20me1) (PubMed:17190600). Does not bind
CC       histone H4 containing unmethylated or trimethylated 'Lys-20' (H4K20me3)
CC       (PubMed:17190600). Has low affinity for histone H3 that has been
CC       dimethylated on 'Lys-79' (PubMed:15525939). Has very low affinity for
CC       histone H3 that has been monomethylated on 'Lys-79' (in vitro)
CC       (PubMed:15525939). Does not bind unmethylated histone H3
CC       (PubMed:15525939). Interacts with histone H2A monoubiquitinated at
CC       'Lys-15' (H2AK15Ub) (PubMed:23760478). Interacts with PWWP3A/EXPAND1
CC       (PubMed:20347427). Interacts with CHEK2; modulates CHEK2
CC       phosphorylation at 'Thr-68' in response to infrared (PubMed:12364621).
CC       Interacts with MSL1; this interaction may be required for MSL1 DNA
CC       repair activity, but not for histone acetyltransferase activity
CC       (PubMed:19650074). Interacts (when phosphorylated by ATM) with RIF1
CC       (PubMed:23727112, PubMed:23333306, PubMed:28241136). Interacts (via the
CC       Tudor-like domain) with NUDT16L1/TIRR; interaction masks the Tudor-like
CC       domain and prevents recruitment to chromatin (PubMed:28241136).
CC       Interacts with PAXIP1 (PubMed:23727112). Interacts with SHLD2
CC       (PubMed:29789392). Interacts (when phosphorylated) with TOPBP1
CC       (PubMed:31135337). {ECO:0000269|PubMed:11877378,
CC       ECO:0000269|PubMed:12110597, ECO:0000269|PubMed:12364621,
CC       ECO:0000269|PubMed:12607005, ECO:0000269|PubMed:15525939,
CC       ECO:0000269|PubMed:15574327, ECO:0000269|PubMed:16294047,
CC       ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:19650074,
CC       ECO:0000269|PubMed:20347427, ECO:0000269|PubMed:23333306,
CC       ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112,
CC       ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:29789392,
CC       ECO:0000269|PubMed:31135337}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via C-terminus) with Epstein-
CC       Barr virus lytic switch protein BZLF1 (via C-terminus); this
CC       interaction is involved in the activation of the viral lytic cycle.
CC       {ECO:0000269|PubMed:19656881}.
CC   -!- INTERACTION:
CC       Q12888; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-396540, EBI-11954519;
CC       Q12888; Q13315: ATM; NbExp=2; IntAct=EBI-396540, EBI-495465;
CC       Q12888; P13637: ATP1A3; NbExp=3; IntAct=EBI-396540, EBI-948169;
CC       Q12888; P46379-2: BAG6; NbExp=3; IntAct=EBI-396540, EBI-10988864;
CC       Q12888; P41182: BCL6; NbExp=3; IntAct=EBI-396540, EBI-765407;
CC       Q12888; P38398: BRCA1; NbExp=5; IntAct=EBI-396540, EBI-349905;
CC       Q12888; Q5SWW7: C10orf55; NbExp=3; IntAct=EBI-396540, EBI-12809220;
CC       Q12888; P55212: CASP6; NbExp=3; IntAct=EBI-396540, EBI-718729;
CC       Q12888; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-396540, EBI-744556;
CC       Q12888; Q02930-3: CREB5; NbExp=3; IntAct=EBI-396540, EBI-10192698;
CC       Q12888; G5E9A7: DMWD; NbExp=3; IntAct=EBI-396540, EBI-10976677;
CC       Q12888; O75190-2: DNAJB6; NbExp=3; IntAct=EBI-396540, EBI-12593112;
CC       Q12888; O14645: DNALI1; NbExp=3; IntAct=EBI-396540, EBI-395638;
CC       Q12888; P50570-2: DNM2; NbExp=3; IntAct=EBI-396540, EBI-10968534;
CC       Q12888; P16104: H2AX; NbExp=6; IntAct=EBI-396540, EBI-494830;
CC       Q12888; P62807: H2BC8; NbExp=6; IntAct=EBI-396540, EBI-354552;
CC       Q12888; P68431: H3C12; NbExp=5; IntAct=EBI-396540, EBI-79722;
CC       Q12888; P62805: H4C9; NbExp=14; IntAct=EBI-396540, EBI-302023;
CC       Q12888; O14964: HGS; NbExp=3; IntAct=EBI-396540, EBI-740220;
CC       Q12888; P10809: HSPD1; NbExp=3; IntAct=EBI-396540, EBI-352528;
CC       Q12888; O14901: KLF11; NbExp=3; IntAct=EBI-396540, EBI-948266;
CC       Q12888; Q96G42: KLHDC7B; NbExp=3; IntAct=EBI-396540, EBI-9478422;
CC       Q12888; P13473-2: LAMP2; NbExp=3; IntAct=EBI-396540, EBI-21591415;
CC       Q12888; P50222: MEOX2; NbExp=3; IntAct=EBI-396540, EBI-748397;
CC       Q12888; Q14686: NCOA6; NbExp=3; IntAct=EBI-396540, EBI-78670;
CC       Q12888; Q8TDS5: OXER1; NbExp=3; IntAct=EBI-396540, EBI-12813389;
CC       Q12888; Q6ZW49: PAXIP1; NbExp=4; IntAct=EBI-396540, EBI-743225;
CC       Q12888; P16284: PECAM1; NbExp=3; IntAct=EBI-396540, EBI-716404;
CC       Q12888; P78337: PITX1; NbExp=3; IntAct=EBI-396540, EBI-748265;
CC       Q12888; Q13393: PLD1; NbExp=3; IntAct=EBI-396540, EBI-2827556;
CC       Q12888; P53350: PLK1; NbExp=6; IntAct=EBI-396540, EBI-476768;
CC       Q12888; D3DTS7: PMP22; NbExp=3; IntAct=EBI-396540, EBI-25882629;
CC       Q12888; P78424: POU6F2; NbExp=3; IntAct=EBI-396540, EBI-12029004;
CC       Q12888; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-396540, EBI-5280197;
CC       Q12888; P62826: RAN; NbExp=3; IntAct=EBI-396540, EBI-286642;
CC       Q12888; Q86V20-2: SHLD2; NbExp=3; IntAct=EBI-396540, EBI-20592761;
CC       Q12888; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-396540, EBI-5235340;
CC       Q12888; O43711: TLX3; NbExp=3; IntAct=EBI-396540, EBI-3939165;
CC       Q12888; P04637: TP53; NbExp=8; IntAct=EBI-396540, EBI-366083;
CC       Q12888; Q5T6F2: UBAP2; NbExp=3; IntAct=EBI-396540, EBI-2514383;
CC       Q12888; P61086: UBE2K; NbExp=3; IntAct=EBI-396540, EBI-473850;
CC       Q12888; Q08AM6: VAC14; NbExp=6; IntAct=EBI-396540, EBI-2107455;
CC       Q12888; P23763-3: VAMP1; NbExp=3; IntAct=EBI-396540, EBI-12097582;
CC       Q12888; P08670: VIM; NbExp=3; IntAct=EBI-396540, EBI-353844;
CC       Q12888; Q99986: VRK1; NbExp=8; IntAct=EBI-396540, EBI-1769146;
CC       Q12888; P04275-2: VWF; NbExp=3; IntAct=EBI-396540, EBI-25896548;
CC       Q12888; O43257: ZNHIT1; NbExp=2; IntAct=EBI-396540, EBI-347522;
CC       Q12888; Q6NZQ4: Paxip1; Xeno; NbExp=5; IntAct=EBI-396540, EBI-1395317;
CC       Q12888-1; P62805: H4C9; NbExp=3; IntAct=EBI-8022649, EBI-302023;
CC       Q12888-1; Q14686: NCOA6; NbExp=3; IntAct=EBI-8022649, EBI-78670;
CC       Q12888-1; P63165: SUMO1; NbExp=2; IntAct=EBI-8022649, EBI-80140;
CC       Q12888-1; P04637: TP53; NbExp=17; IntAct=EBI-8022649, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11331310,
CC       ECO:0000269|PubMed:15525939, ECO:0000269|PubMed:16294045,
CC       ECO:0000269|PubMed:16294047, ECO:0000269|PubMed:17190600,
CC       ECO:0000269|PubMed:19176521, ECO:0000269|PubMed:21144835,
CC       ECO:0000269|PubMed:28241136, ECO:0000269|PubMed:9748285}. Chromosome
CC       {ECO:0000269|PubMed:12824158, ECO:0000269|PubMed:15525939,
CC       ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:23333306,
CC       ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:24703952,
CC       ECO:0000269|PubMed:28241136, ECO:0000269|PubMed:31135337}. Chromosome,
CC       centromere, kinetochore {ECO:0000250|UniProtKB:P70399}. Note=Localizes
CC       to the nucleus in absence of DNA damage (PubMed:28241136). Following
CC       DNA damage, recruited to sites of DNA damage, such as double stand
CC       breaks (DSBs): recognizes and binds histone H2A monoubiquitinated at
CC       'Lys-15' (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2),
CC       two histone marks that are present at DSBs sites (PubMed:23333306,
CC       PubMed:23760478, PubMed:24703952, PubMed:28241136, PubMed:17190600,
CC       PubMed:31135337). Associated with kinetochores during mitosis (By
CC       similarity). {ECO:0000250|UniProtKB:P70399,
CC       ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:23333306,
CC       ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:28241136}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q12888-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q12888-2; Sequence=VSP_018390;
CC       Name=3;
CC         IsoId=Q12888-3; Sequence=VSP_018390, VSP_055062;
CC   -!- DOMAIN: The Tudor-like region mediates binding to histone H4
CC       dimethylated at 'Lys-20' (H4K20me2) (PubMed:17190600). Interaction with
CC       NUDT16L1/TIRR masks the Tudor-like domain and prevents recruitment to
CC       chromatin (PubMed:28241136). {ECO:0000269|PubMed:17190600,
CC       ECO:0000269|PubMed:28241136}.
CC   -!- DOMAIN: The UDR (ubiquitin-dependent recruitment) motif specifically
CC       recognizes and binds histone H2A monoubiquitinated at 'Lys-15'
CC       (H2AK15ub) (PubMed:23760478, PubMed:24703952). Phosphorylation of the
CC       UDR blocks interaction with H2AK15ub (PubMed:24703952).
CC       {ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:24703952}.
CC   -!- PTM: Asymmetrically dimethylated on Arg residues by PRMT1. Methylation
CC       is required for DNA binding. {ECO:0000269|PubMed:16294045,
CC       ECO:0000269|PubMed:16294047}.
CC   -!- PTM: Phosphorylated at basal level in the absence of DNA damage
CC       (PubMed:11042216, PubMed:11331310). Phosphorylated by ATM in response
CC       to DNA damage: phosphorylation at different sites promotes interaction
CC       with different set of proteins: phosphorylation at the N-terminus by
CC       ATM (residues from 6-178) promotes interaction with PAXIP1 and non-
CC       homologous end joining (NHEJ) of dysfunctional telomeres
CC       (PubMed:23727112). Phosphorylation by ATM at residues that are located
CC       more C-terminus (residues 300-650) leads to promote interaction with
CC       RIF1 (PubMed:23727112, PubMed:23333306, PubMed:28241136). Interaction
CC       with RIF1 leads to disrupt interaction with NUDT16L1/TIRR
CC       (PubMed:28241136). Phosphorylation at Thr-1609 and Ser-1618 in the UDR
CC       motif blocks interaction with H2AK15ub (PubMed:24703952).
CC       Dephosphorylated by PPP4C (PubMed:24703952). Hyperphosphorylation
CC       during mitosis correlates with its exclusion from chromatin and DNA
CC       lesions. Hyperphosphorylated in an ATR-dependent manner in response to
CC       DNA damage induced by UV irradiation (PubMed:17553757,
CC       PubMed:21144835). Dephosphorylated by PPP5C (PubMed:19176521).
CC       Phosphorylation at Ser-366 and Thr-670 promotes interaction with TOPBP1
CC       (PubMed:31135337). {ECO:0000269|PubMed:11042216,
CC       ECO:0000269|PubMed:11331310, ECO:0000269|PubMed:17553757,
CC       ECO:0000269|PubMed:19176521, ECO:0000269|PubMed:21144835,
CC       ECO:0000269|PubMed:23333306, ECO:0000269|PubMed:23727112,
CC       ECO:0000269|PubMed:24703952, ECO:0000269|PubMed:28241136,
CC       ECO:0000269|PubMed:31135337}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TP53BP1 is found in a
CC       form of myeloproliferative disorder chronic with eosinophilia.
CC       Translocation t(5;15)(q33;q22) with PDGFRB creating a TP53BP1-PDGFRB
CC       fusion protein. {ECO:0000269|PubMed:15492236}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06107.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tp53bp1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF078776; AAC62018.1; -; mRNA.
DR   EMBL; AB210025; BAE06107.1; ALT_INIT; mRNA.
DR   EMBL; BX537418; CAD97660.1; -; mRNA.
DR   EMBL; AY904026; AAW69392.1; -; Genomic_DNA.
DR   EMBL; AC018924; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC112161; AAI12162.1; -; mRNA.
DR   EMBL; U09477; AAA21596.1; -; mRNA.
DR   CCDS; CCDS10096.1; -. [Q12888-1]
DR   CCDS; CCDS45250.1; -. [Q12888-2]
DR   CCDS; CCDS45251.1; -. [Q12888-3]
DR   PIR; I38604; I38604.
DR   RefSeq; NP_001135451.1; NM_001141979.1. [Q12888-3]
DR   RefSeq; NP_001135452.1; NM_001141980.1. [Q12888-2]
DR   RefSeq; NP_005648.1; NM_005657.2. [Q12888-1]
DR   PDB; 1GZH; X-ray; 2.60 A; B/D=1724-1972.
DR   PDB; 1KZY; X-ray; 2.50 A; C/D=1714-1972.
DR   PDB; 1XNI; X-ray; 2.80 A; A/B/C/D/E/F/G/H/I/J=1485-1602.
DR   PDB; 2G3R; X-ray; 1.25 A; A=1484-1603.
DR   PDB; 2IG0; X-ray; 1.70 A; A=1484-1603.
DR   PDB; 2LVM; NMR; -; A=1484-1603.
DR   PDB; 2MWO; NMR; -; A=1484-1603.
DR   PDB; 2MWP; NMR; -; A=1484-1603.
DR   PDB; 3LGF; X-ray; 1.50 A; A=1484-1603.
DR   PDB; 3LGL; X-ray; 1.60 A; A=1484-1603.
DR   PDB; 3LH0; X-ray; 1.90 A; A=1484-1603.
DR   PDB; 4CRI; X-ray; 2.35 A; A/B=1459-1634.
DR   PDB; 4RG2; X-ray; 1.50 A; A/B=1483-1606.
DR   PDB; 4X34; X-ray; 1.80 A; A/B=1484-1603.
DR   PDB; 5ECG; X-ray; 3.00 A; C/D=1713-1972.
DR   PDB; 5J26; X-ray; 2.50 A; A=1487-1603.
DR   PDB; 5KGF; EM; 4.54 A; K/L=1611-1631.
DR   PDB; 5Z78; X-ray; 1.76 A; C=1484-1603.
DR   PDB; 5ZCJ; X-ray; 2.00 A; C=1459-1634.
DR   PDB; 6CO1; X-ray; 2.18 A; E/F=1484-1603.
DR   PDB; 6CO2; X-ray; 2.49 A; C/D=1484-1603.
DR   PDB; 6IU7; X-ray; 1.90 A; B=1665-1686.
DR   PDB; 6IUA; X-ray; 1.70 A; B=1665-1686.
DR   PDB; 6MXX; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J=1484-1603.
DR   PDB; 6MXY; X-ray; 1.62 A; A/B=1484-1603.
DR   PDB; 6MXZ; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I/J=1484-1603.
DR   PDB; 6MY0; X-ray; 2.20 A; A/B=1484-1603.
DR   PDB; 6RML; X-ray; 2.81 A; C=663-677.
DR   PDB; 6RMM; X-ray; 3.53 A; P/R=359-373.
DR   PDB; 6UPT; X-ray; 1.96 A; A/B=1483-1606.
DR   PDB; 6VA5; X-ray; 1.28 A; A=1483-1606.
DR   PDB; 6VIP; X-ray; 1.36 A; A/B=1483-1606.
DR   PDB; 7LIN; X-ray; 1.44 A; B=1636-1650.
DR   PDB; 7LIO; X-ray; 3.01 A; C/D=1636-1650.
DR   PDB; 7YQK; EM; 3.38 A; K=1613-1630, N=1485-1602.
DR   PDB; 8EOM; X-ray; 1.70 A; A/B=1483-1606.
DR   PDB; 8F0W; X-ray; 1.52 A; A/B=1483-1606.
DR   PDB; 8HKW; X-ray; 1.90 A; C/D=1665-1686.
DR   PDB; 8SWJ; X-ray; 1.60 A; A/B/C/D=1483-1606.
DR   PDB; 8U4U; X-ray; 3.79 A; A/B/C/D/E/F/G/H/I/J=1484-1603.
DR   PDBsum; 1GZH; -.
DR   PDBsum; 1KZY; -.
DR   PDBsum; 1XNI; -.
DR   PDBsum; 2G3R; -.
DR   PDBsum; 2IG0; -.
DR   PDBsum; 2LVM; -.
DR   PDBsum; 2MWO; -.
DR   PDBsum; 2MWP; -.
DR   PDBsum; 3LGF; -.
DR   PDBsum; 3LGL; -.
DR   PDBsum; 3LH0; -.
DR   PDBsum; 4CRI; -.
DR   PDBsum; 4RG2; -.
DR   PDBsum; 4X34; -.
DR   PDBsum; 5ECG; -.
DR   PDBsum; 5J26; -.
DR   PDBsum; 5KGF; -.
DR   PDBsum; 5Z78; -.
DR   PDBsum; 5ZCJ; -.
DR   PDBsum; 6CO1; -.
DR   PDBsum; 6CO2; -.
DR   PDBsum; 6IU7; -.
DR   PDBsum; 6IUA; -.
DR   PDBsum; 6MXX; -.
DR   PDBsum; 6MXY; -.
DR   PDBsum; 6MXZ; -.
DR   PDBsum; 6MY0; -.
DR   PDBsum; 6RML; -.
DR   PDBsum; 6RMM; -.
DR   PDBsum; 6UPT; -.
DR   PDBsum; 6VA5; -.
DR   PDBsum; 6VIP; -.
DR   PDBsum; 7LIN; -.
DR   PDBsum; 7LIO; -.
DR   PDBsum; 7YQK; -.
DR   PDBsum; 8EOM; -.
DR   PDBsum; 8F0W; -.
DR   PDBsum; 8HKW; -.
DR   PDBsum; 8SWJ; -.
DR   PDBsum; 8U4U; -.
DR   AlphaFoldDB; Q12888; -.
DR   BMRB; Q12888; -.
DR   SMR; Q12888; -.
DR   BioGRID; 113011; 519.
DR   CORUM; Q12888; -.
DR   DIP; DIP-5978N; -.
DR   IntAct; Q12888; 369.
DR   MINT; Q12888; -.
DR   STRING; 9606.ENSP00000371475; -.
DR   BindingDB; Q12888; -.
DR   ChEMBL; CHEMBL2424509; -.
DR   GlyCosmos; Q12888; 3 sites, 1 glycan.
DR   GlyGen; Q12888; 10 sites, 1 O-linked glycan (10 sites).
DR   iPTMnet; Q12888; -.
DR   MetOSite; Q12888; -.
DR   PhosphoSitePlus; Q12888; -.
DR   SwissPalm; Q12888; -.
DR   BioMuta; TP53BP1; -.
DR   DMDM; 8928568; -.
DR   CPTAC; CPTAC-1014; -.
DR   CPTAC; CPTAC-1015; -.
DR   CPTAC; CPTAC-1334; -.
DR   CPTAC; CPTAC-2608; -.
DR   CPTAC; CPTAC-2609; -.
DR   CPTAC; CPTAC-5914; -.
DR   CPTAC; CPTAC-5915; -.
DR   CPTAC; CPTAC-5916; -.
DR   CPTAC; CPTAC-5917; -.
DR   EPD; Q12888; -.
DR   jPOST; Q12888; -.
DR   MassIVE; Q12888; -.
DR   MaxQB; Q12888; -.
DR   PaxDb; 9606-ENSP00000371475; -.
DR   PeptideAtlas; Q12888; -.
DR   ProteomicsDB; 29194; -.
DR   ProteomicsDB; 59003; -. [Q12888-1]
DR   ProteomicsDB; 59004; -. [Q12888-2]
DR   Pumba; Q12888; -.
DR   ABCD; Q12888; 6 sequenced antibodies.
DR   Antibodypedia; 1749; 1099 antibodies from 41 providers.
DR   CPTC; Q12888; 1 antibody.
DR   DNASU; 7158; -.
DR   Ensembl; ENST00000263801.7; ENSP00000263801.3; ENSG00000067369.14. [Q12888-1]
DR   Ensembl; ENST00000382044.9; ENSP00000371475.5; ENSG00000067369.14. [Q12888-2]
DR   Ensembl; ENST00000450115.6; ENSP00000393497.2; ENSG00000067369.14. [Q12888-3]
DR   GeneID; 7158; -.
DR   KEGG; hsa:7158; -.
DR   MANE-Select; ENST00000382044.9; ENSP00000371475.5; NM_001141980.3; NP_001135452.1. [Q12888-2]
DR   UCSC; uc001zrq.5; human. [Q12888-1]
DR   AGR; HGNC:11999; -.
DR   CTD; 7158; -.
DR   DisGeNET; 7158; -.
DR   GeneCards; TP53BP1; -.
DR   HGNC; HGNC:11999; TP53BP1.
DR   HPA; ENSG00000067369; Low tissue specificity.
DR   MalaCards; TP53BP1; -.
DR   MIM; 605230; gene.
DR   neXtProt; NX_Q12888; -.
DR   OpenTargets; ENSG00000067369; -.
DR   PharmGKB; PA36680; -.
DR   VEuPathDB; HostDB:ENSG00000067369; -.
DR   eggNOG; KOG3548; Eukaryota.
DR   GeneTree; ENSGT00390000011891; -.
DR   HOGENOM; CLU_002167_0_0_1; -.
DR   InParanoid; Q12888; -.
DR   OMA; EPCVENR; -.
DR   OrthoDB; 5403076at2759; -.
DR   PhylomeDB; Q12888; -.
DR   TreeFam; TF350227; -.
DR   PathwayCommons; Q12888; -.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   SignaLink; Q12888; -.
DR   SIGNOR; Q12888; -.
DR   BioGRID-ORCS; 7158; 38 hits in 1177 CRISPR screens.
DR   ChiTaRS; TP53BP1; human.
DR   EvolutionaryTrace; Q12888; -.
DR   GeneWiki; TP53BP1; -.
DR   GenomeRNAi; 7158; -.
DR   Pharos; Q12888; Tbio.
DR   PRO; PR:Q12888; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q12888; Protein.
DR   Bgee; ENSG00000067369; Expressed in pituitary gland and 200 other cell types or tissues.
DR   ExpressionAtlas; Q12888; baseline and differential.
DR   Genevisible; Q12888; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:ProtInc.
DR   GO; GO:1990391; C:DNA repair complex; IEA:Ensembl.
DR   GO; GO:0000776; C:kinetochore; IEA:UniProtKB-KW.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005657; C:replication fork; IEA:Ensembl.
DR   GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl.
DR   GO; GO:0042393; F:histone binding; IBA:GO_Central.
DR   GO; GO:0140566; F:histone reader activity; IDA:UniProtKB.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:AgBase.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0042162; F:telomeric DNA binding; IEA:Ensembl.
DR   GO; GO:0003712; F:transcription coregulator activity; IMP:BHF-UCL.
DR   GO; GO:0061649; F:ubiquitin modification-dependent histone binding; IDA:UniProtKB.
DR   GO; GO:0071481; P:cellular response to X-ray; IEA:Ensembl.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; IBA:GO_Central.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:0097680; P:double-strand break repair via classical nonhomologous end joining; IDA:UniProt.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IDA:UniProtKB.
DR   GO; GO:2000042; P:negative regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IC:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0045830; P:positive regulation of isotype switching; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   CDD; cd17745; BRCT_p53bp1_rpt1; 1.
DR   CDD; cd17724; BRCT_p53bp1_rpt2; 1.
DR   CDD; cd20383; Tudor_53BP1; 1.
DR   DisProt; DP02954; -.
DR   Gene3D; 2.30.30.140; -; 1.
DR   Gene3D; 2.30.30.30; -; 1.
DR   Gene3D; 3.40.50.10190; BRCT domain; 2.
DR   IDEAL; IID00123; -.
DR   InterPro; IPR015125; 53-BP1_Tudor.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR047249; BRCT_p53bp1-like_rpt1.
DR   InterPro; IPR047250; BRCT_p53bp1-like_rpt2.
DR   InterPro; IPR014722; Rib_uL2_dom2.
DR   InterPro; IPR047252; TP53BP1-like.
DR   PANTHER; PTHR15321:SF3; TP53-BINDING PROTEIN 1; 1.
DR   PANTHER; PTHR15321; TUMOR SUPPRESSOR P53-BINDING PROTEIN 1; 1.
DR   Pfam; PF09038; 53-BP1_Tudor; 1.
DR   Pfam; PF18428; BRCT_3; 1.
DR   SMART; SM00292; BRCT; 2.
DR   SUPFAM; SSF52113; BRCT domain; 2.
DR   SUPFAM; SSF63748; Tudor/PWWP/MBT; 2.
DR   PROSITE; PS50172; BRCT; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Centromere;
KW   Chromosomal rearrangement; Chromosome; DNA damage; DNA repair; DNA-binding;
KW   Host-virus interaction; Isopeptide bond; Kinetochore; Methylation; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1972
FT                   /note="TP53-binding protein 1"
FT                   /id="PRO_0000072643"
FT   DOMAIN          1724..1848
FT                   /note="BRCT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   DOMAIN          1864..1964
FT                   /note="BRCT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   REGION          24..273
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          290..332
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          346..507
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          520..556
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          568..595
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          649..687
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          742..911
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          997..1028
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1045..1103
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1127..1148
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1188..1232
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1269..1478
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1484..1603
FT                   /note="Tudor-like"
FT                   /evidence="ECO:0000305|PubMed:17190600"
FT   REGION          1495..1523
FT                   /note="Interaction with dimethylated histone H4"
FT                   /evidence="ECO:0000269|PubMed:17190600"
FT   REGION          1622..1719
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1745..1768
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1396..1403
FT                   /note="GAR"
FT                   /evidence="ECO:0000269|PubMed:16294045"
FT   MOTIF           1604..1631
FT                   /note="UDR"
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   COMPBIAS        31..63
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        76..92
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        93..124
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        130..152
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        153..209
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        346..366
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        424..441
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        452..469
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        580..595
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        794..822
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        848..878
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        887..905
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1068..1082
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1188..1202
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1216..1232
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1284..1329
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1632..1655
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1669..1683
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19176521"
FT   MOD_RES         63
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         105
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         124
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         166
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757"
FT   MOD_RES         176
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:17553757"
FT   MOD_RES         178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:17553757"
FT   MOD_RES         222
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         265
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         302
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17525332"
FT   MOD_RES         366
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:31135337,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         429
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757"
FT   MOD_RES         464
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         500
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         518
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17525332, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         525
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         543
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         548
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         552
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17525332, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         566
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         580
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         630
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         635
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         639
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         640
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         670
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:31135337"
FT   MOD_RES         692
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         724
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         727
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         771
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         809
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         830
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         831
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17525332, ECO:0007744|PubMed:18669648"
FT   MOD_RES         834
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         855
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         922
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         970
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         975
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         1028
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1056
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1068
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1086
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757"
FT   MOD_RES         1094
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1101
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1114
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1214
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         1216
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1219
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17553757,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1317
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1342
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1355
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         1362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1372
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1426
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1430
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1460
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1462
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1474
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1609
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:24703952,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1618
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:24703952,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1631
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70399"
FT   MOD_RES         1635
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1638
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1648
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1656
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1673
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1678
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1701
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1759
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1778
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19176521,
FT                   ECO:0000269|PubMed:21144835"
FT   CROSSLNK        217
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        217
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        868
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        868
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        930
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        984
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1365
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1434
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        1434
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1563
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        1563
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1
FT                   /note="M -> MPGEQM (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005, ECO:0000303|Ref.2"
FT                   /id="VSP_018390"
FT   VAR_SEQ         1692..1693
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_055062"
FT   VARIANT         353
FT                   /note="D -> E (in dbSNP:rs560191)"
FT                   /evidence="ECO:0000269|PubMed:17974005, ECO:0000269|Ref.4"
FT                   /id="VAR_022172"
FT   VARIANT         412
FT                   /note="G -> S (in dbSNP:rs689647)"
FT                   /evidence="ECO:0000269|PubMed:17974005, ECO:0000269|Ref.4"
FT                   /id="VAR_022173"
FT   VARIANT         648
FT                   /note="M -> V (in dbSNP:rs45443496)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022174"
FT   VARIANT         699
FT                   /note="Q -> R (in dbSNP:rs34823068)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022175"
FT   VARIANT         841
FT                   /note="D -> G (in dbSNP:rs34185035)"
FT                   /id="VAR_034558"
FT   VARIANT         1014
FT                   /note="E -> G (in dbSNP:rs45470395)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022176"
FT   VARIANT         1026
FT                   /note="V -> A (in dbSNP:rs45482998)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022177"
FT   VARIANT         1136
FT                   /note="K -> Q (in dbSNP:rs2602141)"
FT                   /evidence="ECO:0000269|PubMed:17974005, ECO:0000269|Ref.4"
FT                   /id="VAR_022178"
FT   VARIANT         1137
FT                   /note="E -> K (in dbSNP:rs34740611)"
FT                   /id="VAR_034559"
FT   VARIANT         1170
FT                   /note="A -> G (in dbSNP:rs45500399)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022179"
FT   VARIANT         1174
FT                   /note="I -> V (in dbSNP:rs3803339)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022180"
FT   VARIANT         1442
FT                   /note="R -> Q (in dbSNP:rs2230449)"
FT                   /id="VAR_034560"
FT   VARIANT         1488
FT                   /note="G -> W (in dbSNP:rs11554564)"
FT                   /id="VAR_038689"
FT   MUTAGEN         6
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148;
FT                   A-1171 and A-1219. In 8A: Does not affect interaction with
FT                   RIF1 and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-13; A-25; A-29; A-105; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         13
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148;
FT                   A-1171 and A-1219. In 8A: Does not affect interaction with
FT                   RIF1 and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-25; A-29; A-105; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         25
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148;
FT                   A-1171 and A-1219. In 8A: Does not affect interaction with
FT                   RIF1 and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-29; A-105; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         29
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148;
FT                   A-1171 and A-1219. In 8A: Does not affect interaction with
FT                   RIF1 and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-105; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         105
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-166; A-176; A-178; A-302; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219. In 8A: Does not affect interaction with RIF1
FT                   and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-29; A-166; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         166
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-176; A-178; A-302; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219. In 8A: Does not affect interaction with RIF1
FT                   and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-29; A-105; A-176
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         176..178
FT                   /note="SQS->AQA: Loss of phosphorylation site."
FT                   /evidence="ECO:0000269|PubMed:17553757"
FT   MUTAGEN         176
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-178; A-302; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219. In 8A: Does not affect interaction with RIF1
FT                   and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-29; A-105; A-166
FT                   and A-178."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         178
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-302; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219. In 8A: Does not affect interaction with RIF1
FT                   and ability to promote immunoglobulin class-switch
FT                   recombination (CSR), but abolishes interaction with PAXIP1
FT                   and ability to promote NHEJ of dysfunctional telomeres;
FT                   when associated with A-6; A-13; A-25; A-29; A-105; A-166
FT                   and A-176."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112"
FT   MUTAGEN         302
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-437; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         366
FT                   /note="S->A: Decreased interaction with TOPBP1."
FT                   /evidence="ECO:0000269|PubMed:31135337"
FT   MUTAGEN         437
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-452;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         452
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-523; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         523
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-543; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         543
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-580; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         580
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-625; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         625
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-674; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         670
FT                   /note="T->A: Decreased interaction with TOPBP1."
FT                   /evidence="ECO:0000269|PubMed:31135337"
FT   MUTAGEN         674
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-696; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         696
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-698; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         698
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-784;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         784
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         831
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-855; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         855
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-892; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         892
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-1068; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1068
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1086; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1086
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1104; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1104
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1148; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1148
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1171
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1171
FT                   /note="T->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148
FT                   and A-1219."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1219
FT                   /note="S->A: In 28A: Defects in recruitment to double
FT                   strand breaks (DSBs), abolished interaction with RIF1 and
FT                   abolished ability to repair DSBs; when associated with A-6;
FT                   A-13; A-25; A-29; A-105; A-166; A-176; A-178; A-302; A-437;
FT                   A-452; A-523; A-543; A-580; A-625; A-674; A-696; A-698;
FT                   A-784; A-831; A-855; A-892; A-1068; A-1086; A-1104; A-1148
FT                   and A-1171."
FT                   /evidence="ECO:0000269|PubMed:23333306,
FT                   ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1396
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1398; A-1400; A-1401 and A-1403."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1396
FT                   /note="R->K: No detectable effect on methylation by PRMT1
FT                   (in vitro)."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1398..1401
FT                   /note="RGRR->AGAA: No effect on in class-switch
FT                   recombination (CSR)."
FT                   /evidence="ECO:0000269|PubMed:23345425"
FT   MUTAGEN         1398
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1396; A-1400; A-1401 and A-1403."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1398
FT                   /note="R->K: Reduced methylation by PRMT1 (in vitro).
FT                   Strongly reduced methylation; when associated with K-1400.
FT                   Strongly reduced methylation; when associated with K-1401."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1400
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1396; A-1398; A-1401 and A-1403."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1400
FT                   /note="R->K: Reduced methylation by PRMT1 (in vitro).
FT                   Strongly reduced methylation; when associated with K-1398.
FT                   Strongly reduced methylation; when associated with K-1401."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1401
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1396; A-1398; A-1400 and A-1403."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1401
FT                   /note="R->K: Reduced methylation by PRMT1 (in vitro).
FT                   Strongly reduced methylation; when associated with K-1398.
FT                   Strongly reduced methylation; when associated with K-1400."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1403
FT                   /note="R->A: No detectable effect on methylation by PRMT1
FT                   (in vitro). Loss of methylation; when associated with
FT                   A-1396; A-1398; A-1400 and A-1401."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1403
FT                   /note="R->K: No detectable effect on methylation by PRMT1
FT                   (in vitro)."
FT                   /evidence="ECO:0000269|PubMed:16294045,
FT                   ECO:0000269|PubMed:16294047"
FT   MUTAGEN         1495
FT                   /note="W->A,H: Loss of interaction with histone H4 that has
FT                   been dimethylated at 'Lys-20' (H4K20me2). Abolishes
FT                   recruitment to double strand breaks. Loss of interaction
FT                   with histone H4 that has been dimethylated at 'Lys-20'
FT                   (H4K20me2). Abolishes recruitment to double strand breaks;
FT                   when associated with A-1521."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:28241136"
FT   MUTAGEN         1495
FT                   /note="W->F: No effect on recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1495
FT                   /note="W->V: Reduces recruitment to double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1500
FT                   /note="Y->A: Reduces affinity for histone H4 that has been
FT                   dimethylated at 'Lys-20'."
FT                   /evidence="ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1502
FT                   /note="Y->A: Reduces affinity for histone H4 that has been
FT                   dimethylated at 'Lys-20'."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1502
FT                   /note="Y->L,Q: Abolishes recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1521
FT                   /note="D->A: Loss of interaction with histone H4 that has
FT                   been dimethylated at 'Lys-20' (H4K20me2). Abolishes
FT                   recruitment to double strand breaks. Loss of interaction
FT                   with histone H4 that has been dimethylated at 'Lys-20'
FT                   (H4K20me2). Abolishes recruitment to double strand breaks;
FT                   when associated with A-1495."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:28241136"
FT   MUTAGEN         1521
FT                   /note="D->R: Abolishes recruitment to double strand breaks
FT                   and induces defects in class-switch recombination (CSR)."
FT                   /evidence="ECO:0000269|PubMed:15525939,
FT                   ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:23345425,
FT                   ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1523
FT                   /note="Y->A: Increases affinity for histone H4 that has
FT                   been dimethylated at 'Lys-20'. No effect on recruitment to
FT                   double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1523
FT                   /note="Y->S: Decreases affinity for histone H4 that has
FT                   been dimethylated at 'Lys-20'."
FT                   /evidence="ECO:0000269|PubMed:17190600"
FT   MUTAGEN         1609
FT                   /note="T->A: Constitutive recruitment to mitotic DNA
FT                   lesions, leading to mitotic defects; when associated with
FT                   A-1618."
FT                   /evidence="ECO:0000269|PubMed:24703952"
FT   MUTAGEN         1609
FT                   /note="T->E: Phosphomimetic mutant that abolishes
FT                   recruitment to double strand breaks; when associated with
FT                   D-1618."
FT                   /evidence="ECO:0000269|PubMed:24703952"
FT   MUTAGEN         1613
FT                   /note="K->A: Does not affect recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1616
FT                   /note="D->A: Does not affect recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1617
FT                   /note="I->A: Strongly reduced recruitment to double strand
FT                   breaks. Defects in class-switch recombination (CSR)."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1618
FT                   /note="S->A: Constitutive recruitment to mitotic DNA
FT                   lesions, leading to mitotic defects; when associated with
FT                   A-1609."
FT                   /evidence="ECO:0000269|PubMed:24703952"
FT   MUTAGEN         1618
FT                   /note="S->D: Phosphomimetic mutant that abolishes
FT                   recruitment to double strand breaks; when associated with
FT                   E-1609."
FT                   /evidence="ECO:0000269|PubMed:24703952"
FT   MUTAGEN         1619
FT                   /note="L->A: Strongly reduced recruitment to double strand
FT                   breaks. Defects in class-switch recombination (CSR). Does
FT                   not affect interaction with histone H4 dimethylated at
FT                   'Lys-20' (H4K20me2). Impaired interaction with histone H2A
FT                   monoubiquitinated at 'Lys-15' (H2AK15ub)."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1621
FT                   /note="N->A: Reduced recruitment to double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1622
FT                   /note="L->A: Reduced recruitment to double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1624
FT                   /note="E->A: Does not affect recruitment to double strand
FT                   breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   MUTAGEN         1627
FT                   /note="R->A: Reduced recruitment to double strand breaks."
FT                   /evidence="ECO:0000269|PubMed:23760478"
FT   CONFLICT        796
FT                   /note="P -> S (in Ref. 3; CAD97660)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1600
FT                   /note="Y -> C (in Ref. 3; CAD97660)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1958
FT                   /note="G -> R (in Ref. 3; CAD97660)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1490..1494
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   TURN            1496..1498
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1501..1511
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1514..1519
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1524..1528
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   HELIX           1529..1531
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1532..1535
FT                   /evidence="ECO:0007829|PDB:2LVM"
FT   STRAND          1543..1547
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   TURN            1549..1551
FT                   /evidence="ECO:0007829|PDB:6VA5"
FT   STRAND          1553..1564
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1567..1574
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1577..1582
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   HELIX           1583..1585
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1586..1588
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   HELIX           1590..1594
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   HELIX           1597..1600
FT                   /evidence="ECO:0007829|PDB:2G3R"
FT   STRAND          1615..1617
FT                   /evidence="ECO:0007829|PDB:7YQK"
FT   TURN            1674..1676
FT                   /evidence="ECO:0007829|PDB:6IUA"
FT   HELIX           1715..1719
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1726..1731
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1732..1736
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1741..1745
FT                   /evidence="ECO:0007829|PDB:1GZH"
FT   HELIX           1773..1781
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1782..1784
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1793..1799
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1801..1808
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1813..1821
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1825..1827
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1829..1837
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1843..1845
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1851..1853
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1854..1857
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1858..1860
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1868..1871
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1873..1879
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   TURN            1881..1884
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1885..1894
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1898..1908
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1914..1916
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   STRAND          1918..1922
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1928..1937
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1944..1953
FT                   /evidence="ECO:0007829|PDB:1KZY"
FT   HELIX           1963..1965
FT                   /evidence="ECO:0007829|PDB:1KZY"
SQ   SEQUENCE   1972 AA;  213574 MW;  13E2CC8A265F9D2A CRC64;
     MDPTGSQLDS DFSQQDTPCL IIEDSQPESQ VLEDDSGSHF SMLSRHLPNL QTHKENPVLD
     VVSNPEQTAG EERGDGNSGF NEHLKENKVA DPVDSSNLDT CGSISQVIEQ LPQPNRTSSV
     LGMSVESAPA VEEEKGEELE QKEKEKEEDT SGNTTHSLGA EDTASSQLGF GVLELSQSQD
     VEENTVPYEV DKEQLQSVTT NSGYTRLSDV DANTAIKHEE QSNEDIPIAE QSSKDIPVTA
     QPSKDVHVVK EQNPPPARSE DMPFSPKASV AAMEAKEQLS AQELMESGLQ IQKSPEPEVL
     STQEDLFDQS NKTVSSDGCS TPSREEGGCS LASTPATTLH LLQLSGQRSL VQDSLSTNSS
     DLVAPSPDAF RSTPFIVPSS PTEQEGRQDK PMDTSVLSEE GGEPFQKKLQ SGEPVELENP
     PLLPESTVSP QASTPISQST PVFPPGSLPI PSQPQFSHDI FIPSPSLEEQ SNDGKKDGDM
     HSSSLTVECS KTSEIEPKNS PEDLGLSLTG DSCKLMLSTS EYSQSPKMES LSSHRIDEDG
     ENTQIEDTEP MSPVLNSKFV PAENDSILMN PAQDGEVQLS QNDDKTKGDD TDTRDDISIL
     ATGCKGREET VAEDVCIDLT CDSGSQAVPS PATRSEALSS VLDQEEAMEI KEHHPEEGSS
     GSEVEEIPET PCESQGEELK EENMESVPLH LSLTETQSQG LCLQKEMPKK ECSEAMEVET
     SVISIDSPQK LAILDQELEH KEQEAWEEAT SEDSSVVIVD VKEPSPRVDV SCEPLEGVEK
     CSDSQSWEDI APEIEPCAEN RLDTKEEKSV EYEGDLKSGT AETEPVEQDS SQPSLPLVRA
     DDPLRLDQEL QQPQTQEKTS NSLTEDSKMA NAKQLSSDAE AQKLGKPSAH ASQSFCESSS
     ETPFHFTLPK EGDIIPPLTG ATPPLIGHLK LEPKRHSTPI GISNYPESTI ATSDVMSESM
     VETHDPILGS GKGDSGAAPD VDDKLCLRMK LVSPETEASE ESLQFNLEKP ATGERKNGST
     AVAESVASPQ KTMSVLSCIC EARQENEARS EDPPTTPIRG NLLHFPSSQG EEEKEKLEGD
     HTIRQSQQPM KPISPVKDPV SPASQKMVIQ GPSSPQGEAM VTDVLEDQKE GRSTNKENPS
     KALIERPSQN NIGIQTMECS LRVPETVSAA TQTIKNVCEQ GTSTVDQNFG KQDATVQTER
     GSGEKPVSAP GDDTESLHSQ GEEEFDMPQP PHGHVLHRHM RTIREVRTLV TRVITDVYYV
     DGTEVERKVT EETEEPIVEC QECETEVSPS QTGGSSGDLG DISSFSSKAS SLHRTSSGTS
     LSAMHSSGSS GKGAGPLRGK TSGTEPADFA LPSSRGGPGK LSPRKGVSQT GTPVCEEDGD
     AGLGIRQGGK APVTPRGRGR RGRPPSRTTG TRETAVPGPL GIEDISPNLS PDDKSFSRVV
     PRVPDSTRRT DVGAGALRRS DSPEIPFQAA AGPSDGLDAS SPGNSFVGLR VVAKWSSNGY
     FYSGKITRDV GAGKYKLLFD DGYECDVLGK DILLCDPIPL DTEVTALSED EYFSAGVVKG
     HRKESGELYY SIEKEGQRKW YKRMAVILSL EQGNRLREQY GLGPYEAVTP LTKAADISLD
     NLVEGKRKRR SNVSSPATPT ASSSSSTTPT RKITESPRAS MGVLSGKRKL ITSEEERSPA
     KRGRKSATVK PGAVGAGEFV SPCESGDNTG EPSALEEQRG PLPLNKTLFL GYAFLLTMAT
     TSDKLASRSK LPDGPTGSSE EEEEFLEIPP FNKQYTESQL RAGAGYILED FNEAQCNTAY
     QCLLIADQHC RTRKYFLCLA SGIPCVSHVW VHDSCHANQL QNYRNYLLPA GYSLEEQRIL
     DWQPRENPFQ NLKVLLVSDQ QQNFLELWSE ILMTGGAASV KQHHSSAHNK DIALGVFDVV
     VTDPSCPASV LKCAEALQLP VVSQEWVIQC LIVGERIGFK QHPKYKHDYV SH
//
ID   NPM_HUMAN               Reviewed;         294 AA.
AC   P06748; A8K3N7; B5BU00; D3DQL6; P08693; Q12826; Q13440; Q13441; Q14115;
AC   Q5EU94; Q5EU95; Q5EU96; Q5EU97; Q5EU98; Q5EU99; Q6V962; Q8WTW5; Q96AT6;
AC   Q96DC4; Q96EA5; Q9BYG9; Q9UDJ7;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 2.
DT   24-JAN-2024, entry version 262.
DE   RecName: Full=Nucleophosmin;
DE            Short=NPM;
DE   AltName: Full=Nucleolar phosphoprotein B23;
DE   AltName: Full=Nucleolar protein NO38;
DE   AltName: Full=Numatrin;
GN   Name=NPM1; Synonyms=NPM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2713355; DOI=10.1021/bi00429a017;
RA   Chan W.-Y., Liu Q.R., Borjigin J., Busch H., Rennert O.M., Tease L.A.,
RA   Chan P.-K.;
RT   "Characterization of the cDNA encoding human nucleophosmin and studies of
RT   its role in normal and abnormal growth.";
RL   Biochemistry 28:1033-1039(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=B-cell lymphoma;
RX   PubMed=2775293; DOI=10.1016/0006-291x(89)92100-1;
RA   Li X., McNeilage L.J., Whittingham S.;
RT   "The nucleotide sequence of a human cDNA encoding the highly conserved
RT   nucleolar phosphoprotein B23.";
RL   Biochem. Biophys. Res. Commun. 163:72-78(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Amnion;
RX   PubMed=2478125; DOI=10.1016/0006-291x(89)91699-9;
RA   Zhang X.T., Thomis D.C., Samuel C.E.;
RT   "Isolation and characterization of a molecular cDNA clone of a human mRNA
RT   from interferon-treated cells encoding nucleolar protein B23, numatrin.";
RL   Biochem. Biophys. Res. Commun. 164:176-184(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=9092633; DOI=10.1093/nar/25.6.1225;
RA   Chan P.-K., Chan F.Y., Morris S.W., Xie Z.;
RT   "Isolation and characterization of the human nucleophosmin/B23 (NPM) gene:
RT   identification of the YY1 binding site at the 5' enhancer region.";
RL   Nucleic Acids Res. 25:1225-1232(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Okuwaki M., Nagata K.;
RT   "Human homologue of Rat B23.2.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND
RP   INVOLVEMENT IN ACUTE MYELOGENOUS LEUKEMIA.
RC   TISSUE=Bone marrow;
RX   PubMed=15659725; DOI=10.1056/nejmoa041974;
RA   Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L.,
RA   La Starza R., Diverio D., Colombo E., Santucci A., Bigerna B., Pacini R.,
RA   Pucciarini A., Liso A., Vignetti M., Fazi P., Meani N., Pettirossi V.,
RA   Saglio G., Mandelli F., Lo-Coco F., Pelicci P.-G., Martelli M.F.;
RT   "Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal
RT   karyotype.";
RL   N. Engl. J. Med. 352:254-266(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=16574551; DOI=10.1016/s1470-2045(06)70661-1;
RA   Bolli N., Galimberti S., Martelli M.P., Tabarrini A., Roti G., Mecucci C.,
RA   Martelli M.F., Petrini M., Falini B.;
RT   "Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after
RT   diagnosis of acute myeloid leukaemia.";
RL   Lancet Oncol. 7:350-352(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RA   Lu L., Huang X.Y., Yin L.L., Xu M., Li J.M., Zhou Z.M., Sha J.H.;
RT   "Cloning of a new transcript of nucleophosmin in testis.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Bone marrow, Brain, Kidney, Lung, Prostate, Testis, and Urinary
RC   bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-133, AND CHROMOSOMAL TRANSLOCATION WITH
RP   RARA.
RC   TISSUE=Bone marrow;
RX   PubMed=8562957;
RA   Redner R.L., Rush E.A., Faas S., Rudert W.A., Corey S.J.;
RT   "The t(5;17) variant of acute promyelocytic leukemia expresses a
RT   nucleophosmin-retinoic acid receptor fusion.";
RL   Blood 87:882-886(1996).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-117, AND CHROMOSOMAL TRANSLOCATION WITH
RP   ALK.
RC   TISSUE=T-cell lymphoma;
RX   PubMed=8122112; DOI=10.1126/science.8122112;
RA   Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N.,
RA   Saltman D.L., Look A.T.;
RT   "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-
RT   Hodgkin's lymphoma.";
RL   Science 263:1281-1284(1994).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-117, AND CHROMOSOMAL TRANSLOCATION WITH
RP   ALK.
RC   TISSUE=Lymphoma;
RX   PubMed=8633037; DOI=10.1073/pnas.93.9.4181;
RA   Fujimoto J., Shiota M., Iwahara T., Seki N., Satoh H., Mori S.,
RA   Yamamoto T.;
RT   "Characterization of the transforming activity of p80, a
RT   hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal
RT   translocation t(2;5).";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:4181-4186(1996).
RN   [17]
RP   PROTEIN SEQUENCE OF 1-24; 33-101; 104-141; 240-248 AND 278-291, ACETYLATION
RP   AT MET-1, PHOSPHORYLATION AT SER-125, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-294 (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2602120;
RA   Hale T.K., Mansfield B.C.;
RT   "Nucleotide sequence of a cDNA clone representing a third allele of human
RT   protein B23.";
RL   Nucleic Acids Res. 17:10112-10112(1989).
RN   [19]
RP   PROTEIN SEQUENCE OF 33-54.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [20]
RP   PROTEIN SEQUENCE OF 34-42; 50-67; 137-151; 218-227; 252-266 AND 277-286
RP   (ISOFORM 1), AND INTERACTION WITH HTLV1 REX PROTEIN (MICROBIAL INFECTION).
RX   PubMed=8314759; DOI=10.1016/s0021-9258(19)85191-8;
RA   Adachi Y., Copeland T.D., Hatanaka M., Oroszlan S.;
RT   "Nucleolar targeting signal of Rex protein of human T-cell leukemia virus
RT   type I specifically binds to nucleolar shuttle protein B-23.";
RL   J. Biol. Chem. 268:13930-13934(1993).
RN   [21]
RP   PROTEIN SEQUENCE OF 33-42; 213-221; 251-257 AND 268-274, FUNCTION,
RP   INTERACTION WITH EIF2AK2, AND PHOSPHORYLATION.
RX   PubMed=12882984; DOI=10.1074/jbc.m301392200;
RA   Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W.,
RA   Faulkner G.R., Speckhart A., Bagby G.C.;
RT   "Nucleophosmin interacts with and inhibits the catalytic function of
RT   eukaryotic initiation factor 2 kinase PKR.";
RL   J. Biol. Chem. 278:41709-41717(2003).
RN   [22]
RP   PROTEIN SEQUENCE OF 115-134.
RX   PubMed=3944116; DOI=10.1016/s0021-9258(17)36022-2;
RA   Chan P.-K., Aldrich M.B., Cook R.G., Busch H.;
RT   "Amino acid sequence of protein B23 phosphorylation site.";
RL   J. Biol. Chem. 261:1868-1872(1986).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 213-294 (ISOFORM 1), AND PROTEIN SEQUENCE OF
RP   227-294.
RX   PubMed=2429957; DOI=10.1016/s0021-9258(18)67023-1;
RA   Chan P.-K., Chan W.-Y., Yung B.Y.M., Cook R.G., Aldrich M.B., Ku D.,
RA   Goldknopf I.L., Busch H.;
RT   "Amino acid sequence of a specific antigenic peptide of protein B23.";
RL   J. Biol. Chem. 261:14335-14341(1986).
RN   [24]
RP   ADP-RIBOSYLATION.
RX   PubMed=7631008; DOI=10.2307/3579152;
RA   Ramsamooj P., Notario V., Dritschilo A.;
RT   "Modification of nucleolar protein B23 after exposure to ionizing
RT   radiation.";
RL   Radiat. Res. 143:158-164(1995).
RN   [25]
RP   CHROMOSOMAL TRANSLOCATION WITH MLF1.
RX   PubMed=8570204;
RA   Yoneda-Kato N., Look A.T., Kirstein M.N., Valentine M.B., Raimondi S.C.,
RA   Cohen K.J., Carroll A.J., Morris S.W.;
RT   "The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid
RT   leukemia produces a novel fusion gene, NPM-MLF1.";
RL   Oncogene 12:265-275(1996).
RN   [26]
RP   PHOSPHORYLATION BY CDK2.
RX   PubMed=11051553; DOI=10.1016/s0092-8674(00)00093-3;
RA   Okuda M., Horn H.F., Tarapore P., Tokuyama Y., Smulian A.G., Chan P.K.,
RA   Knudsen E.S., Hofmann I.A., Snyder J.D., Bove K.E., Fukasawa K.;
RT   "Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome
RT   duplication.";
RL   Cell 103:127-140(2000).
RN   [27]
RP   INTERACTION WITH HEPATITIS DELTA VIRUS S-HDAG (MICROBIAL INFECTION).
RX   PubMed=11309377; DOI=10.1074/jbc.m010087200;
RA   Huang W.H., Yung B.Y., Syu W.J., Lee Y.H.;
RT   "The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens
RT   and modulates the hepatitis delta virus RNA replication.";
RL   J. Biol. Chem. 276:25166-25175(2001).
RN   [28]
RP   PHOSPHORYLATION AT THR-199; THR-219 AND THR-237, AND MUTAGENESIS OF
RP   THR-199; THR-219; THR-234 AND THR-237.
RX   PubMed=12058066; DOI=10.1091/mbc.02-03-0036;
RA   Okuwaki M., Tsujimoto M., Nagata K.;
RT   "The RNA binding activity of a ribosome biogenesis factor,
RT   nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-
RT   dependent kinase and by association with its subtype.";
RL   Mol. Biol. Cell 13:2016-2030(2002).
RN   [29]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.e02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [30]
RP   REVIEW.
RX   PubMed=12214246; DOI=10.1038/sj.onc.1205708;
RA   Okuda M.;
RT   "The role of nucleophosmin in centrosome duplication.";
RL   Oncogene 21:6170-6174(2002).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [32]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH NEK2.
RX   PubMed=15388344; DOI=10.1016/j.febslet.2004.08.047;
RA   Yao J., Fu C., Ding X., Guo Z., Zenreski A., Chen Y., Ahmed K., Liao J.,
RA   Dou Z., Yao X.;
RT   "Nek2A kinase regulates the localization of numatrin to centrosome in
RT   mitosis.";
RL   FEBS Lett. 575:112-118(2004).
RN   [33]
RP   PHOSPHORYLATION AT SER-4 BY PLK1.
RX   PubMed=15190079; DOI=10.1074/jbc.m403264200;
RA   Zhang H., Shi X., Paddon H., Hampong M., Dai W., Pelech S.;
RT   "B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of
RT   polo-like kinase 1.";
RL   J. Biol. Chem. 279:35726-35734(2004).
RN   [34]
RP   INTERACTION WITH RPGR.
RX   PubMed=15772089; DOI=10.1093/hmg/ddi129;
RA   Shu X., Fry A.M., Tulloch B., Manson F.D., Crabb J.W., Khanna H.,
RA   Faragher A.J., Lennon A., He S., Trojan P., Giessl A., Wolfrum U.,
RA   Vervoort R., Swaroop A., Wright A.F.;
RT   "RPGR ORF15 isoform co-localizes with RPGRIP1 at centrioles and basal
RT   bodies and interacts with nucleophosmin.";
RL   Hum. Mol. Genet. 14:1183-1197(2005).
RN   [35]
RP   ACETYLATION AT LYS-212; LYS-229; LYS-230; LYS-250; LYS-257 AND LYS-292, AND
RP   FUNCTION AS A CHAPERONE.
RX   PubMed=16107701; DOI=10.1128/mcb.25.17.7534-7545.2005;
RA   Swaminathan V., Kishore A.H., Febitha K.K., Kundu T.K.;
RT   "Human histone chaperone nucleophosmin enhances acetylation-dependent
RT   chromatin transcription.";
RL   Mol. Cell. Biol. 25:7534-7545(2005).
RN   [36]
RP   SUMOYLATION AT LYS-230 AND LYS-263.
RX   PubMed=15897463; DOI=10.1073/pnas.0502978102;
RA   Tago K., Chiocca S., Sherr C.J.;
RT   "Sumoylation induced by the Arf tumor suppressor: a p53-independent
RT   function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7689-7694(2005).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70 AND THR-95, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-150; LYS-154 AND LYS-212, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16916647; DOI=10.1016/j.molcel.2006.06.026;
RA   Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y.,
RA   Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
RT   "Substrate and functional diversity of lysine acetylation revealed by a
RT   proteomics survey.";
RL   Mol. Cell 23:607-618(2006).
RN   [39]
RP   FUNCTION, AND INTERACTION WITH ROCK2.
RX   PubMed=17015463; DOI=10.1128/mcb.01383-06;
RA   Ma Z., Kanai M., Kawamura K., Kaibuchi K., Ye K., Fukasawa K.;
RT   "Interaction between ROCK II and nucleophosmin/B23 in the regulation of
RT   centrosome duplication.";
RL   Mol. Cell. Biol. 26:9016-9034(2006).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; THR-199 AND SER-254, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [41]
RP   INTERACTION WITH NSUN2.
RX   PubMed=17215513; DOI=10.1091/mbc.e06-11-1021;
RA   Sakita-Suto S., Kanda A., Suzuki F., Sato S., Takata T., Tatsuka M.;
RT   "Aurora-B regulates RNA methyltransferase NSUN2.";
RL   Mol. Biol. Cell 18:1107-1117(2007).
RN   [42]
RP   INTERACTION WITH SENP3, AND MUTAGENESIS OF LYS-263.
RX   PubMed=18259216; DOI=10.1038/embor.2008.3;
RA   Haindl M., Harasim T., Eick D., Muller S.;
RT   "The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of
RT   nucleophosmin and is required for rRNA processing.";
RL   EMBO Rep. 9:273-279(2008).
RN   [43]
RP   INTERACTION WITH SENP3, AND SUBCELLULAR LOCATION.
RX   PubMed=19015314; DOI=10.1083/jcb.200807185;
RA   Yun C., Wang Y., Mukhopadhyay D., Backlund P., Kolli N., Yergey A.,
RA   Wilkinson K.D., Dasso M.;
RT   "Nucleolar protein B23/nucleophosmin regulates the vertebrate SUMO pathway
RT   through SENP3 and SENP5 proteases.";
RL   J. Cell Biol. 183:589-595(2008).
RN   [44]
RP   REVIEW.
RX   PubMed=18024471; DOI=10.1093/jb/mvm222;
RA   Okuwaki M.;
RT   "The structure and functions of NPM1/Nucleophosmin/B23, a multifunctional
RT   nucleolar acidic protein.";
RL   J. Biochem. 143:441-448(2008).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-125 AND THR-279, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70 AND SER-125, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [47]
RP   FUNCTION.
RX   PubMed=18809582; DOI=10.1128/mcb.01548-07;
RA   Maggi L.B. Jr., Kuchenruether M., Dadey D.Y., Schwope R.M., Grisendi S.,
RA   Townsend R.R., Pandolfi P.P., Weber J.D.;
RT   "Nucleophosmin serves as a rate-limiting nuclear export chaperone for the
RT   Mammalian ribosome.";
RL   Mol. Cell. Biol. 28:7050-7065(2008).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; THR-75; THR-95; SER-125;
RP   SER-139; THR-234; THR-237 AND SER-243, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [50]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [51]
RP   INTERACTION WITH RRP1B.
RX   PubMed=19710015; DOI=10.1074/jbc.m109.023457;
RA   Crawford N.P., Yang H., Mattaini K.R., Hunter K.W.;
RT   "The metastasis efficiency modifier ribosomal RNA processing 1 homolog B
RT   (RRP1B) is a chromatin-associated factor.";
RL   J. Biol. Chem. 284:28660-28673(2009).
RN   [52]
RP   SUBCELLULAR LOCATION, UBIQUITINATION, AND DEUBIQUITINATION BY USP36.
RX   PubMed=19208757; DOI=10.1242/jcs.044461;
RA   Endo A., Matsumoto M., Inada T., Yamamoto A., Nakayama K.I., Kitamura N.,
RA   Komada M.;
RT   "Nucleolar structure and function are regulated by the deubiquitylating
RT   enzyme USP36.";
RL   J. Cell Sci. 122:678-686(2009).
RN   [53]
RP   FUNCTION, INTERACTION WITH APEX1, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19188445; DOI=10.1128/mcb.01337-08;
RA   Vascotto C., Fantini D., Romanello M., Cesaratto L., Deganuto M.,
RA   Leonardi A., Radicella J.P., Kelley M.R., D'Ambrosio C., Scaloni A.,
RA   Quadrifoglio F., Tell G.;
RT   "APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the
RT   rRNA quality control process.";
RL   Mol. Cell. Biol. 29:1834-1854(2009).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [55]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70 AND SER-125, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [56]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-32; LYS-150; LYS-257; LYS-267 AND
RP   LYS-273, ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-257 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [57]
RP   INTERACTION WITH CEBPA.
RX   PubMed=20075868; DOI=10.1038/emboj.2009.404;
RA   Muller C., Bremer A., Schreiber S., Eichwald S., Calkhoven C.F.;
RT   "Nucleolar retention of a translational C/EBPalpha isoform stimulates rDNA
RT   transcription and cell size.";
RL   EMBO J. 29:897-909(2010).
RN   [58]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH RPS10.
RX   PubMed=20159986; DOI=10.1074/jbc.m110.103911;
RA   Ren J., Wang Y., Liang Y., Zhang Y., Bao S., Xu Z.;
RT   "Methylation of ribosomal protein S10 by protein-arginine methyltransferase
RT   5 regulates ribosome biogenesis.";
RL   J. Biol. Chem. 285:12695-12705(2010).
RN   [59]
RP   INTERACTION WITH RRP1B.
RX   PubMed=20926688; DOI=10.1091/mbc.e10-04-0287;
RA   Chamousset D., De Wever V., Moorhead G.B., Chen Y., Boisvert F.M.,
RA   Lamond A.I., Trinkle-Mulcahy L.;
RT   "RRP1B targets PP1 to mammalian cell nucleoli and is associated with pre-
RT   60S ribosomal subunits.";
RL   Mol. Biol. Cell 21:4212-4226(2010).
RN   [60]
RP   FUNCTION, PHOSPHORYLATION AT SER-4 BY PLK2, AND MUTAGENESIS OF SER-4;
RP   THR-95; SER-125 AND THR-199.
RX   PubMed=20352051; DOI=10.1371/journal.pone.0009849;
RA   Krause A., Hoffmann I.;
RT   "Polo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4
RT   triggers centriole duplication.";
RL   PLoS ONE 5:E9849-E9849(2010).
RN   [61]
RP   PHOSPHORYLATION AT THR-199 BY CDK6.
RX   PubMed=20333249; DOI=10.1371/journal.ppat.1000818;
RA   Sarek G., Jaerviluoma A., Moore H.M., Tojkander S., Vartia S.,
RA   Biberfeld P., Laiho M., Ojala P.M.;
RT   "Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.";
RL   PLoS Pathog. 6:E1000818-E1000818(2010).
RN   [62]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-4; SER-10; SER-70; THR-95; SER-125; SER-137; SER-139;
RP   THR-199; SER-242; SER-243; SER-260 AND THR-279, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-254 (ISOFORM 3), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [63]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [64]
RP   FUNCTION, AND INTERACTION WITH BRCA2.
RX   PubMed=21084279; DOI=10.1158/0008-5472.can-10-0030;
RA   Wang H.F., Takenaka K., Nakanishi A., Miki Y.;
RT   "BRCA2 and nucleophosmin coregulate centrosome amplification and form a
RT   complex with the Rho effector kinase ROCK2.";
RL   Cancer Res. 71:68-77(2011).
RN   [65]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CENPW.
RX   PubMed=22002061; DOI=10.1074/jbc.m111.228411;
RA   Chun Y., Park B., Koh W., Lee S., Cheon Y., Kim R., Che L., Lee S.;
RT   "New centromeric component CENP-W is an RNA-associated nuclear matrix
RT   protein that interacts with nucleophosmin/B23 protein.";
RL   J. Biol. Chem. 286:42758-42769(2011).
RN   [66]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-4; SER-70; SER-125; SER-227; SER-243 AND SER-254, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [67]
RP   FUNCTION, INTERACTION WITH ATF5, AND SUBCELLULAR LOCATION.
RX   PubMed=22528486; DOI=10.1074/jbc.m112.363622;
RA   Liu X., Liu D., Qian D., Dai J., An Y., Jiang S., Stanley B., Yang J.,
RA   Wang B., Liu X., Liu D.X.;
RT   "Nucleophosmin (NPM1/B23) interacts with activating transcription factor 5
RT   (ATF5) protein and promotes proteasome- and caspase-dependent ATF5
RT   degradation in hepatocellular carcinoma cells.";
RL   J. Biol. Chem. 287:19599-19609(2012).
RN   [68]
RP   INTERACTION WITH DDX31.
RX   PubMed=23019224; DOI=10.1158/0008-5472.can-12-1645;
RA   Fukawa T., Ono M., Matsuo T., Uehara H., Miki T., Nakamura Y.,
RA   Kanayama H.O., Katagiri T.;
RT   "DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through
RT   its interaction with NPM1 in renal cell carcinomas.";
RL   Cancer Res. 72:5867-5877(2012).
RN   [69]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [70]
RP   INTERACTION WITH NPM3.
RX   PubMed=22362753; DOI=10.1093/nar/gks162;
RA   Okuwaki M., Sumi A., Hisaoka M., Saotome-Nakamura A., Akashi S.,
RA   Nishimura Y., Nagata K.;
RT   "Function of homo- and hetero-oligomers of human
RT   nucleoplasmin/nucleophosmin family proteins NPM1, NPM2 and NPM3 during
RT   sperm chromatin remodeling.";
RL   Nucleic Acids Res. 40:4861-4878(2012).
RN   [71]
RP   INTERACTION WITH ALKBH2.
RX   PubMed=23972994; DOI=10.1016/j.celrep.2013.07.027;
RA   Li P., Gao S., Wang L., Yu F., Li J., Wang C., Li J., Wong J.;
RT   "ABH2 couples regulation of ribosomal DNA transcription with DNA alkylation
RT   repair.";
RL   Cell Rep. 4:817-829(2013).
RN   [72]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4; SER-10; SER-43; SER-70;
RP   THR-95; SER-125; SER-139; THR-234; THR-237; SER-242; SER-243; SER-254 AND
RP   SER-260, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [73]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70 AND SER-243, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [74]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-27; LYS-32; LYS-248 AND LYS-250,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [75]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32; LYS-248; LYS-257 AND LYS-267,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [76]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND NOP53.
RX   PubMed=25956029; DOI=10.1016/j.ajpath.2015.03.016;
RA   Kim J.Y., Cho Y.E., Park J.H.;
RT   "The nucleolar protein GLTSCR2 is an upstream negative regulator of the
RT   oncogenic Nucleophosmin-MYC axis.";
RL   Am. J. Pathol. 185:2061-2068(2015).
RN   [77]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32 AND LYS-215, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [78]
RP   SUBUNIT, SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=25818168; DOI=10.1111/jcmm.12474;
RA   Kim J.Y., Cho Y.E., An Y.M., Kim S.H., Lee Y.G., Park J.H., Lee S.;
RT   "GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical
RT   cancer.";
RL   J. Cell. Mol. Med. 19:1245-1252(2015).
RN   [79]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [80]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [81]
RP   ADP-RIBOSYLATION AT SER-207.
RX   PubMed=28190768; DOI=10.1016/j.molcel.2017.01.003;
RA   Bonfiglio J.J., Fontana P., Zhang Q., Colby T., Gibbs-Seymour I.,
RA   Atanassov I., Bartlett E., Zaja R., Ahel I., Matic I.;
RT   "Serine ADP-ribosylation depends on HPF1.";
RL   Mol. Cell 0:0-0(2017).
RN   [82]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32; LYS-141; LYS-150; LYS-215;
RP   LYS-248; LYS-250; LYS-257; LYS-263; LYS-267 AND LYS-273, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [83]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 9-124.
RX   PubMed=17879352; DOI=10.1002/prot.21504;
RA   Lee H.H., Kim H.S., Kang J.Y., Lee B.I., Ha J.Y., Yoon H.J., Lim S.O.,
RA   Jung G., Suh S.W.;
RT   "Crystal structure of human nucleophosmin-core reveals plasticity of the
RT   pentamer-pentamer interface.";
RL   Proteins 69:672-678(2007).
RN   [84]
RP   STRUCTURE BY NMR OF 243-294, AND MUTAGENESIS OF LYS-248; LYS-250; LYS-267;
RP   PHE-268; PHE-276; TRP-288 AND TRP-290.
RX   PubMed=18511415; DOI=10.1074/jbc.m801706200;
RA   Grummitt C.G., Townsley F.M., Johnson C.M., Warren A.J., Bycroft M.;
RT   "Structural consequences of nucleophosmin mutations in acute myeloid
RT   leukemia.";
RL   J. Biol. Chem. 283:23326-23332(2008).
CC   -!- FUNCTION: Involved in diverse cellular processes such as ribosome
CC       biogenesis, centrosome duplication, protein chaperoning, histone
CC       assembly, cell proliferation, and regulation of tumor suppressors
CC       p53/TP53 and ARF. Binds ribosome presumably to drive ribosome nuclear
CC       export. Associated with nucleolar ribonucleoprotein structures and bind
CC       single-stranded nucleic acids. Acts as a chaperonin for the core
CC       histones H3, H2B and H4. Stimulates APEX1 endonuclease activity on
CC       apurinic/apyrimidinic (AP) double-stranded DNA but inhibits APEX1
CC       endonuclease activity on AP single-stranded RNA. May exert a control of
CC       APEX1 endonuclease activity within nucleoli devoted to repair AP on
CC       rDNA and the removal of oxidized rRNA molecules. In concert with BRCA2,
CC       regulates centrosome duplication. Regulates centriole duplication:
CC       phosphorylation by PLK2 is able to trigger centriole replication.
CC       Negatively regulates the activation of EIF2AK2/PKR and suppresses
CC       apoptosis through inhibition of EIF2AK2/PKR autophosphorylation.
CC       Antagonizes the inhibitory effect of ATF5 on cell proliferation and
CC       relieves ATF5-induced G2/M blockade (PubMed:22528486). In complex with
CC       MYC enhances the transcription of MYC target genes (PubMed:25956029).
CC       May act as chaperonin or cotransporter in the nucleolar localization of
CC       transcription termination factor TTF1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q61937, ECO:0000269|PubMed:12882984,
CC       ECO:0000269|PubMed:16107701, ECO:0000269|PubMed:17015463,
CC       ECO:0000269|PubMed:18809582, ECO:0000269|PubMed:19188445,
CC       ECO:0000269|PubMed:20352051, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:22002061, ECO:0000269|PubMed:22528486,
CC       ECO:0000269|PubMed:25956029}.
CC   -!- SUBUNIT: Decamer formed by two pentameric rings associated in a head-
CC       to-head fashion (By similarity). Disulfide-linked dimers under certain
CC       conditions (PubMed:25818168). The SWAP complex consists of NPM1, NCL,
CC       PARP1 and SWAP70 (By similarity). Interacts with NSUN2 and SENP3.
CC       Interacts with the methylated form of RPS10. Interacts (via N-terminal
CC       domain) with APEX1; the interaction is RNA-dependent and decreases in
CC       hydrogen peroxide-damaged cells. Interacts with isoform 1 of NEK2.
CC       Interacts with ROCK2 and BRCA2. Interacts with RPGR. Interacts with
CC       CENPW. Interacts with EIF2AK2/PKR. Interacts with CEBPA (isoform 4)
CC       (PubMed:20075868). Interacts with DDX31; this interaction prevents
CC       interaction between NPM1 and HDM2 (PubMed:23019224). Interacts with
CC       MYC; competitive with NOP53 (PubMed:25956029). Interacts with NOP53;
CC       the interaction is direct and competitive with MYC (PubMed:25956029).
CC       Interacts with LRRC34 (By similarity). Interacts with RRP1B
CC       (PubMed:19710015, PubMed:20926688). Interacts with NPM3
CC       (PubMed:22362753). Interacts with ALKBH2 (PubMed:23972994). Interacts
CC       with TTF1 (via C-terminal region) (By similarity).
CC       {ECO:0000250|UniProtKB:Q61937, ECO:0000269|PubMed:12882984,
CC       ECO:0000269|PubMed:15388344, ECO:0000269|PubMed:15772089,
CC       ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:17215513,
CC       ECO:0000269|PubMed:18259216, ECO:0000269|PubMed:19015314,
CC       ECO:0000269|PubMed:19188445, ECO:0000269|PubMed:19710015,
CC       ECO:0000269|PubMed:20075868, ECO:0000269|PubMed:20159986,
CC       ECO:0000269|PubMed:20926688, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:22002061, ECO:0000269|PubMed:22362753,
CC       ECO:0000269|PubMed:22528486, ECO:0000269|PubMed:23019224,
CC       ECO:0000269|PubMed:23972994, ECO:0000269|PubMed:25818168,
CC       ECO:0000269|PubMed:25956029}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with hepatitis delta virus S-
CC       HDAg. {ECO:0000269|PubMed:11309377}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HTLV1 Rex protein (via N-
CC       terminal nuclear localization signal). {ECO:0000269|PubMed:8314759}.
CC   -!- INTERACTION:
CC       P06748; O14965: AURKA; NbExp=3; IntAct=EBI-78579, EBI-448680;
CC       P06748; Q96GD4: AURKB; NbExp=5; IntAct=EBI-78579, EBI-624291;
CC       P06748; Q8N726: CDKN2A; NbExp=2; IntAct=EBI-78579, EBI-625922;
CC       P06748; Q96MT8: CEP63; NbExp=2; IntAct=EBI-78579, EBI-741977;
CC       P06748; P10176: COX8A; NbExp=3; IntAct=EBI-78579, EBI-3904738;
CC       P06748; Q10570: CPSF1; NbExp=2; IntAct=EBI-78579, EBI-347859;
CC       P06748; P19525: EIF2AK2; NbExp=3; IntAct=EBI-78579, EBI-640775;
CC       P06748; Q13547: HDAC1; NbExp=2; IntAct=EBI-78579, EBI-301834;
CC       P06748; Q92769: HDAC2; NbExp=2; IntAct=EBI-78579, EBI-301821;
CC       P06748; Q9BXL5: HEMGN; NbExp=7; IntAct=EBI-78579, EBI-3916399;
CC       P06748; Q92876: KLK6; NbExp=3; IntAct=EBI-78579, EBI-2432309;
CC       P06748; Q71RC2: LARP4; NbExp=2; IntAct=EBI-78579, EBI-2878091;
CC       P06748; Q00987: MDM2; NbExp=5; IntAct=EBI-78579, EBI-389668;
CC       P06748; Q9BZQ8: NIBAN1; NbExp=7; IntAct=EBI-78579, EBI-6916466;
CC       P06748; Q86SE8: NPM2; NbExp=6; IntAct=EBI-78579, EBI-6658150;
CC       P06748; Q86SE8-2: NPM2; NbExp=5; IntAct=EBI-78579, EBI-12193061;
CC       P06748; Q8IZL8: PELP1; NbExp=3; IntAct=EBI-78579, EBI-716449;
CC       P06748; Q96BK5: PINX1; NbExp=11; IntAct=EBI-78579, EBI-721782;
CC       P06748; P62753: RPS6; NbExp=3; IntAct=EBI-78579, EBI-356625;
CC       P06748; Q9H4L4: SENP3; NbExp=6; IntAct=EBI-78579, EBI-2880236;
CC       P06748; O14746: TERT; NbExp=5; IntAct=EBI-78579, EBI-1772203;
CC       P06748; P05549: TFAP2A; NbExp=6; IntAct=EBI-78579, EBI-347351;
CC       P06748; P04637: TP53; NbExp=6; IntAct=EBI-78579, EBI-366083;
CC       P06748; P63104: YWHAZ; NbExp=2; IntAct=EBI-78579, EBI-347088;
CC       P06748; Q64364: Cdkn2a; Xeno; NbExp=2; IntAct=EBI-78579, EBI-1202287;
CC       P06748; P24938: L2; Xeno; NbExp=4; IntAct=EBI-78579, EBI-7481199;
CC       P06748; P68951: L2; Xeno; NbExp=5; IntAct=EBI-78579, EBI-7481182;
CC       P06748; P0DOE7: M; Xeno; NbExp=3; IntAct=EBI-78579, EBI-10042882;
CC       P06748; Q6UPD4: NP; Xeno; NbExp=4; IntAct=EBI-78579, EBI-25616456;
CC       P06748; P03427: PB2; Xeno; NbExp=3; IntAct=EBI-78579, EBI-8430745;
CC       P06748; B1Q2W9: pre-C/C; Xeno; NbExp=8; IntAct=EBI-78579, EBI-9081051;
CC       P06748; Q98147; Xeno; NbExp=2; IntAct=EBI-78579, EBI-626601;
CC       P06748-1; P49450-1: CENPA; NbExp=3; IntAct=EBI-354150, EBI-15826012;
CC       P06748-1; P63165: SUMO1; NbExp=3; IntAct=EBI-354150, EBI-80140;
CC       P06748-1; P04637: TP53; NbExp=3; IntAct=EBI-354150, EBI-366083;
CC       P06748-1; Q14669: TRIP12; NbExp=2; IntAct=EBI-354150, EBI-308443;
CC       P06748-2; Q86SE8-2: NPM2; NbExp=4; IntAct=EBI-354154, EBI-12193061;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:19208757,
CC       ECO:0000269|PubMed:22528486, ECO:0000269|PubMed:25818168,
CC       ECO:0000269|PubMed:25956029}. Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:25818168}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:14654843}.
CC       Note=Generally nucleolar, but is translocated to the nucleoplasm in
CC       case of serum starvation or treatment with anticancer drugs. Has been
CC       found in the cytoplasm in patients with primary acute myelogenous
CC       leukemia (AML), but not with secondary AML. Can shuttle between
CC       cytoplasm and nucleus. Co- localizes with the methylated form of RPS10
CC       in the granular component (GC) region of the nucleolus. Colocalized
CC       with nucleolin and APEX1 in nucleoli. Isoform 1 of NEK2 is required for
CC       its localization to the centrosome during mitosis.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P06748-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P06748-2; Sequence=VSP_003616;
CC       Name=3;
CC         IsoId=P06748-3; Sequence=VSP_043599;
CC   -!- PTM: Acetylated at C-terminal lysine residues, thereby increasing
CC       affinity to histones. {ECO:0000269|PubMed:16107701,
CC       ECO:0000269|Ref.17}.
CC   -!- PTM: ADP-ribosylated.
CC   -!- PTM: Phosphorylated at Ser-4 by PLK1 and PLK2. Phosphorylation at Ser-4
CC       by PLK2 in S phase is required for centriole duplication and is
CC       sufficient to trigger centriole replication. Phosphorylation at Ser-4
CC       by PLK1 takes place during mitosis. Phosphorylated by CDK2 at Ser-125
CC       and Thr-199. Phosphorylation at Thr-199 may trigger initiation of
CC       centrosome duplication. Phosphorylated by CDK1 at Thr-199, Thr-219,
CC       Thr-234 and Thr-237 during cell mitosis. When these four sites are
CC       phosphorated, RNA-binding activity seem to be abolished. May be
CC       phosphorylated at Ser-70 by NEK2. The Thr-199 phosphorylated form has
CC       higher affinity for ROCK2. CDK6 triggers Thr-199 phosphorylation when
CC       complexed to Kaposi's sarcoma herpesvirus (KSHV) V-cyclin, leading to
CC       viral reactivation by reducing viral LANA levels.
CC       {ECO:0000269|PubMed:11051553, ECO:0000269|PubMed:12058066,
CC       ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15190079,
CC       ECO:0000269|PubMed:15388344, ECO:0000269|PubMed:20333249,
CC       ECO:0000269|PubMed:20352051, ECO:0000269|Ref.17}.
CC   -!- PTM: Sumoylated by ARF. {ECO:0000269|PubMed:15897463}.
CC   -!- PTM: Ubiquitinated. Ubiquitination leads to proteasomal degradation.
CC       Deubiquitinated by USP36 (PubMed:19208757).
CC       {ECO:0000269|PubMed:19208757, ECO:0000269|PubMed:25818168}.
CC   -!- DISEASE: Note=A chromosomal aberration involving NPM1 is found in a
CC       form of non-Hodgkin lymphoma. Translocation t(2;5)(p23;q35) with ALK.
CC       The resulting chimeric NPM1-ALK protein homodimerize and the kinase
CC       becomes constitutively activated. {ECO:0000269|PubMed:8122112,
CC       ECO:0000269|PubMed:8633037}.
CC   -!- DISEASE: Note=A chromosomal aberration involving NPM1 is found in a
CC       form of acute promyelocytic leukemia. Translocation t(5;17)(q32;q11)
CC       with RARA. {ECO:0000269|PubMed:8562957}.
CC   -!- DISEASE: Note=A chromosomal aberration involving NPM1 is a cause of
CC       myelodysplastic syndrome (MDS). Translocation t(3;5)(q25.1;q34) with
CC       MLF1. {ECO:0000269|PubMed:8570204}.
CC   -!- DISEASE: Note=Defects in NPM1 are associated with acute myelogenous
CC       leukemia (AML). Mutations in exon 12 affecting the C-terminus of the
CC       protein are associated with an aberrant cytoplasmic location.
CC       {ECO:0000269|PubMed:15659725}.
CC   -!- SIMILARITY: Belongs to the nucleoplasmin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/22/NPM1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23613; AAA36380.1; -; mRNA.
DR   EMBL; M28699; AAA58386.1; -; mRNA.
DR   EMBL; M26697; AAA36385.1; -; mRNA.
DR   EMBL; U89321; AAB94739.1; -; Genomic_DNA.
DR   EMBL; U89309; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89310; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89311; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89313; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89314; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89317; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89319; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; AB042278; BAB40600.1; -; mRNA.
DR   EMBL; AY740634; AAW67752.1; -; mRNA.
DR   EMBL; AY740635; AAW67753.1; -; mRNA.
DR   EMBL; AY740636; AAW67754.1; -; mRNA.
DR   EMBL; AY740637; AAW67755.1; -; mRNA.
DR   EMBL; AY740638; AAW67756.1; -; mRNA.
DR   EMBL; AY740639; AAW67757.1; -; mRNA.
DR   EMBL; AY740640; AAW67758.1; -; mRNA.
DR   EMBL; DQ303464; ABC40399.1; -; mRNA.
DR   EMBL; AY347529; AAQ24860.1; -; mRNA.
DR   EMBL; BT007011; AAP35657.1; -; mRNA.
DR   EMBL; AK290652; BAF83341.1; -; mRNA.
DR   EMBL; AB451236; BAG70050.1; -; mRNA.
DR   EMBL; AB451361; BAG70175.1; -; mRNA.
DR   EMBL; CH471062; EAW61443.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61446.1; -; Genomic_DNA.
DR   EMBL; BC002398; AAH02398.1; -; mRNA.
DR   EMBL; BC008495; AAH08495.1; -; mRNA.
DR   EMBL; BC009623; AAH09623.1; -; mRNA.
DR   EMBL; BC012566; AAH12566.1; -; mRNA.
DR   EMBL; BC014349; AAH14349.1; -; mRNA.
DR   EMBL; BC016716; AAH16716.1; -; mRNA.
DR   EMBL; BC016768; AAH16768.1; -; mRNA.
DR   EMBL; BC016824; AAH16824.1; -; mRNA.
DR   EMBL; BC021668; AAH21668.1; -; mRNA.
DR   EMBL; BC021983; AAH21983.1; -; mRNA.
DR   EMBL; BC050628; AAH50628.1; -; mRNA.
DR   EMBL; BC107754; AAI07755.1; -; mRNA.
DR   EMBL; U41742; AAB00112.1; ALT_TERM; mRNA.
DR   EMBL; U41743; AAB00113.1; ALT_TERM; mRNA.
DR   EMBL; U04946; AAA58698.1; ALT_TERM; mRNA.
DR   EMBL; D45915; BAA08343.1; ALT_TERM; mRNA.
DR   EMBL; X16934; CAA34809.1; -; mRNA.
DR   EMBL; J02590; AAA36473.1; -; mRNA.
DR   EMBL; M31004; AAA36474.1; -; mRNA.
DR   CCDS; CCDS43399.1; -. [P06748-3]
DR   CCDS; CCDS4376.1; -. [P06748-1]
DR   CCDS; CCDS4377.1; -. [P06748-2]
DR   PIR; A33423; A32915.
DR   PIR; I38491; I38491.
DR   RefSeq; NP_001032827.1; NM_001037738.2. [P06748-3]
DR   RefSeq; NP_002511.1; NM_002520.6. [P06748-1]
DR   RefSeq; NP_954654.1; NM_199185.3. [P06748-2]
DR   PDB; 2LLH; NMR; -; A=225-294.
DR   PDB; 2P1B; X-ray; 2.75 A; A/B/C/D/E/F/G/H/I/J=9-122.
DR   PDB; 2VXD; NMR; -; A=243-294.
DR   PDB; 5EHD; X-ray; 2.55 A; A/B/C/D/E/F/G/H/I/J/a/b/c/d/e/f/g/h/i/j=9-124.
DR   PDB; 7OBG; X-ray; 1.80 A; B=284-294.
DR   PDB; 7OBH; X-ray; 2.00 A; B=284-294.
DR   PDB; 8AH2; X-ray; 2.90 A; A/C=44-55.
DR   PDB; 8AS5; EM; 2.50 A; A/B/C/D/E=1-294.
DR   PDBsum; 2LLH; -.
DR   PDBsum; 2P1B; -.
DR   PDBsum; 2VXD; -.
DR   PDBsum; 5EHD; -.
DR   PDBsum; 7OBG; -.
DR   PDBsum; 7OBH; -.
DR   PDBsum; 8AH2; -.
DR   PDBsum; 8AS5; -.
DR   AlphaFoldDB; P06748; -.
DR   BMRB; P06748; -.
DR   SMR; P06748; -.
DR   BioGRID; 110929; 1120.
DR   CORUM; P06748; -.
DR   DIP; DIP-30932N; -.
DR   IntAct; P06748; 445.
DR   MINT; P06748; -.
DR   STRING; 9606.ENSP00000296930; -.
DR   BindingDB; P06748; -.
DR   ChEMBL; CHEMBL5178; -.
DR   DrugBank; DB11638; Artenimol.
DR   DrugCentral; P06748; -.
DR   GlyCosmos; P06748; 4 sites, 1 glycan.
DR   GlyGen; P06748; 7 sites, 1 O-linked glycan (7 sites).
DR   iPTMnet; P06748; -.
DR   MetOSite; P06748; -.
DR   PhosphoSitePlus; P06748; -.
DR   SwissPalm; P06748; -.
DR   BioMuta; NPM1; -.
DR   DMDM; 114762; -.
DR   DOSAC-COBS-2DPAGE; P06748; -.
DR   REPRODUCTION-2DPAGE; IPI00549248; -.
DR   SWISS-2DPAGE; P06748; -.
DR   EPD; P06748; -.
DR   jPOST; P06748; -.
DR   MassIVE; P06748; -.
DR   MaxQB; P06748; -.
DR   PaxDb; 9606-ENSP00000296930; -.
DR   PeptideAtlas; P06748; -.
DR   PRIDE; P06748; -.
DR   ProteomicsDB; 51927; -. [P06748-1]
DR   ProteomicsDB; 51928; -. [P06748-2]
DR   ProteomicsDB; 51929; -. [P06748-3]
DR   Pumba; P06748; -.
DR   TopDownProteomics; P06748-1; -. [P06748-1]
DR   TopDownProteomics; P06748-2; -. [P06748-2]
DR   TopDownProteomics; P06748-3; -. [P06748-3]
DR   Antibodypedia; 1828; 1497 antibodies from 48 providers.
DR   DNASU; 4869; -.
DR   Ensembl; ENST00000296930.10; ENSP00000296930.5; ENSG00000181163.14. [P06748-1]
DR   Ensembl; ENST00000351986.10; ENSP00000341168.6; ENSG00000181163.14. [P06748-2]
DR   Ensembl; ENST00000393820.2; ENSP00000377408.2; ENSG00000181163.14. [P06748-3]
DR   Ensembl; ENST00000517671.5; ENSP00000428755.1; ENSG00000181163.14. [P06748-1]
DR   Ensembl; ENST00000678280.1; ENSP00000503235.1; ENSG00000181163.14. [P06748-3]
DR   GeneID; 4869; -.
DR   KEGG; hsa:4869; -.
DR   MANE-Select; ENST00000296930.10; ENSP00000296930.5; NM_002520.7; NP_002511.1.
DR   UCSC; uc003mbh.4; human. [P06748-1]
DR   AGR; HGNC:7910; -.
DR   CTD; 4869; -.
DR   DisGeNET; 4869; -.
DR   GeneCards; NPM1; -.
DR   HGNC; HGNC:7910; NPM1.
DR   HPA; ENSG00000181163; Low tissue specificity.
DR   MalaCards; NPM1; -.
DR   MIM; 164040; gene.
DR   neXtProt; NX_P06748; -.
DR   OpenTargets; ENSG00000181163; -.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 98833; Acute myeloblastic leukemia without maturation.
DR   Orphanet; 402026; Acute myeloid leukemia with NPM1 somatic mutations.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 1775; Dyskeratosis congenita.
DR   Orphanet; 98842; Lymphomatoid papulosis.
DR   Orphanet; 300865; Primary cutaneous anaplastic large cell lymphoma.
DR   PharmGKB; PA31712; -.
DR   VEuPathDB; HostDB:ENSG00000181163; -.
DR   eggNOG; KOG0488; Eukaryota.
DR   GeneTree; ENSGT00940000153052; -.
DR   HOGENOM; CLU_058838_0_0_1; -.
DR   InParanoid; P06748; -.
DR   OMA; KNDEWIT; -.
DR   OrthoDB; 5360624at2759; -.
DR   PhylomeDB; P06748; -.
DR   TreeFam; TF327704; -.
DR   PathwayCommons; P06748; -.
DR   Reactome; R-HSA-180746; Nuclear import of Rev protein.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-606279; Deposition of new CENPA-containing nucleosomes at the centromere.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-8869496; TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation.
DR   Reactome; R-HSA-9692914; SARS-CoV-1-host interactions.
DR   Reactome; R-HSA-9700645; ALK mutants bind TKIs.
DR   Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants.
DR   Reactome; R-HSA-9725371; Nuclear events stimulated by ALK signaling in cancer.
DR   Reactome; R-HSA-9833482; PKR-mediated signaling.
DR   SignaLink; P06748; -.
DR   SIGNOR; P06748; -.
DR   BioGRID-ORCS; 4869; 540 hits in 1103 CRISPR screens.
DR   ChiTaRS; NPM1; human.
DR   EvolutionaryTrace; P06748; -.
DR   GeneWiki; NPM1; -.
DR   GenomeRNAi; 4869; -.
DR   Pharos; P06748; Tbio.
DR   PRO; PR:P06748; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P06748; Protein.
DR   Bgee; ENSG00000181163; Expressed in calcaneal tendon and 191 other cell types or tissues.
DR   ExpressionAtlas; P06748; baseline and differential.
DR   Genevisible; P06748; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0001652; C:granular component; TAS:Reactome.
DR   GO; GO:0015934; C:large ribosomal subunit; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:CAFA.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:CAFA.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:MGI.
DR   GO; GO:0015935; C:small ribosomal subunit; IEA:Ensembl.
DR   GO; GO:0031616; C:spindle pole centrosome; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:CAFA.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0051059; F:NF-kappaB binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0043023; F:ribosomal large subunit binding; IDA:MGI.
DR   GO; GO:0043024; F:ribosomal small subunit binding; IDA:MGI.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0019843; F:rRNA binding; EXP:DisProt.
DR   GO; GO:0030957; F:Tat protein binding; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0006884; P:cell volume homeostasis; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IDA:CAFA.
DR   GO; GO:0090398; P:cellular senescence; IMP:GO_Central.
DR   GO; GO:0007098; P:centrosome cycle; IMP:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IBA:GO_Central.
DR   GO; GO:0006281; P:DNA repair; IDA:UniProtKB.
DR   GO; GO:0006886; P:intracellular protein transport; TAS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0010826; P:negative regulation of centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0048025; P:negative regulation of mRNA splicing, via spliceosome; IEA:Ensembl.
DR   GO; GO:0044387; P:negative regulation of protein kinase activity by regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006913; P:nucleocytoplasmic transport; IDA:UniProtKB.
DR   GO; GO:0006334; P:nucleosome assembly; IDA:UniProtKB.
DR   GO; GO:1902751; P:positive regulation of cell cycle G2/M phase transition; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0010825; P:positive regulation of centrosome duplication; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:1904751; P:positive regulation of protein localization to nucleolus; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:CAFA.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB.
DR   GO; GO:0008104; P:protein localization; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IEA:Ensembl.
DR   GO; GO:0001558; P:regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0046599; P:regulation of centriole replication; IMP:UniProtKB.
DR   GO; GO:0010824; P:regulation of centrosome duplication; IBA:GO_Central.
DR   GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0060735; P:regulation of eIF2 alpha phosphorylation by dsRNA; IDA:UniProtKB.
DR   GO; GO:0032071; P:regulation of endodeoxyribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0060699; P:regulation of endoribonuclease activity; IDA:UniProtKB.
DR   GO; GO:1902629; P:regulation of mRNA stability involved in cellular response to UV; IMP:UniProtKB.
DR   GO; GO:0042273; P:ribosomal large subunit biogenesis; IBA:GO_Central.
DR   GO; GO:0000055; P:ribosomal large subunit export from nucleus; IBA:GO_Central.
DR   GO; GO:0042274; P:ribosomal small subunit biogenesis; IBA:GO_Central.
DR   GO; GO:0000056; P:ribosomal small subunit export from nucleus; IBA:GO_Central.
DR   GO; GO:0042255; P:ribosome assembly; TAS:UniProtKB.
DR   GO; GO:0006407; P:rRNA export from nucleus; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   DisProt; DP01474; -.
DR   Gene3D; 1.10.10.2100; -; 1.
DR   Gene3D; 2.60.120.340; Nucleoplasmin core domain; 1.
DR   IDEAL; IID00295; -.
DR   InterPro; IPR032569; NPM1_C.
DR   InterPro; IPR004301; Nucleoplasmin.
DR   InterPro; IPR024057; Nucleoplasmin_core_dom.
DR   InterPro; IPR036824; Nucleoplasmin_core_dom_sf.
DR   PANTHER; PTHR22747:SF28; NUCLEOPHOSMIN; 1.
DR   PANTHER; PTHR22747; NUCLEOPLASMIN; 1.
DR   Pfam; PF16276; NPM1-C; 1.
DR   Pfam; PF03066; Nucleoplasmin; 1.
DR   SUPFAM; SSF69203; Nucleoplasmin-like core domain; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ADP-ribosylation; Alternative splicing;
KW   Chaperone; Chromosomal rearrangement; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disulfide bond; Host-virus interaction;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; RNA-binding; Ubl conjugation.
FT   CHAIN           1..294
FT                   /note="Nucleophosmin"
FT                   /id="PRO_0000219481"
FT   REGION          1..186
FT                   /note="Required for interaction with SENP3"
FT   REGION          1..117
FT                   /note="Necessary for interaction with APEX1"
FT                   /evidence="ECO:0000269|PubMed:19188445"
FT   REGION          120..247
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          243..294
FT                   /note="Required for nucleolar localization"
FT   MOTIF           152..157
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           191..197
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        162..186
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        201..224
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            55
FT                   /note="Interaction between pentamers"
FT                   /evidence="ECO:0000250"
FT   SITE            80
FT                   /note="Interaction between pentamers"
FT                   /evidence="ECO:0000250"
FT   SITE            175..176
FT                   /note="Breakpoint for translocation to form NPM1-MLF1"
FT                   /evidence="ECO:0000269|PubMed:8570204"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|Ref.17, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:22223895"
FT   MOD_RES         4
FT                   /note="Phosphoserine; by PLK1 and PLK2"
FT                   /evidence="ECO:0000269|PubMed:15190079,
FT                   ECO:0000269|PubMed:20352051, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         32
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         43
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         67
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61937"
FT   MOD_RES         70
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17924679, ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         75
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         95
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         125
FT                   /note="Phosphoserine; by CDK2"
FT                   /evidence="ECO:0000269|Ref.17, ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         137
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         150
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:16916647,
FT                   ECO:0007744|PubMed:19608861"
FT   MOD_RES         154
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:16916647"
FT   MOD_RES         199
FT                   /note="Phosphothreonine; by CDK1, CDK2 and CDK6"
FT                   /evidence="ECO:0000269|PubMed:12058066,
FT                   ECO:0000269|PubMed:20333249, ECO:0007744|PubMed:17924679,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         207
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000269|PubMed:28190768"
FT   MOD_RES         212
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16107701,
FT                   ECO:0007744|PubMed:16916647"
FT   MOD_RES         219
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000305|PubMed:12058066"
FT   MOD_RES         227
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         229
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16107701"
FT   MOD_RES         230
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:16107701"
FT   MOD_RES         234
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         237
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:12058066,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         242
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         243
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         250
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:16107701"
FT   MOD_RES         254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17924679,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         257
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:16107701,
FT                   ECO:0007744|PubMed:19608861"
FT   MOD_RES         260
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         267
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         267
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q61937"
FT   MOD_RES         273
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         279
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         292
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16107701"
FT   CROSSLNK        27
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447"
FT   CROSSLNK        32
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        32
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        141
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        150
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        215
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        230
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   CROSSLNK        248
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        248
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        250
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        257
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        257
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        263
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:15897463"
FT   CROSSLNK        263
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        267
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        267
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        273
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         195..223
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_003616"
FT   VAR_SEQ         258..294
FT                   /note="GGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL -> AH (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.5"
FT                   /id="VSP_043599"
FT   MUTAGEN         4
FT                   /note="S->A: Abolishes phosphorylation by PLK2 and impairs
FT                   centriole duplication."
FT                   /evidence="ECO:0000269|PubMed:20352051"
FT   MUTAGEN         4
FT                   /note="S->D,E: Mimicks phosphorylation state, inducing
FT                   accumulation of centrioles."
FT                   /evidence="ECO:0000269|PubMed:20352051"
FT   MUTAGEN         95
FT                   /note="T->A: Does not affect phosphorylation by PLK2."
FT                   /evidence="ECO:0000269|PubMed:20352051"
FT   MUTAGEN         125
FT                   /note="S->A: Does not affect phosphorylation by PLK2."
FT                   /evidence="ECO:0000269|PubMed:20352051"
FT   MUTAGEN         199
FT                   /note="T->A: Partial loss of phosphorylation. Does not
FT                   affect phosphorylation by PLK2."
FT                   /evidence="ECO:0000269|PubMed:12058066,
FT                   ECO:0000269|PubMed:20352051"
FT   MUTAGEN         219
FT                   /note="T->A: Partial loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:12058066"
FT   MUTAGEN         234
FT                   /note="T->A: Partial loss of phosphorylation; when
FT                   associated with A-237."
FT                   /evidence="ECO:0000269|PubMed:12058066"
FT   MUTAGEN         237
FT                   /note="T->A: Partial loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:12058066"
FT   MUTAGEN         248
FT                   /note="K->A: Partial destabilization of the structure."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         250
FT                   /note="K->A: Increase in the stabilization of the
FT                   structure."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         263
FT                   /note="K->A: Increase in the stabilization of the structure
FT                   and partial delocalization to the nucleoplasm. Complete
FT                   delocalization to the nucleoplasm; when associated with
FT                   A-267."
FT                   /evidence="ECO:0000269|PubMed:18259216"
FT   MUTAGEN         263
FT                   /note="K->R: No change in the sumoylation level."
FT                   /evidence="ECO:0000269|PubMed:18259216"
FT   MUTAGEN         267
FT                   /note="K->A: Increase in the stabilization of the structure
FT                   and complete delocalization to the nucleoplasm. Complete
FT                   delocalization to the nucleoplasm; when associated with
FT                   A-263."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         268
FT                   /note="F->A: Complete destabilization of the structure and
FT                   loss of nucleolus localization; when associated with
FT                   A-276."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         276
FT                   /note="F->A: Complete destabilization of the structure and
FT                   loss of nucleolus localization; when associated with
FT                   A-268."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         288
FT                   /note="W->A: Complete destabilization of the structure;
FT                   when associated with A-290."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         290
FT                   /note="W->A: Partial destabilization of the structure.
FT                   Complete destabilization of the structure; when associated
FT                   with A-288."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   CONFLICT        80
FT                   /note="K -> E (in Ref. 13; AAH21983)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        129
FT                   /note="E -> D (in Ref. 22; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        168
FT                   /note="Missing (in Ref. 6; AAW67758)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        178
FT                   /note="D -> G (in Ref. 13; AAH16768)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        183
FT                   /note="D -> N (in Ref. 11; BAG70175/BAG70050)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        213
FT                   /note="D -> P (in Ref. 23; AAA36473/AAA36474)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        214
FT                   /note="S -> L (in Ref. 21; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="P -> S (in Ref. 23; AAA36473)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        219..221
FT                   /note="TPR -> SSS (in Ref. 23; AAA36473)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        231
FT                   /note="Q -> R (in Ref. 8; AAQ24860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        271
FT                   /note="Y -> C (in Ref. 13; AAH16768)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        287
FT                   /note="L -> F (in Ref. 13; AAH12566)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288..294
FT                   /note="WQWRKSL -> CLAVEEVSLRK (in Ref. 6;
FT                   AAW67752/AAW67755)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288..294
FT                   /note="WQWRKSL -> CMAVEEVSLRK (in Ref. 6; AAW67753 and 7;
FT                   ABC40399)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288..294
FT                   /note="WQWRKSL -> CVAVEEVSLRK (in Ref. 6; AAW67754)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        290..294
FT                   /note="WRKSL -> SLAQVSLRK (in Ref. 6; AAW67756)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        290..294
FT                   /note="WRKSL -> SLEKVSLRK (in Ref. 6; AAW67757)"
FT                   /evidence="ECO:0000305"
FT   STRAND          15..24
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          29..31
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          40..49
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          58..65
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          71..80
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   TURN            81..83
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          84..94
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          96..104
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          109..117
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   HELIX           244..257
FT                   /evidence="ECO:0007829|PDB:2LLH"
FT   HELIX           265..275
FT                   /evidence="ECO:0007829|PDB:2LLH"
FT   HELIX           281..292
FT                   /evidence="ECO:0007829|PDB:2LLH"
FT   MOD_RES         P06748-3:254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         P06748-3:257
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
SQ   SEQUENCE   294 AA;  32575 MW;  620BC7BA2E4A0054 CRC64;
     MEDSMDMDMS PLRPQNYLFG CELKADKDYH FKVDNDENEH QLSLRTVSLG AGAKDELHIV
     EAEAMNYEGS PIKVTLATLK MSVQPTVSLG GFEITPPVVL RLKCGSGPVH ISGQHLVAVE
     EDAESEDEEE EDVKLLSISG KRSAPGGGSK VPQKKVKLAA DEDDDDDDEE DDDEDDDDDD
     FDDEEAEEKA PVKKSIRDTP AKNAQKSNQN GKDSKPSSTP RSKGQESFKK QEKTPKTPKG
     PSSVEDIKAK MQASIEKGGS LPKVEAKFIN YVKNCFRMTD QEAIQDLWQW RKSL
//
ID   FLT3_HUMAN              Reviewed;         993 AA.
AC   P36888; A0AVG9; B7ZLT7; B7ZLT8; F5H0A0; Q13414;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   21-AUG-2007, sequence version 2.
DT   24-JAN-2024, entry version 216.
DE   RecName: Full=Receptor-type tyrosine-protein kinase FLT3;
DE            EC=2.7.10.1;
DE   AltName: Full=FL cytokine receptor;
DE   AltName: Full=Fetal liver kinase-2;
DE            Short=FLK-2;
DE   AltName: Full=Fms-like tyrosine kinase 3;
DE            Short=FLT-3;
DE   AltName: Full=Stem cell tyrosine kinase 1;
DE            Short=STK-1;
DE   AltName: CD_antigen=CD135;
DE   Flags: Precursor;
GN   Name=FLT3; Synonyms=CD135, FLK2, STK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Bone marrow;
RX   PubMed=7507245; DOI=10.1073/pnas.91.2.459;
RA   Small D., Levenstein M., Kim E., Carow C., Amin S., Rockwell P., Witte L.,
RA   Burrow C., Ratajczak M.Z., Gewirtz A.M., Civin C.I.;
RT   "STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+
RT   human bone marrow cells and is involved in the proliferation of early
RT   progenitor/stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:459-463(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT
RP   MET-227.
RC   TISSUE=Lymphocyte;
RX   PubMed=8394751;
RA   Rosnet O., Schiff C., Pebusque M.J., Marchetto S., Tonnelle C., Toiron Y.,
RA   Birg F., Birnbaum D.;
RT   "Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic
RT   cells.";
RL   Blood 82:1110-1119(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT MET-227.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   MET-227.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 783-942 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=2004790; DOI=10.1016/0888-7543(91)90270-o;
RA   Rosnet O., Mattei M.-G., Marchetto S., Birnbaum D.;
RT   "Isolation and chromosomal localization of a novel FMS-like tyrosine kinase
RT   gene.";
RL   Genomics 9:380-385(1991).
RN   [7]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=8637232;
RA   Rosnet O., Buhring H.J., Marchetto S., Rappold I., Lavagna C., Sainty D.,
RA   Arnoulet C., Chabannon C., Kanz L., Hannum C., Birnbaum D.;
RT   "Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of
RT   normal and malignant hematopoietic cells.";
RL   Leukemia 10:238-248(1996).
RN   [8]
RP   INVOLVEMENT IN AML.
RX   PubMed=8946930;
RA   Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y.,
RA   Fujimoto T., Misawa S.;
RT   "Internal tandem duplication of the flt3 gene found in acute myeloid
RT   leukemia.";
RL   Leukemia 10:1911-1918(1996).
RN   [9]
RP   INVOLVEMENT IN AML, SUBUNIT, PHOSPHORYLATION, AND MUTAGENESIS OF TYR-589
RP   AND TYR-591.
RX   PubMed=9737679; DOI=10.1038/sj.leu.2401130;
RA   Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H., Naoe T.;
RT   "Internal tandem duplication of the FLT3 gene is a novel modality of
RT   elongation mutation which causes constitutive activation of the product.";
RL   Leukemia 12:1333-1337(1998).
RN   [10]
RP   FUNCTION IN PROMOTING PHOSPHORYLATION OF SHC1; PTPN6/SHP; PTPN11/SHP-2;
RP   MAPK1/ERK2; MAPK3/ERK1, AUTOPHOSPHORYLATION, AND INTERACTION WITH GRB2.
RX   PubMed=10080542; DOI=10.1002/jlb.65.3.372;
RA   Zhang S., Mantel C., Broxmeyer H.E.;
RT   "Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and
RT   their association with Grb2 and Shc in Baf3/Flt3 cells.";
RL   J. Leukoc. Biol. 65:372-380(1999).
RN   [11]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2; MAPK3/ERK1; STAT5A AND STAT5B,
RP   PHOSPHORYLATION, FUNCTION IN ACTIVATION OF THE RAS PATHWAY, AND INVOLVEMENT
RP   IN AML.
RX   PubMed=11090077;
RA   Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C.,
RA   Gruning W., Kratz-Albers K., Serve S., Steur C., Buchner T., Kienast J.,
RA   Kanakura Y., Berdel W.E., Serve H.;
RT   "Flt3 mutations from patients with acute myeloid leukemia induce
RT   transformation of 32D cells mediated by the Ras and STAT5 pathways.";
RL   Blood 96:3907-3914(2000).
RN   [12]
RP   FUNCTION IN ACTIVATION OF AKT1, AND INVOLVEMENT IN AML.
RX   PubMed=16266983; DOI=10.1158/0008-5472.can-05-0422;
RA   Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J.,
RA   Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E.,
RA   Serve H.;
RT   "Constitutive activation of Akt by Flt3 internal tandem duplications is
RT   necessary for increased survival, proliferation, and myeloid
RT   transformation.";
RL   Cancer Res. 65:9643-9650(2005).
RN   [13]
RP   SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-591,
RP   DEPHOSPHORYLATION BY PTPN1; PTPN6/SHP-1 AND PTPN12, PROTEASOMAL
RP   DEGRADATION, GLYCOSYLATION, AND MUTAGENESIS OF LYS-644.
RX   PubMed=15831474; DOI=10.1128/mcb.25.9.3690-3703.2005;
RA   Schmidt-Arras D.E., Bohmer A., Markova B., Choudhary C., Serve H.,
RA   Bohmer F.D.;
RT   "Tyrosine phosphorylation regulates maturation of receptor tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 25:3690-3703(2005).
RN   [14]
RP   FUNCTION IN ACTIVATION OF STAT5A AND/OR STAT5B, PHOSPHORYLATION AT TYR-591;
RP   TYR-726; TYR-842; TYR-955 AND TYR-969, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND MUTAGENESIS OF TYR-589 AND TYR-591.
RX   PubMed=16627759; DOI=10.1182/blood-2005-11-011429;
RA   Rocnik J.L., Okabe R., Yu J.C., Lee B.H., Giese N., Schenkein D.P.,
RA   Gilliland D.G.;
RT   "Roles of tyrosine 589 and 591 in STAT5 activation and transformation
RT   mediated by FLT3-ITD.";
RL   Blood 108:1339-1345(2006).
RN   [15]
RP   INTERACTION WITH PTPN11/SHP2; LYN; FGR; HCK AND SRC, AUTOPHOSPHORYLATION,
RP   MUTAGENESIS OF TYR-589 AND TYR-599, AND PHOSPHORYLATION AT TYR-572;
RP   SER-574; TYR-589; TYR-591 AND TYR-599.
RX   PubMed=16684964; DOI=10.1182/blood-2005-07-008896;
RA   Heiss E., Masson K., Sundberg C., Pedersen M., Sun J., Bengtsson S.,
RA   Ronnstrand L.;
RT   "Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as
RT   ligand-induced autophosphorylation sites involved in binding of Src family
RT   kinases and the protein tyrosine phosphatase SHP2.";
RL   Blood 108:1542-1550(2006).
RN   [16]
RP   REGION INVOLVED IN REGULATION OF KINASE ACTIVITY, AUTOREGULATORY DOMAIN,
RP   AND INVOLVEMENT IN AML.
RX   PubMed=18305215; DOI=10.1182/blood-2008-01-117770;
RA   Meshinchi S., Stirewalt D.L., Alonzo T.A., Boggon T.J., Gerbing R.B.,
RA   Rocnik J.L., Lange B.J., Gilliland D.G., Radich J.P.;
RT   "Structural and numerical variation of FLT3/ITD in pediatric AML.";
RL   Blood 111:4930-4933(2008).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18490735; DOI=10.4049/jimmunol.180.11.7358;
RA   Kikushige Y., Yoshimoto G., Miyamoto T., Iino T., Mori Y., Iwasaki H.,
RA   Niiro H., Takenaka K., Nagafuji K., Harada M., Ishikawa F., Akashi K.;
RT   "Human Flt3 is expressed at the hematopoietic stem cell and the
RT   granulocyte/macrophage progenitor stages to maintain cell survival.";
RL   J. Immunol. 180:7358-7367(2008).
RN   [18]
RP   PHOSPHORYLATION AT TYR-589; TYR-591; TYR-599; TYR-726; TYR-768; TYR-793;
RP   TYR-842 AND TYR-955.
RX   PubMed=19477218; DOI=10.1016/j.exphem.2009.05.008;
RA   Razumovskaya E., Masson K., Khan R., Bengtsson S., Ronnstrand L.;
RT   "Oncogenic Flt3 receptors display different specificity and kinetics of
RT   autophosphorylation.";
RL   Exp. Hematol. 37:979-989(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-759 AND SER-993, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   FUNCTION IN ACTIVATION OF FES AND FER, AND INTERACTION WITH FES AND FER.
RX   PubMed=20111072; DOI=10.1038/leu.2009.301;
RA   Voisset E., Lopez S., Chaix A., Georges C., Hanssens K., Prebet T.,
RA   Dubreuil P., De Sepulveda P.;
RT   "FES kinases are required for oncogenic FLT3 signaling.";
RL   Leukemia 24:721-728(2010).
RN   [21]
RP   UBIQUITINATION.
RX   PubMed=20508617; DOI=10.1038/leu.2010.114;
RA   Buchwald M., Pietschmann K., Muller J.P., Bohmer F.D., Heinzel T.,
RA   Kramer O.H.;
RT   "Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for
RT   proteasomal degradation.";
RL   Leukemia 24:1412-1421(2010).
RN   [22]
RP   FUNCTION.
RX   PubMed=21067588; DOI=10.1186/1476-4598-9-292;
RA   Chen W., Drakos E., Grammatikakis I., Schlette E.J., Li J., Leventaki V.,
RA   Staikou-Drakopoulou E., Patsouris E., Panayiotidis P., Medeiros L.J.,
RA   Rassidakis G.Z.;
RT   "mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-
RT   mutated acute myeloid leukemia cells.";
RL   Mol. Cancer 9:292-292(2010).
RN   [23]
RP   INTERACTION WITH PTPRJ/DEP1, FUNCTION IN ACTIVATION OF MAPK1/ERK2;
RP   MAPK3/ERK1; PLCG1; STAT5A AND/OR STAT5B, GLYCOSYLATION, UBIQUITINATION, AND
RP   PHOSPHORYLATION AT TYR-572; TYR-589; TYR-591; TYR-599; TYR-768; TYR-793;
RP   TYR-842 AND TYR-955.
RX   PubMed=21262971; DOI=10.1074/jbc.m110.205021;
RA   Arora D., Stopp S., Bohmer S.A., Schons J., Godfrey R., Masson K.,
RA   Razumovskaya E., Ronnstrand L., Tanzer S., Bauer R., Bohmer F.D.,
RA   Muller J.P.;
RT   "Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3
RT   signaling.";
RL   J. Biol. Chem. 286:10918-10929(2011).
RN   [24]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=21516120; DOI=10.1038/onc.2011.110;
RA   Zheng R., Bailey E., Nguyen B., Yang X., Piloto O., Levis M., Small D.;
RT   "Further activation of FLT3 mutants by FLT3 ligand.";
RL   Oncogene 30:4004-4014(2011).
RN   [25]
RP   REVIEW.
RX   PubMed=12951584; DOI=10.1038/nrc1169;
RA   Stirewalt D.L., Radich J.P.;
RT   "The role of FLT3 in haematopoietic malignancies.";
RL   Nat. Rev. Cancer 3:650-665(2003).
RN   [26]
RP   REVIEW.
RX   PubMed=19549778; DOI=10.1158/1078-0432.ccr-08-1123;
RA   Meshinchi S., Appelbaum F.R.;
RT   "Structural and functional alterations of FLT3 in acute myeloid leukemia.";
RL   Clin. Cancer Res. 15:4263-4269(2009).
RN   [27]
RP   INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL7.
RX   PubMed=29691342; DOI=10.1128/mbio.00682-18;
RA   Crawford L.B., Kim J.H., Collins-McMillen D., Lee B.J., Landais I.,
RA   Held C., Nelson J.A., Yurochko A.D., Caposio P.;
RT   "Human Cytomegalovirus Encodes a Novel FLT3 Receptor Ligand Necessary for
RT   Hematopoietic Cell Differentiation and Viral Reactivation.";
RL   MBio 9:0-0(2018).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 564-958, AND ACTIVITY REGULATION.
RX   PubMed=14759363; DOI=10.1016/s1097-2765(03)00505-7;
RA   Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., Lippke J.,
RA   Saxena K.;
RT   "The structural basis for autoinhibition of FLT3 by the juxtamembrane
RT   domain.";
RL   Mol. Cell 13:169-178(2004).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (4.3 ANGSTROMS) OF 27-436 IN COMPLEX WITH FLT3LG,
RP   SUBUNIT, INTERACTION WITH FLT3LG, GLYCOSYLATION AT ASN-43; ASN-100;
RP   ASN-151; ASN-306; ASN-323; ASN-351 AND ASN-354, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND DISULFIDE BONDS.
RX   PubMed=21389326; DOI=10.1182/blood-2011-01-329532;
RA   Verstraete K., Vandriessche G., Januar M., Elegheert J., Shkumatov A.V.,
RA   Desfosses A., Van Craenenbroeck K., Svergun D.I., Gutsche I., Vergauwen B.,
RA   Savvides S.N.;
RT   "Structural insights into the extracellular assembly of the hematopoietic
RT   Flt3 signaling complex.";
RL   Blood 118:60-68(2011).
RN   [30]
RP   VARIANTS TYR-835 DEL; HIS-835 AND TYR-835, AND INVOLVEMENT IN AML.
RX   PubMed=11442493; DOI=10.1046/j.1365-2141.2001.02850.x;
RA   Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R.,
RA   Reilly J.T.;
RT   "Identification of novel FLT-3 Asp835 mutations in adult acute myeloid
RT   leukaemia.";
RL   Br. J. Haematol. 113:983-988(2001).
RN   [31]
RP   VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND TYR-835, CHARACTERIZATION
RP   OF VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND TYR-835,
RP   PHOSPHORYLATION, AND INVOLVEMENT IN AML.
RX   PubMed=11290608; DOI=10.1182/blood.v97.8.2434;
RA   Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S.,
RA   Asou N., Kuriyama K., Yagasaki F., Shimazaki C., Akiyama H., Saito K.,
RA   Nishimura M., Motoji T., Shinagawa K., Takeshita A., Saito H., Ueda R.,
RA   Ohno R., Naoe T.;
RT   "Activating mutation of D835 within the activation loop of FLT3 in human
RT   hematologic malignancies.";
RL   Blood 97:2434-2439(2001).
RN   [32]
RP   VARIANTS GLU-835; HIS-835; TYR-835; ILE-836 DEL AND MET-836, FUNCTION IN
RP   ACTIVATION OF STAT5A AND/OR STAT5B, PHOSPHORYLATION, AND INVOLVEMENT IN
RP   AML.
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric ALL
RT   with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-158; MET-227; ASN-324; VAL-358 AND
RP   ILE-557.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [34]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-194.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S.,
RA   Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A.,
RA   DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor
CC       for the cytokine FLT3LG and regulates differentiation, proliferation
CC       and survival of hematopoietic progenitor cells and of dendritic cells.
CC       Promotes phosphorylation of SHC1 and AKT1, and activation of the
CC       downstream effector MTOR. Promotes activation of RAS signaling and
CC       phosphorylation of downstream kinases, including MAPK1/ERK2 and/or
CC       MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP,
CC       PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type
CC       FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations
CC       that cause constitutive kinase activity promote cell proliferation and
CC       resistance to apoptosis via the activation of multiple signaling
CC       pathways. {ECO:0000269|PubMed:10080542, ECO:0000269|PubMed:11090077,
CC       ECO:0000269|PubMed:14504097, ECO:0000269|PubMed:16266983,
CC       ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:18490735,
CC       ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:21067588,
CC       ECO:0000269|PubMed:21262971, ECO:0000269|PubMed:21516120,
CC       ECO:0000269|PubMed:7507245}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:15831474};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. FLT3LG binding leads to dimerization and activation by
CC       autophosphorylation. {ECO:0000269|PubMed:14759363,
CC       ECO:0000269|PubMed:21516120}.
CC   -!- SUBUNIT: Monomer in the absence of bound FLT3LG. Homodimer in the
CC       presence of bound FLT3LG. Interacts with FIZ1 following ligand
CC       activation (By similarity). Interacts with FES, FER, LYN, FGR, HCK, SRC
CC       and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2. Interacts with
CC       RNF115 and RNF126 (By similarity). {ECO:0000250|UniProtKB:Q00342,
CC       ECO:0000269|PubMed:10080542, ECO:0000269|PubMed:16684964,
CC       ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:21262971,
CC       ECO:0000269|PubMed:21389326, ECO:0000269|PubMed:9737679}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus
CC       protein UL7. {ECO:0000269|PubMed:29691342}.
CC   -!- INTERACTION:
CC       P36888; P00519: ABL1; NbExp=2; IntAct=EBI-3946257, EBI-375543;
CC       P36888; P42684: ABL2; NbExp=3; IntAct=EBI-3946257, EBI-1102694;
CC       P36888; P46108: CRK; NbExp=2; IntAct=EBI-3946257, EBI-886;
CC       P36888; P46109: CRKL; NbExp=2; IntAct=EBI-3946257, EBI-910;
CC       P36888; P06241: FYN; NbExp=2; IntAct=EBI-3946257, EBI-515315;
CC       P36888; Q13322: GRB10; NbExp=6; IntAct=EBI-3946257, EBI-80275;
CC       P36888; Q9Y6K9: IKBKG; NbExp=2; IntAct=EBI-3946257, EBI-81279;
CC       P36888; P06239: LCK; NbExp=2; IntAct=EBI-3946257, EBI-1348;
CC       P36888; P27986: PIK3R1; NbExp=2; IntAct=EBI-3946257, EBI-79464;
CC       P36888; P20936: RASA1; NbExp=2; IntAct=EBI-3946257, EBI-1026476;
CC       P36888; P43405: SYK; NbExp=22; IntAct=EBI-3946257, EBI-78302;
CC       P36888; Q8R4L0: Sla2; Xeno; NbExp=14; IntAct=EBI-3946257, EBI-20766300;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC       Endoplasmic reticulum lumen. Note=Constitutively activated mutant forms
CC       with internal tandem duplications are less efficiently transported to
CC       the cell surface and a significant proportion is retained in an
CC       immature form in the endoplasmic reticulum lumen. The activated kinase
CC       is rapidly targeted for degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P36888-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P36888-2; Sequence=VSP_041796;
CC   -!- TISSUE SPECIFICITY: Detected in bone marrow, in hematopoietic stem
CC       cells, in myeloid progenitor cells and in granulocyte/macrophage
CC       progenitor cells (at protein level). Detected in bone marrow, liver,
CC       thymus, spleen and lymph node, and at low levels in kidney and
CC       pancreas. Highly expressed in T-cell leukemia.
CC       {ECO:0000269|PubMed:18490735, ECO:0000269|PubMed:7507245,
CC       ECO:0000269|PubMed:8394751, ECO:0000269|PubMed:8637232}.
CC   -!- DOMAIN: The juxtamembrane autoregulatory region is important for normal
CC       regulation of the kinase activity and for maintaining the kinase in an
CC       inactive state in the absence of bound ligand. Upon tyrosine
CC       phosphorylation, it mediates interaction with the SH2 domains of
CC       numerous signaling partners. In-frame internal tandem duplications
CC       (ITDs) result in constitutive activation of the kinase. The activity of
CC       the mutant kinase can be stimulated further by FLT3LG binding.
CC   -!- PTM: N-glycosylated, contains complex N-glycans with sialic acid.
CC       {ECO:0000269|PubMed:15831474, ECO:0000269|PubMed:21262971,
CC       ECO:0000269|PubMed:21389326}.
CC   -!- PTM: Autophosphorylated on several tyrosine residues in response to
CC       FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant
CC       kinases that are constitutively activated. Dephosphorylated by
CC       PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12.
CC       Dephosphorylation is important for export from the endoplasmic
CC       reticulum and location at the cell membrane.
CC   -!- PTM: Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein
CC       ligase SIAH1 after autophosphorylation, leading to its proteasomal
CC       degradation. {ECO:0000269|PubMed:20508617,
CC       ECO:0000269|PubMed:21262971}.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of
CC       acute leukemia, a cancer of the white blood cells. AML is a malignant
CC       disease of bone marrow characterized by maturational arrest of
CC       hematopoietic precursors at an early stage of development. Clonal
CC       expansion of myeloid blasts occurs in bone marrow, blood, and other
CC       tissue. Myelogenous leukemias develop from changes in cells that
CC       normally produce neutrophils, basophils, eosinophils and monocytes.
CC       {ECO:0000269|PubMed:11090077, ECO:0000269|PubMed:11290608,
CC       ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097,
CC       ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:18305215,
CC       ECO:0000269|PubMed:8946930, ECO:0000269|PubMed:9737679}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC       Somatic mutations that lead to constitutive activation of FLT3 are
CC       frequent in AML patients. These mutations fall into two classes, the
CC       most common being in-frame internal tandem duplications of variable
CC       length in the juxtamembrane region that disrupt the normal regulation
CC       of the kinase activity. Likewise, point mutations in the activation
CC       loop of the kinase domain can result in a constitutively activated
CC       kinase.
CC   -!- MISCELLANEOUS: Can be used as diagnostic tool to establish the exact
CC       cause of acute myeloid leukemia, and to determine the optimal therapy.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/144/FLT3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U02687; AAA18947.1; -; mRNA.
DR   EMBL; Z26652; CAA81393.1; -; mRNA.
DR   EMBL; AL356915; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445262; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591024; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08424.1; -; Genomic_DNA.
DR   EMBL; BC126350; AAI26351.1; -; mRNA.
DR   EMBL; BC144039; AAI44040.1; -; mRNA.
DR   EMBL; BC144040; AAI44041.1; -; mRNA.
DR   EMBL; L36162; AAA35487.1; -; mRNA.
DR   CCDS; CCDS31953.1; -. [P36888-1]
DR   PIR; A36873; A36873.
DR   PIR; A39061; A39061.
DR   RefSeq; NP_004110.2; NM_004119.2. [P36888-1]
DR   PDB; 1RJB; X-ray; 2.10 A; A=564-958.
DR   PDB; 3QS7; X-ray; 4.30 A; E/F/G/H=27-436.
DR   PDB; 3QS9; X-ray; 7.80 A; E/F/G/H=27-540.
DR   PDB; 4RT7; X-ray; 3.10 A; A=564-958.
DR   PDB; 4XUF; X-ray; 3.20 A; A/B=600-947.
DR   PDB; 5X02; X-ray; 2.40 A; A=564-958.
DR   PDB; 6IL3; X-ray; 2.50 A; A=564-958.
DR   PDB; 6JQR; X-ray; 2.20 A; A=571-951.
DR   PDB; 7QDP; X-ray; 3.69 A; E/F/G/H=1-541.
DR   PDB; 7ZV9; X-ray; 4.51 A; B/D/F/H/J/L/N/P=1-541.
DR   PDBsum; 1RJB; -.
DR   PDBsum; 3QS7; -.
DR   PDBsum; 3QS9; -.
DR   PDBsum; 4RT7; -.
DR   PDBsum; 4XUF; -.
DR   PDBsum; 5X02; -.
DR   PDBsum; 6IL3; -.
DR   PDBsum; 6JQR; -.
DR   PDBsum; 7QDP; -.
DR   PDBsum; 7ZV9; -.
DR   AlphaFoldDB; P36888; -.
DR   SMR; P36888; -.
DR   BioGRID; 108610; 306.
DR   DIP; DIP-59769N; -.
DR   IntAct; P36888; 222.
DR   MINT; P36888; -.
DR   STRING; 9606.ENSP00000241453; -.
DR   BindingDB; P36888; -.
DR   ChEMBL; CHEMBL1974; -.
DR   DrugBank; DB12742; Amuvatinib.
DR   DrugBank; DB12267; Brigatinib.
DR   DrugBank; DB12500; Fedratinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugBank; DB06469; Lestaurtinib.
DR   DrugBank; DB06080; Linifanib.
DR   DrugBank; DB06595; Midostaurin.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB11697; Pacritinib.
DR   DrugBank; DB12978; Pexidartinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB15822; Pralsetinib.
DR   DrugBank; DB12874; Quizartinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05465; Tandutinib.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugBank; DB05014; XL999.
DR   DrugCentral; P36888; -.
DR   GuidetoPHARMACOLOGY; 1807; -.
DR   GlyCosmos; P36888; 10 sites, No reported glycans.
DR   GlyGen; P36888; 10 sites.
DR   iPTMnet; P36888; -.
DR   PhosphoSitePlus; P36888; -.
DR   BioMuta; FLT3; -.
DR   DMDM; 156630887; -.
DR   CPTAC; CPTAC-2792; -.
DR   CPTAC; CPTAC-2823; -.
DR   CPTAC; CPTAC-3121; -.
DR   CPTAC; CPTAC-3122; -.
DR   jPOST; P36888; -.
DR   MassIVE; P36888; -.
DR   MaxQB; P36888; -.
DR   PaxDb; 9606-ENSP00000241453; -.
DR   PeptideAtlas; P36888; -.
DR   ProteomicsDB; 55226; -. [P36888-1]
DR   ProteomicsDB; 55227; -. [P36888-2]
DR   ABCD; P36888; 40 sequenced antibodies.
DR   Antibodypedia; 4334; 1774 antibodies from 51 providers.
DR   DNASU; 2322; -.
DR   Ensembl; ENST00000241453.12; ENSP00000241453.7; ENSG00000122025.15. [P36888-1]
DR   GeneID; 2322; -.
DR   KEGG; hsa:2322; -.
DR   MANE-Select; ENST00000241453.12; ENSP00000241453.7; NM_004119.3; NP_004110.2.
DR   UCSC; uc001urw.3; human. [P36888-1]
DR   AGR; HGNC:3765; -.
DR   CTD; 2322; -.
DR   DisGeNET; 2322; -.
DR   GeneCards; FLT3; -.
DR   HGNC; HGNC:3765; FLT3.
DR   HPA; ENSG00000122025; Tissue enhanced (bone marrow, brain, lymphoid tissue).
DR   MalaCards; FLT3; -.
DR   MIM; 136351; gene.
DR   MIM; 601626; phenotype.
DR   neXtProt; NX_P36888; -.
DR   OpenTargets; ENSG00000122025; -.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 98833; Acute myeloblastic leukemia without maturation.
DR   Orphanet; 98829; Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22).
DR   Orphanet; 98832; Acute myeloid leukemia with minimal differentiation.
DR   Orphanet; 102724; Acute myeloid leukemia with t(8;21)(q22;q22) translocation.
DR   Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2).
DR   Orphanet; 589534; Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2).
DR   Orphanet; 589595; Mixed phenotype acute leukemia with t(v;11q23.3).
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA28181; -.
DR   VEuPathDB; HostDB:ENSG00000122025; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000160575; -.
DR   HOGENOM; CLU_000288_49_1_1; -.
DR   InParanoid; P36888; -.
DR   OMA; NSQGESC; -.
DR   OrthoDB; 1614410at2759; -.
DR   PhylomeDB; P36888; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P36888; -.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-9607240; FLT3 Signaling.
DR   Reactome; R-HSA-9645135; STAT5 Activation.
DR   Reactome; R-HSA-9702509; FLT3 mutants bind TKIs.
DR   Reactome; R-HSA-9702518; STAT5 activation downstream of FLT3 ITD mutants.
DR   Reactome; R-HSA-9702569; KW2449-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702577; semaxanib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702581; crenolanib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702590; gilteritinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702596; lestaurtinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702600; midostaurin-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702605; pexidartinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702614; ponatinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702620; quizartinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702624; sorafenib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702632; sunitinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702636; tandutinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702998; linifanib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9703009; tamatinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants.
DR   Reactome; R-HSA-9706369; Negative regulation of FLT3.
DR   Reactome; R-HSA-9706374; FLT3 signaling through SRC family kinases.
DR   Reactome; R-HSA-9706377; FLT3 signaling by CBL mutants.
DR   SignaLink; P36888; -.
DR   SIGNOR; P36888; -.
DR   BioGRID-ORCS; 2322; 22 hits in 1197 CRISPR screens.
DR   ChiTaRS; FLT3; human.
DR   EvolutionaryTrace; P36888; -.
DR   GeneWiki; CD135; -.
DR   GenomeRNAi; 2322; -.
DR   Pharos; P36888; Tclin.
DR   PRO; PR:P36888; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P36888; Protein.
DR   Bgee; ENSG00000122025; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 104 other cell types or tissues.
DR   ExpressionAtlas; P36888; baseline and differential.
DR   Genevisible; P36888; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004896; F:cytokine receptor activity; ISS:UniProtKB.
DR   GO; GO:0019838; F:growth factor binding; IBA:GO_Central.
DR   GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IEA:Ensembl.
DR   GO; GO:0141038; F:phosphatidylinositol 3-kinase activator activity; TAS:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IMP:CAFA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor activity; TAS:ProtInc.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; ISS:UniProtKB.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0035726; P:common myeloid progenitor cell proliferation; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IDA:MGI.
DR   GO; GO:0001776; P:leukocyte homeostasis; ISS:UniProtKB.
DR   GO; GO:0046651; P:lymphocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; TAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; TAS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; TAS:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; TAS:UniProtKB.
DR   GO; GO:0002328; P:pro-B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 2.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF356; RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3; 1.
DR   PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Disease variant;
KW   Disulfide bond; Endoplasmic reticulum; Glycoprotein;
KW   Host-virus interaction; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Receptor;
KW   Reference proteome; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   CHAIN           27..993
FT                   /note="Receptor-type tyrosine-protein kinase FLT3"
FT                   /id="PRO_0000016778"
FT   TOPO_DOM        27..543
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        544..563
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        564..993
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          253..343
FT                   /note="Ig-like C2-type"
FT   DOMAIN          610..943
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          591..597
FT                   /note="Important for normal regulation of the kinase
FT                   activity and for maintaining the kinase in an inactive
FT                   state in the absence of bound ligand"
FT   ACT_SITE        811
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         616..624
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         644
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         572
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16684964,
FT                   ECO:0000269|PubMed:21262971"
FT   MOD_RES         574
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16684964"
FT   MOD_RES         589
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16684964,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         591
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15831474,
FT                   ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:16684964,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         599
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16684964,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         726
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:19477218"
FT   MOD_RES         759
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         768
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19477218,
FT                   ECO:0000269|PubMed:21262971"
FT   MOD_RES         793
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19477218,
FT                   ECO:0000269|PubMed:21262971"
FT   MOD_RES         842
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         955
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         969
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16627759"
FT   MOD_RES         993
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   CARBOHYD        43
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        100
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        151
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        306
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        323
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        351
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        354
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        473
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   CARBOHYD        502
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   CARBOHYD        541
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        35..65
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        103..114
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        199..206
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        232..241
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        272..330
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        368..407
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        381..392
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   VAR_SEQ         807..847
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041796"
FT   VARIANT         7
FT                   /note="D -> G (in dbSNP:rs12872889)"
FT                   /id="VAR_034677"
FT   VARIANT         158
FT                   /note="V -> A (in dbSNP:rs56321896)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042069"
FT   VARIANT         194
FT                   /note="V -> M (in dbSNP:rs146030737)"
FT                   /evidence="ECO:0000269|PubMed:18987736"
FT                   /id="VAR_054149"
FT   VARIANT         227
FT                   /note="T -> M (in dbSNP:rs1933437)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8394751,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_034678"
FT   VARIANT         324
FT                   /note="D -> N (in dbSNP:rs35602083)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042070"
FT   VARIANT         358
FT                   /note="D -> V (in dbSNP:rs34172843)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042071"
FT   VARIANT         417
FT                   /note="I -> L (in dbSNP:rs56090538)"
FT                   /id="VAR_061291"
FT   VARIANT         557
FT                   /note="V -> I (in dbSNP:rs35958982)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042072"
FT   VARIANT         835
FT                   /note="D -> E (in acute lymphoblastic leukemia patients and
FT                   acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121913487)"
FT                   /evidence="ECO:0000269|PubMed:11290608,
FT                   ECO:0000269|PubMed:14504097"
FT                   /id="VAR_065679"
FT   VARIANT         835
FT                   /note="D -> H (in acute lymphoblastic leukemia patients and
FT                   in acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121913488)"
FT                   /evidence="ECO:0000269|PubMed:11290608,
FT                   ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"
FT                   /id="VAR_065680"
FT   VARIANT         835
FT                   /note="D -> N (in acute lymphoblastic leukemia patients and
FT                   in acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121913488)"
FT                   /evidence="ECO:0000269|PubMed:11290608"
FT                   /id="VAR_065681"
FT   VARIANT         835
FT                   /note="D -> V (in acute lymphoblastic leukemia patients and
FT                   in acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121909646)"
FT                   /evidence="ECO:0000269|PubMed:11290608"
FT                   /id="VAR_065682"
FT   VARIANT         835
FT                   /note="D -> Y (in acute lymphoblastic leukemia patients and
FT                   in acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121913488)"
FT                   /evidence="ECO:0000269|PubMed:11290608,
FT                   ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"
FT                   /id="VAR_065683"
FT   VARIANT         836
FT                   /note="I -> M (in acute lymphoblastic leukemia patients;
FT                   somatic mutation; dbSNP:rs121913232)"
FT                   /evidence="ECO:0000269|PubMed:14504097"
FT                   /id="VAR_065684"
FT   MUTAGEN         589
FT                   /note="Y->F: Reduced phosphorylation of the wild-type
FT                   kinase in response to ligand binding. No effect on the
FT                   phosphorylation of the constitutively activated mutant
FT                   kinase variants. Abolishes activation of STAT5A."
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:16684964, ECO:0000269|PubMed:9737679"
FT   MUTAGEN         591
FT                   /note="Y->F: No significant effect on tyrosine
FT                   phosphorylation. Abolishes activation of STAT5A."
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:9737679"
FT   MUTAGEN         599
FT                   /note="Y->F: Abolishes interaction with PTPN11/SHP2 and
FT                   phosphorylation of PTPN11/SHP2."
FT                   /evidence="ECO:0000269|PubMed:16684964"
FT   MUTAGEN         644
FT                   /note="K->A: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15831474"
FT   CONFLICT        8
FT                   /note="G -> A (in Ref. 1; AAA18947)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        10..11
FT                   /note="QL -> TV (in Ref. 1; AAA18947)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        71
FT                   /note="S -> N (in Ref. 5; AAI44040)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        78
FT                   /note="A -> R (in Ref. 2; CAA81393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        346
FT                   /note="E -> G (in Ref. 1; AAA18947)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        940
FT                   /note="T -> H (in Ref. 6; AAA35487)"
FT                   /evidence="ECO:0000305"
FT   STRAND          575..581
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          583..585
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          589..591
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           594..596
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           601..603
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           607..609
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          610..618
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          620..631
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          633..636
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          638..646
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           656..668
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          677..681
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          683..686
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          688..692
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           699..704
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   TURN            705..708
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           785..804
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          807..809
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           814..816
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          817..820
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   TURN            821..823
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          824..827
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           831..833
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           836..838
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          842..845
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          848..850
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           852..854
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           857..862
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           867..881
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   TURN            882..884
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           896..903
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           916..925
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           930..932
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           936..946
FT                   /evidence="ECO:0007829|PDB:1RJB"
SQ   SEQUENCE   993 AA;  112903 MW;  6C1995718F352ECE CRC64;
     MPALARDGGQ LPLLVVFSAM IFGTITNQDL PVIKCVLINH KNNDSSVGKS SSYPMVSESP
     EDLGCALRPQ SSGTVYEAAA VEVDVSASIT LQVLVDAPGN ISCLWVFKHS SLNCQPHFDL
     QNRGVVSMVI LKMTETQAGE YLLFIQSEAT NYTILFTVSI RNTLLYTLRR PYFRKMENQD
     ALVCISESVP EPIVEWVLCD SQGESCKEES PAVVKKEEKV LHELFGTDIR CCARNELGRE
     CTRLFTIDLN QTPQTTLPQL FLKVGEPLWI RCKAVHVNHG FGLTWELENK ALEEGNYFEM
     STYSTNRTMI RILFAFVSSV ARNDTGYYTC SSSKHPSQSA LVTIVEKGFI NATNSSEDYE
     IDQYEEFCFS VRFKAYPQIR CTWTFSRKSF PCEQKGLDNG YSISKFCNHK HQPGEYIFHA
     ENDDAQFTKM FTLNIRRKPQ VLAEASASQA SCFSDGYPLP SWTWKKCSDK SPNCTEEITE
     GVWNRKANRK VFGQWVSSST LNMSEAIKGF LVKCCAYNSL GTSCETILLN SPGPFPFIQD
     NISFYATIGV CLLFIVVLTL LICHKYKKQF RYESQLQMVQ VTGSSDNEYF YVDFREYEYD
     LKWEFPRENL EFGKVLGSGA FGKVMNATAY GISKTGVSIQ VAVKMLKEKA DSSEREALMS
     ELKMMTQLGS HENIVNLLGA CTLSGPIYLI FEYCCYGDLL NYLRSKREKF HRTWTEIFKE
     HNFSFYPTFQ SHPNSSMPGS REVQIHPDSD QISGLHGNSF HSEDEIEYEN QKRLEEEEDL
     NVLTFEDLLC FAYQVAKGME FLEFKSCVHR DLAARNVLVT HGKVVKICDF GLARDIMSDS
     NYVVRGNARL PVKWMAPESL FEGIYTIKSD VWSYGILLWE IFSLGVNPYP GIPVDANFYK
     LIQNGFKMDQ PFYATEEIYI IMQSCWAFDS RKRPSFPNLT SFLGCQLADA EEAMYQNVDG
     RVSECPHTYQ NRRPFSREMD LGLLSPQAQV EDS
//
ID   CEBPA_HUMAN             Reviewed;         358 AA.
AC   P49715; A7LNP2; P78319; Q05CA4;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   05-FEB-2008, sequence version 3.
DT   24-JAN-2024, entry version 211.
DE   RecName: Full=CCAAT/enhancer-binding protein alpha {ECO:0000312|HGNC:HGNC:1833};
DE            Short=C/EBP alpha {ECO:0000312|HGNC:HGNC:1833};
GN   Name=CEBPA {ECO:0000312|HGNC:HGNC:1833};
GN   Synonyms=CEBP {ECO:0000312|HGNC:HGNC:1833};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Umbilical cord;
RX   PubMed=7575576; DOI=10.1006/bbrc.1995.2439;
RA   Antonson P., Xanthopoulos K.G.;
RT   "Molecular cloning, sequence, and expression patterns of the human gene
RT   encoding CCAAT/enhancer binding protein alpha (C/EBP alpha).";
RL   Biochem. Biophys. Res. Commun. 215:106-113(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RA   Swart G.W.M., van Groningen J.J.M., van Ruissen F., Bergers M.,
RA   Schalwijk J.;
RT   "Transcription factor C/EBP-alpha: novel sites of expression and cloning of
RT   the human gene.";
RL   Biol. Chem. Hoppe-Seyler 378:373-379(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-133.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH HBV PROTEIN X (MICROBIAL INFECTION).
RX   PubMed=9915821; DOI=10.1074/jbc.274.5.2858;
RA   Choi B.H., Park G.T., Rho H.M.;
RT   "Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding
RT   protein alpha synergistically activates the hepatitis B viral enhancer
RT   II/pregenomic promoter.";
RL   J. Biol. Chem. 274:2858-2865(1999).
RN   [7]
RP   INTERACTION WITH UBN1.
RX   PubMed=10725330; DOI=10.1083/jcb.148.6.1165;
RA   Aho S., Buisson M., Pajunen T., Ryoo Y.W., Giot J.-F., Gruffat H.,
RA   Sergeant A., Uitto J.;
RT   "Ubinuclein, a novel nuclear protein interacting with cellular and viral
RT   transcription factors.";
RL   J. Cell Biol. 148:1165-1176(2000).
RN   [8]
RP   INVOLVEMENT IN AML.
RX   PubMed=12661007; DOI=10.1002/gcc.10185;
RA   Snaddon J., Smith M.L., Neat M., Cambal-Parrales M., Dixon-McIver A.,
RA   Arch R., Amess J.A., Rohatiner A.Z., Lister T.A., Fitzgibbon J.;
RT   "Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.";
RL   Genes Chromosomes Cancer 37:72-78(2003).
RN   [9]
RP   INTERACTION WITH CDK2; CDK4; E2F4; RB1 AND SMARCA2, AND PHOSPHORYLATION AT
RP   SER-190.
RX   PubMed=15107404; DOI=10.1101/gad.1183304;
RA   Wang G.L., Iakova P., Wilde M., Awad S., Timchenko N.A.;
RT   "Liver tumors escape negative control of proliferation via PI3K/Akt-
RT   mediated block of C/EBP alpha growth inhibitory activity.";
RL   Genes Dev. 18:912-925(2004).
RN   [10]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS BZLF1 PROTEIN (MICROBIAL INFECTION).
RX   PubMed=15078966; DOI=10.1128/jvi.78.9.4847-4865.2004;
RA   Wu F.Y., Wang S.E., Chen H., Wang L., Hayward S.D., Hayward G.S.;
RT   "CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV)
RT   ZTA protein through oligomeric interactions and contributes to cooperative
RT   transcriptional activation of the ZTA promoter through direct binding to
RT   the ZII and ZIIIB motifs during induction of the EBV lytic cycle.";
RL   J. Virol. 78:4847-4865(2004).
RN   [11]
RP   FUNCTION (ISOFORMS 1 AND 3).
RX   PubMed=14660596; DOI=10.1074/jbc.m312709200;
RA   Muller C., Calkhoven C.F., Sha X., Leutz A.;
RT   "The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF
RT   complex for proliferation arrest.";
RL   J. Biol. Chem. 279:7353-7358(2004).
RN   [12]
RP   INVOLVEMENT IN AML.
RX   PubMed=15575056; DOI=10.1056/nejmoa041331;
RA   Smith M.L., Cavenagh J.D., Lister T.A., Fitzgibbon J.;
RT   "Mutation of CEBPA in familial acute myeloid leukemia.";
RL   N. Engl. J. Med. 351:2403-2407(2004).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-161, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   INTERACTION WITH TRIB1.
RX   PubMed=20410507; DOI=10.1182/blood-2009-07-229450;
RA   Dedhia P.H., Keeshan K., Uljon S., Xu L., Vega M.E., Shestova O.,
RA   Zaks-Zilberman M., Romany C., Blacklow S.C., Pear W.S.;
RT   "Differential ability of Tribbles family members to promote degradation of
RT   C/EBPalpha and induce acute myelogenous leukemia.";
RL   Blood 116:1321-1328(2010).
RN   [15]
RP   FUNCTION (ISOFORM 4), ALTERNATIVE INITIATION, IDENTIFICATION OF
RP   NON-CANONICAL INITIATION CODON, SUBCELLULAR LOCATION (ISOFORM 4), AND
RP   INTERACTION WITH NPM1; TAF1A AND UBTF.
RX   PubMed=20075868; DOI=10.1038/emboj.2009.404;
RA   Muller C., Bremer A., Schreiber S., Eichwald S., Calkhoven C.F.;
RT   "Nucleolar retention of a translational C/EBPalpha isoform stimulates rDNA
RT   transcription and cell size.";
RL   EMBO J. 29:897-909(2010).
RN   [16]
RP   INTERACTION WITH TFDP1; TFDP2 AND E2F1.
RX   PubMed=20176812; DOI=10.1128/mcb.01619-09;
RA   Zaragoza K., Begay V., Schuetz A., Heinemann U., Leutz A.;
RT   "Repression of transcriptional activity of C/EBPalpha by E2F-dimerization
RT   partner complexes.";
RL   Mol. Cell. Biol. 30:2293-2304(2010).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-161, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [18]
RP   INTERACTION WITH TRIB1, DOMAIN, AND MUTAGENESIS OF ILE-55; GLU-57; HIS-58;
RP   GLU-59; SER-61; ILE-62; ASP-63; ILE-64; SER-65; TYR-67; ILE-68 AND ASP-69.
RX   PubMed=26455797; DOI=10.1016/j.str.2015.08.017;
RA   Murphy J.M., Nakatani Y., Jamieson S.A., Dai W., Lucet I.S., Mace P.D.;
RT   "Molecular mechanism of CCAAT-enhancer binding protein recruitment by the
RT   TRIB1 pseudokinase.";
RL   Structure 23:2111-2121(2015).
RN   [19]
RP   INTERACTION WITH SIX1.
RX   PubMed=27923061; DOI=10.1371/journal.pgen.1006474;
RA   Brunmeir R., Wu J., Peng X., Kim S.Y., Julien S.G., Zhang Q., Xie W.,
RA   Xu F.;
RT   "Comparative Transcriptomic and Epigenomic Analyses Reveal New Regulators
RT   of Murine Brown Adipogenesis.";
RL   PLoS Genet. 12:E1006474-E1006474(2016).
RN   [20]
RP   UBIQUITINATION.
RX   PubMed=27041596; DOI=10.1016/j.str.2016.03.002;
RA   Uljon S., Xu X., Durzynska I., Stein S., Adelmant G., Marto J.A.,
RA   Pear W.S., Blacklow S.C.;
RT   "Structural basis for substrate selectivity of the E3 ligase COP1.";
RL   Structure 24:687-696(2016).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-161, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [22]
RP   VARIANTS AML LEU-84 AND LYS-312 INS, CHARACTERIZATION OF VARIANTS AML
RP   LEU-84 AND LYS-312 INS, INVOLVEMENT IN AML, FUNCTION, SUBCELLULAR LOCATION,
RP   ALTERNATIVE TRANSLATIONAL INITIATION, AND DNA-BINDING.
RX   PubMed=11242107; DOI=10.1038/85820;
RA   Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S.,
RA   Schnittger S., Behre G., Hiddemann W., Tenen D.G.;
RT   "Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding
RT   protein-alpha (C/EBPalpha), in acute myeloid leukemia.";
RL   Nat. Genet. 27:263-270(2001).
CC   -!- FUNCTION: Transcription factor that coordinates proliferation arrest
CC       and the differentiation of myeloid progenitors, adipocytes,
CC       hepatocytes, and cells of the lung and the placenta. Binds directly to
CC       the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator
CC       on distinct target genes (PubMed:11242107). During early embryogenesis,
CC       plays essential and redundant functions with CEBPB. Essential for the
CC       transition from common myeloid progenitors (CMP) to
CC       granulocyte/monocyte progenitors (GMP). Critical for the proper
CC       development of the liver and the lung (By similarity). Necessary for
CC       terminal adipocyte differentiation, is required for postnatal
CC       maintenance of systemic energy homeostasis and lipid storage (By
CC       similarity). To regulate these different processes at the proper moment
CC       and tissue, interplays with other transcription factors and modulators.
CC       Down-regulates the expression of genes that maintain cells in an
CC       undifferentiated and proliferative state through E2F1 repression, which
CC       is critical for its ability to induce adipocyte and granulocyte
CC       terminal differentiation. Reciprocally E2F1 blocks adipocyte
CC       differentiation by binding to specific promoters and repressing CEBPA
CC       binding to its target gene promoters. Proliferation arrest also depends
CC       on a functional binding to SWI/SNF complex (PubMed:14660596). In liver,
CC       regulates gluconeogenesis and lipogenesis through different mechanisms.
CC       To regulate gluconeogenesis, functionally cooperates with FOXO1 binding
CC       to IRE-controlled promoters and regulating the expression of target
CC       genes such as PCK1 or G6PC1. To modulate lipogenesis, interacts and
CC       transcriptionally synergizes with SREBF1 in promoter activation of
CC       specific lipogenic target genes such as ACAS2. In adipose tissue, seems
CC       to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1
CC       binding sites (By similarity). {ECO:0000250|UniProtKB:P05554,
CC       ECO:0000250|UniProtKB:P53566, ECO:0000269|PubMed:11242107,
CC       ECO:0000269|PubMed:14660596}.
CC   -!- FUNCTION: [Isoform 3]: Can act as dominant-negative. Binds DNA and have
CC       transctivation activity, even if much less efficiently than isoform 2.
CC       Does not inhibit cell proliferation (PubMed:14660596).
CC       {ECO:0000250|UniProtKB:P05554, ECO:0000250|UniProtKB:P53566,
CC       ECO:0000269|PubMed:14660596}.
CC   -!- FUNCTION: [Isoform 4]: Directly and specifically enhances ribosomal DNA
CC       transcription interacting with RNA polymerase I-specific cofactors and
CC       inducing histone acetylation. {ECO:0000269|PubMed:20075868}.
CC   -!- SUBUNIT: Binds DNA as a homodimer and as a heterodimer. Can form stable
CC       heterodimers with CEBPB, CEBPD, CEBPE and CEBPG (By similarity).
CC       Interacts with PRDM16 (By similarity). Interacts with UBN1
CC       (PubMed:10725330). Interacts with ZNF638; this interaction increases
CC       transcriptional activation (By similarity). Interacts with the complex
CC       TFDP2:E2F1; the interaction prevents CEBPA binding to target gene
CC       promoters and represses its transcriptional activity (PubMed:20176812).
CC       Interacts with RB1 (PubMed:15107404). Interacts (when phosphorylated at
CC       Ser-190) with CDK2, CDK4, E2F4 and SMARCA2 (PubMed:15107404). Interacts
CC       with SREBPF1 (By similarity). Interacts with FOXO1 (via the Fork-head
CC       domain); the interaction increases when FOXO1 is deacetylated (By
CC       similarity). Interacts with SIX1 (PubMed:27923061). Interacts (via
CC       recognition sequence) with TRIB1 (PubMed:20410507, PubMed:26455797).
CC       Interacts (via bZIP domain) with OVOL2 (via zinc-finger domains); the
CC       interaction inhibits the transcription factor activity of CEBPA and is
CC       required to repress adipogenesis (By similarity).
CC       {ECO:0000250|UniProtKB:P05554, ECO:0000250|UniProtKB:P53566,
CC       ECO:0000269|PubMed:10725330, ECO:0000269|PubMed:15107404,
CC       ECO:0000269|PubMed:20075868, ECO:0000269|PubMed:20176812,
CC       ECO:0000269|PubMed:20410507, ECO:0000269|PubMed:26455797,
CC       ECO:0000269|PubMed:27923061}.
CC   -!- SUBUNIT: [Isoform 1]: Interacts with TAF1A and UBTF.
CC       {ECO:0000269|PubMed:20075868}.
CC   -!- SUBUNIT: [Isoform 4]: Interacts with TAF1A and UBTF (PubMed:20075868).
CC       Interacts with NPM1 (PubMed:20075868). {ECO:0000269|PubMed:20075868}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HBV protein X.
CC       {ECO:0000269|PubMed:9915821}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus lytic
CC       switch protein BZLF1; this interaction induces G1 cell cycle arrest.
CC       {ECO:0000269|PubMed:15078966}.
CC   -!- INTERACTION:
CC       P49715; P18847: ATF3; NbExp=2; IntAct=EBI-1172054, EBI-712767;
CC       P49715; P18848: ATF4; NbExp=4; IntAct=EBI-1172054, EBI-492498;
CC       P49715; Q9Y2D1: ATF5; NbExp=2; IntAct=EBI-1172054, EBI-492509;
CC       P49715; Q16520: BATF; NbExp=3; IntAct=EBI-1172054, EBI-749503;
CC       P49715; Q8N1L9: BATF2; NbExp=2; IntAct=EBI-1172054, EBI-742695;
CC       P49715; Q9NR55: BATF3; NbExp=2; IntAct=EBI-1172054, EBI-10312707;
CC       P49715; P47902: CDX1; NbExp=3; IntAct=EBI-1172054, EBI-8514176;
CC       P49715; P49715: CEBPA; NbExp=2; IntAct=EBI-1172054, EBI-1172054;
CC       P49715; P17676: CEBPB; NbExp=2; IntAct=EBI-1172054, EBI-969696;
CC       P49715; P49716: CEBPD; NbExp=2; IntAct=EBI-1172054, EBI-7962058;
CC       P49715; Q15744: CEBPE; NbExp=2; IntAct=EBI-1172054, EBI-3907048;
CC       P49715; P53567: CEBPG; NbExp=4; IntAct=EBI-1172054, EBI-740209;
CC       P49715; P35638: DDIT3; NbExp=4; IntAct=EBI-1172054, EBI-742651;
CC       P49715; P01100: FOS; NbExp=2; IntAct=EBI-1172054, EBI-852851;
CC       P49715; P24001-2: IL32; NbExp=7; IntAct=EBI-1172054, EBI-8800907;
CC       P49715; P09874: PARP1; NbExp=2; IntAct=EBI-1172054, EBI-355676;
CC       P49715; P03122: E2; Xeno; NbExp=2; IntAct=EBI-1172054, EBI-7028618;
CC       P49715; P06422: E2; Xeno; NbExp=4; IntAct=EBI-1172054, EBI-7136851;
CC       P49715-1; Q96RU8-1: TRIB1; NbExp=2; IntAct=EBI-16180754, EBI-16180744;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11242107}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus, nucleolus
CC       {ECO:0000269|PubMed:20075868}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=4;
CC       Name=1;
CC         IsoId=P49715-1; Sequence=Displayed;
CC       Name=2; Synonyms=C/EBPalpha-p42 {ECO:0000303|PubMed:11242107};
CC         IsoId=P49715-2; Sequence=VSP_057548;
CC       Name=3; Synonyms=C/EBPalpha-p30 {ECO:0000303|PubMed:11242107};
CC         IsoId=P49715-3; Sequence=VSP_057547;
CC       Name=4; Synonyms=extended-C/EBPalpha {ECO:0000303|PubMed:20075868};
CC         IsoId=P49715-4; Sequence=VSP_057607;
CC   -!- DOMAIN: The recognition sequence (54-72) is required for interaction
CC       with TRIB1. {ECO:0000269|PubMed:26455797}.
CC   -!- PTM: Phosphorylation at Ser-190 is required for interaction with CDK2,
CC       CDK4 and SWI/SNF complex leading to cell cycle inhibition.
CC       Dephosphorylated at Ser-190 by protein phosphatase 2A (PP2A) through
CC       PI3K/AKT signaling pathway regulation (PubMed:15107404).
CC       Phosphorylation at Thr-226 and Thr-230 by GSK3 is constitutive in
CC       adipose tissue and lung. In liver, both Thr-226 and Thr-230 are
CC       phosphorylated only during feeding but not during fasting.
CC       Phosphorylation of the GSK3 consensus sites selectively decreases
CC       transactivation activity on IRE-controlled promoters.
CC       {ECO:0000250|UniProtKB:P53566}.
CC   -!- PTM: Sumoylated, sumoylation blocks the inhibitory effect on cell
CC       proliferation by disrupting the interaction with SMARCA2.
CC       {ECO:0000250|UniProtKB:P05554}.
CC   -!- PTM: Ubiquitinated by COP1 upon interaction with TRIB1.
CC       {ECO:0000303|PubMed:27041596}.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of
CC       acute leukemia, a cancer of the white blood cells. AML is a malignant
CC       disease of bone marrow characterized by maturational arrest of
CC       hematopoietic precursors at an early stage of development. Clonal
CC       expansion of myeloid blasts occurs in bone marrow, blood, and other
CC       tissue. Myelogenous leukemias develop from changes in cells that
CC       normally produce neutrophils, basophils, eosinophils and monocytes.
CC       {ECO:0000269|PubMed:11242107, ECO:0000269|PubMed:12661007,
CC       ECO:0000269|PubMed:15575056}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the bZIP family. C/EBP subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/40050/CEBPA";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/cebpa/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U34070; AAC50235.1; -; Genomic_DNA.
DR   EMBL; Y11525; CAA72289.1; -; mRNA.
DR   EMBL; EU048234; ABS82765.1; -; Genomic_DNA.
DR   EMBL; AC008738; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC027902; AAH27902.1; -; mRNA.
DR   CCDS; CCDS54243.1; -. [P49715-1]
DR   PIR; JC4311; JC4311.
DR   RefSeq; NP_001272758.1; NM_001285829.1. [P49715-3]
DR   RefSeq; NP_001274353.1; NM_001287424.1. [P49715-4]
DR   RefSeq; NP_001274364.1; NM_001287435.1. [P49715-2]
DR   RefSeq; NP_004355.2; NM_004364.4. [P49715-1]
DR   PDB; 6DC0; X-ray; 2.80 A; A/B=51-75.
DR   PDBsum; 6DC0; -.
DR   AlphaFoldDB; P49715; -.
DR   SMR; P49715; -.
DR   BioGRID; 107479; 110.
DR   ComplexPortal; CPX-509; bZIP transcription factor complex, CEBPA-CEBPB.
DR   ComplexPortal; CPX-6469; bZIP transcription factor complex, ATF3-CEBPA.
DR   ComplexPortal; CPX-6525; bZIP transcription factor complex, ATF4-CEBPA.
DR   ComplexPortal; CPX-6586; bZIP transcription factor complex, ATF5-CEBPA.
DR   ComplexPortal; CPX-69; bZIP transcription factor complex, CEBPA-DDIT3.
DR   ComplexPortal; CPX-7006; bZIP transcription factor complex, BATF-CEBPA.
DR   ComplexPortal; CPX-7065; bZIP transcription factor complex, BATF2-CEBPA.
DR   ComplexPortal; CPX-7095; bZIP transcription factor complex, BATF3-CEBPA.
DR   ComplexPortal; CPX-71; bZIP transcription factor complex, CEBPA-CEBPA.
DR   CORUM; P49715; -.
DR   DIP; DIP-37882N; -.
DR   ELM; P49715; -.
DR   IntAct; P49715; 31.
DR   MINT; P49715; -.
DR   STRING; 9606.ENSP00000427514; -.
DR   iPTMnet; P49715; -.
DR   PhosphoSitePlus; P49715; -.
DR   BioMuta; CEBPA; -.
DR   DMDM; 166898082; -.
DR   EPD; P49715; -.
DR   jPOST; P49715; -.
DR   MassIVE; P49715; -.
DR   MaxQB; P49715; -.
DR   PaxDb; 9606-ENSP00000427514; -.
DR   PeptideAtlas; P49715; -.
DR   ProteomicsDB; 56054; -.
DR   Antibodypedia; 38083; 828 antibodies from 40 providers.
DR   DNASU; 1050; -.
DR   Ensembl; ENST00000498907.3; ENSP00000427514.1; ENSG00000245848.3. [P49715-1]
DR   GeneID; 1050; -.
DR   KEGG; hsa:1050; -.
DR   MANE-Select; ENST00000498907.3; ENSP00000427514.1; NM_004364.5; NP_004355.2.
DR   UCSC; uc002nun.4; human. [P49715-1]
DR   AGR; HGNC:1833; -.
DR   CTD; 1050; -.
DR   DisGeNET; 1050; -.
DR   GeneCards; CEBPA; -.
DR   GeneReviews; CEBPA; -.
DR   HGNC; HGNC:1833; CEBPA.
DR   HPA; ENSG00000245848; Group enriched (adipose tissue, breast, liver, skin).
DR   MalaCards; CEBPA; -.
DR   MIM; 116897; gene.
DR   MIM; 601626; phenotype.
DR   neXtProt; NX_P49715; -.
DR   OpenTargets; ENSG00000245848; -.
DR   Orphanet; 319480; Acute myeloid leukemia with CEBPA somatic mutations.
DR   Orphanet; 102724; Acute myeloid leukemia with t(8;21)(q22;q22) translocation.
DR   Orphanet; 319465; Inherited acute myeloid leukemia.
DR   PharmGKB; PA26376; -.
DR   VEuPathDB; HostDB:ENSG00000245848; -.
DR   eggNOG; KOG3119; Eukaryota.
DR   GeneTree; ENSGT00940000162646; -.
DR   HOGENOM; CLU_043327_2_0_1; -.
DR   InParanoid; P49715; -.
DR   OMA; QMPHLQY; -.
DR   OrthoDB; 2959124at2759; -.
DR   PhylomeDB; P49715; -.
DR   TreeFam; TF105008; -.
DR   PathwayCommons; P49715; -.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   SignaLink; P49715; -.
DR   SIGNOR; P49715; -.
DR   BioGRID-ORCS; 1050; 82 hits in 1196 CRISPR screens.
DR   ChiTaRS; CEBPA; human.
DR   GeneWiki; CEBPA; -.
DR   GenomeRNAi; 1050; -.
DR   Pharos; P49715; Tbio.
DR   PRO; PR:P49715; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P49715; Protein.
DR   Bgee; ENSG00000245848; Expressed in nipple and 187 other cell types or tissues.
DR   Genevisible; P49715; HS.
DR   GO; GO:1990647; C:C/EBP complex; IPI:ComplexPortal.
DR   GO; GO:0036488; C:CHOP-C/EBP complex; IPI:ComplexPortal.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IMP:BHF-UCL.
DR   GO; GO:0005667; C:transcription regulator complex; IDA:ARUK-UCL.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IMP:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0001163; F:RNA polymerase I transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ARUK-UCL.
DR   GO; GO:0097677; F:STAT family protein binding; IPI:UniProtKB.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB.
DR   GO; GO:0050873; P:brown fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0071285; P:cellular response to lithium ion; IEA:Ensembl.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; NAS:UniProtKB.
DR   GO; GO:0006351; P:DNA-templated transcription; IEA:InterPro.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0002070; P:epithelial cell maturation; IEA:Ensembl.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0030851; P:granulocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0140467; P:integrated stress response signaling; NAS:ComplexPortal.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0055088; P:lipid homeostasis; ISS:UniProtKB.
DR   GO; GO:0001889; P:liver development; ISS:UniProtKB.
DR   GO; GO:0030324; P:lung development; ISS:UniProtKB.
DR   GO; GO:0030225; P:macrophage differentiation; IEA:Ensembl.
DR   GO; GO:0007005; P:mitochondrion organization; IEA:Ensembl.
DR   GO; GO:0030099; P:myeloid cell differentiation; IBA:GO_Central.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:1902034; P:negative regulation of hematopoietic stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:ComplexPortal.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:2000144; P:positive regulation of DNA-templated transcription initiation; IDA:UniProtKB.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISS:ARUK-UCL.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; ISS:ARUK-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006360; P:transcription by RNA polymerase I; IDA:UniProtKB.
DR   GO; GO:0000050; P:urea cycle; IEA:Ensembl.
DR   GO; GO:0050872; P:white fat cell differentiation; IEA:Ensembl.
DR   CDD; cd14711; bZIP_CEBPA; 1.
DR   Gene3D; 1.20.5.170; -; 1.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR046347; bZIP_sf.
DR   InterPro; IPR031106; C/EBP.
DR   InterPro; IPR016468; C/EBP_chordates.
DR   PANTHER; PTHR23334; CCAAT/ENHANCER BINDING PROTEIN; 1.
DR   PANTHER; PTHR23334:SF5; CCAAT/ENHANCER-BINDING PROTEIN ALPHA; 1.
DR   Pfam; PF07716; bZIP_2; 1.
DR   PIRSF; PIRSF005879; CCAAT/enhancer-binding; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   SUPFAM; SSF57959; Leucine zipper domain; 1.
DR   PROSITE; PS50217; BZIP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative initiation;
KW   Developmental protein; Disease variant; DNA-binding;
KW   Host-virus interaction; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..358
FT                   /note="CCAAT/enhancer-binding protein alpha"
FT                   /id="PRO_0000076613"
FT   DOMAIN          282..345
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   DNA_BIND        285..300
FT                   /evidence="ECO:0000250|UniProtKB:P05554"
FT   REGION          1..70
FT                   /note="Required to repress E2F1:TFDP1-mediated
FT                   transcription, to inhibit cell cycle and to induce
FT                   adipocyte differentiation"
FT                   /evidence="ECO:0000250|UniProtKB:P05554"
FT   REGION          1..55
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          54..72
FT                   /note="Required for interaction with TRIB1"
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   REGION          128..204
FT                   /note="Required to induce adipocyte differentiation"
FT                   /evidence="ECO:0000250|UniProtKB:P05554"
FT   REGION          178..201
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          182..198
FT                   /note="Required to functionally cooperate with SREBF1 in
FT                   promoter activation"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   REGION          217..291
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          244..358
FT                   /note="Interaction with FOXO1"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   REGION          286..313
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          317..345
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   COMPBIAS        179..201
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        222..242
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        277..291
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         161
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         190
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15107404"
FT   MOD_RES         226
FT                   /note="Phosphothreonine; by GSK3"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   MOD_RES         230
FT                   /note="Phosphothreonine; by GSK3"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   MOD_RES         234
FT                   /note="Phosphoserine; by GSK3"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   CROSSLNK        161
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..119
FT                   /note="Missing (in isoform 3)"
FT                   /id="VSP_057547"
FT   VAR_SEQ         1..14
FT                   /note="Missing (in isoform 2)"
FT                   /id="VSP_057548"
FT   VAR_SEQ         1
FT                   /note="M -> MRGRGRAGSPGGRRRRPAQAGGRRGSPCRENSNSPM (in
FT                   isoform 4)"
FT                   /id="VSP_057607"
FT   VARIANT         84
FT                   /note="H -> L (in AML; no effect on expression; no effect
FT                   on DNA-binding or transactivation activity;
FT                   dbSNP:rs28931590)"
FT                   /evidence="ECO:0000269|PubMed:11242107"
FT                   /id="VAR_072677"
FT   VARIANT         312
FT                   /note="Q -> QK (in AML; nuclear; no effect on expression;
FT                   loss of DNA-binding and transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:11242107"
FT                   /id="VAR_072678"
FT   MUTAGEN         55
FT                   /note="I->A: Decreased interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         57
FT                   /note="E->T: No effect on interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         58
FT                   /note="H->D: No effect on interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         59
FT                   /note="E->A: Decreased interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         61
FT                   /note="S->A: Decreased interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         62
FT                   /note="I->A: Decreased interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         63
FT                   /note="D->A: No effect on interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         64
FT                   /note="I->A: Decreased interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         65
FT                   /note="S->A: No effect on interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         67
FT                   /note="Y->A: Decreased interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         67
FT                   /note="Y->F: No effect on interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         68
FT                   /note="I->A: Decreased interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   MUTAGEN         69
FT                   /note="D->A: No effect on interaction with TRIB1."
FT                   /evidence="ECO:0000269|PubMed:26455797"
FT   CONFLICT        40..41
FT                   /note="AQ -> PK (in Ref. 1; AAC50235)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        95..98
FT                   /note="VGPT -> WAH (in Ref. 2; CAA72289)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        241
FT                   /note="L -> V (in Ref. 2; CAA72289)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        248..250
FT                   /note="GPG -> ALA (in Ref. 2; CAA72289)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        269
FT                   /note="S -> T (in Ref. 1; AAC50235)"
FT                   /evidence="ECO:0000305"
FT   HELIX           64..66
FT                   /evidence="ECO:0007829|PDB:6DC0"
FT   HELIX           70..73
FT                   /evidence="ECO:0007829|PDB:6DC0"
SQ   SEQUENCE   358 AA;  37561 MW;  574C0A049E25BCAC CRC64;
     MESADFYEAE PRPPMSSHLQ SPPHAPSSAA FGFPRGAGPA QPPAPPAAPE PLGGICEHET
     SIDISAYIDP AAFNDEFLAD LFQHSRQQEK AKAAVGPTGG GGGGDFDYPG APAGPGGAVM
     PGGAHGPPPG YGCAAAGYLD GRLEPLYERV GAPALRPLVI KQEPREEDEA KQLALAGLFP
     YQPPPPPPPS HPHPHPPPAH LAAPHLQFQI AHCGQTTMHL QPGHPTPPPT PVPSPHPAPA
     LGAAGLPGPG SALKGLGAAH PDLRASGGSG AGKAKKSVDK NSNEYRVRRE RNNIAVRKSR
     DKAKQRNVET QQKVLELTSD NDRLRKRVEQ LSRELDTLRG IFRQLPESSL VKAMGNCA
//
ID   IDHC_HUMAN              Reviewed;         414 AA.
AC   O75874; Q567U4; Q6FHQ6; Q7Z3V0; Q93090; Q9NTJ9; Q9UKW8;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2002, sequence version 2.
DT   24-JAN-2024, entry version 230.
DE   RecName: Full=Isocitrate dehydrogenase [NADP] cytoplasmic;
DE            Short=IDH;
DE            Short=IDH1 {ECO:0000303|PubMed:19935646};
DE            EC=1.1.1.42 {ECO:0000269|PubMed:10521434, ECO:0000269|PubMed:19935646};
DE   AltName: Full=Cytosolic NADP-isocitrate dehydrogenase;
DE   AltName: Full=IDPc;
DE   AltName: Full=NADP(+)-specific ICDH;
DE   AltName: Full=Oxalosuccinate decarboxylase;
GN   Name=IDH1; Synonyms=PICD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9866202; DOI=10.1093/oxfordjournals.molbev.a025894;
RA   Nekrutenko A., Hillis D.M., Patton J.C., Bradley R.D., Baker R.J.;
RT   "Cytosolic isocitrate dehydrogenase in humans, mice, and voles and
RT   phylogenetic analysis of the enzyme family.";
RL   Mol. Biol. Evol. 15:1674-1684(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, FUNCTION, CATALYTIC
RP   ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10521434; DOI=10.1074/jbc.274.43.30527;
RA   Geisbrecht B.V., Gould S.J.;
RT   "The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-
RT   dependent isocitrate dehydrogenase.";
RL   J. Biol. Chem. 274:30527-30533(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 5-20; 30-49; 101-109; 120-132; 141-212; 223-233;
RP   250-270; 322-338 AND 389-400, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 100-253.
RA   Kullmann F., Vogt T., Welsh J., McClelland M.;
RT   "Differential gene expression in epithelial cells induced by bile salts:
RT   identification by RNA arbitrarily primed PCR.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-321, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-42, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [16] {ECO:0007744|PDB:1T09, ECO:0007744|PDB:1T0L}
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEXES WITH NADP; ISOCITRATE
RP   AND CALCIUM IONS, AND SUBUNIT.
RX   PubMed=15173171; DOI=10.1074/jbc.m404298200;
RA   Xu X., Zhao J., Xu Z., Peng B., Huang Q., Arnold E., Ding J.;
RT   "Structures of human cytosolic NADP-dependent isocitrate dehydrogenase
RT   reveal a novel self-regulatory mechanism of activity.";
RL   J. Biol. Chem. 279:33946-33957(2004).
RN   [17] {ECO:0007744|PDB:3INM}
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF VARIANT HIS-132 IN COMPLEX WITH
RP   NADP AND ALPHA-KETOGLUTARATE, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT,
RP   COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, CHARACTERIZATION OF VARIANTS
RP   CYS-132; HIS-132; LEU-132 AND SER-132, INVOLVEMENT IN DISEASE, AND
RP   INVOLVEMENT IN GLM.
RX   PubMed=19935646; DOI=10.1038/nature08617;
RA   Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M.,
RA   Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M.,
RA   Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C.,
RA   Thompson C.B., Vander Heiden M.G., Su S.M.;
RT   "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.";
RL   Nature 462:739-744(2009).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-132.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [19]
RP   VARIANTS HIS-132 AND SER-132.
RX   PubMed=18772396; DOI=10.1126/science.1164382;
RA   Parsons D.W., Jones S., Zhang X., Lin J.C.-H., Leary R.J., Angenendt P.,
RA   Mankoo P., Carter H., Siu I.-M., Gallia G.L., Olivi A., McLendon R.,
RA   Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H.,
RA   Diaz L.A. Jr., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K.N.,
RA   Shinjo S.M.O., Yan H., Riggins G.J., Bigner D.D., Karchin R.,
RA   Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E.,
RA   Kinzler K.W.;
RT   "An integrated genomic analysis of human glioblastoma multiforme.";
RL   Science 321:1807-1812(2008).
RN   [20]
RP   VARIANTS CYS-132; GLY-132 AND LEU-132, AND INVOLVEMENT IN GLM.
RX   PubMed=19117336; DOI=10.1002/humu.20937;
RA   Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T.,
RA   Vandertop W.P., Frattini M., Molinari F., Knowles M., Cerrato A.,
RA   Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S.,
RA   Marchetti A., Bardelli A.;
RT   "IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-
RT   grade gliomas but not in other solid tumors.";
RL   Hum. Mutat. 30:7-11(2009).
RN   [21]
RP   VARIANTS CYS-132; GLY-132 AND HIS-132, INVOLVEMENT IN DISEASE, AND
RP   CHARACTERIZATION OF VARIANT CYS-132.
RX   PubMed=26161668; DOI=10.1371/journal.pone.0131998;
RA   Jin Y., Elalaf H., Watanabe M., Tamaki S., Hineno S., Matsunaga K.,
RA   Woltjen K., Kobayashi Y., Nagata S., Ikeya M., Kato T. Jr., Okamoto T.,
RA   Matsuda S., Toguchida J.;
RT   "Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in
RT   Association with Gene-Specific Histone Modifications to Cartilage- and
RT   Bone-Related Genes.";
RL   PLoS ONE 10:E0131998-E0131998(2015).
CC   -!- FUNCTION: Catalyzes the NADP(+)-dependent oxidative decarboxylation of
CC       isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate),
CC       which is required by other enzymes such as the phytanoyl-CoA
CC       dioxygenase (PubMed:10521434, PubMed:19935646). Plays a critical role
CC       in the generation of NADPH, an important cofactor in many biosynthesis
CC       pathways (PubMed:10521434). May act as a corneal epithelial crystallin
CC       and may be involved in maintaining corneal epithelial transparency (By
CC       similarity). {ECO:0000250|UniProtKB:Q9XSG3,
CC       ECO:0000269|PubMed:10521434, ECO:0000269|PubMed:19935646,
CC       ECO:0000303|PubMed:10521434}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-threo-isocitrate + NADP(+) = 2-oxoglutarate + CO2 + NADPH;
CC         Xref=Rhea:RHEA:19629, ChEBI:CHEBI:15562, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:16810, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.42;
CC         Evidence={ECO:0000269|PubMed:10521434, ECO:0000269|PubMed:19935646};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19630;
CC         Evidence={ECO:0000269|PubMed:19935646};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:19935646};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:19935646};
CC       Note=Binds 1 Mg(2+) or Mn(2+) ion per subunit.
CC       {ECO:0000269|PubMed:19935646};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=112 uM for NADP(+) {ECO:0000269|PubMed:10521434};
CC         KM=49 uM for NADP(+) {ECO:0000269|PubMed:19935646};
CC         KM=29 uM for magnesium chloride {ECO:0000269|PubMed:19935646};
CC         KM=76 uM for isocitrate {ECO:0000269|PubMed:10521434};
CC         KM=65 uM for isocitrate {ECO:0000269|PubMed:19935646};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15173171,
CC       ECO:0000269|PubMed:19935646}.
CC   -!- INTERACTION:
CC       O75874; P0DP23: CALM1; NbExp=7; IntAct=EBI-715695, EBI-25817233;
CC       O75874; P27797: CALR; NbExp=3; IntAct=EBI-715695, EBI-1049597;
CC       O75874; P36957: DLST; NbExp=3; IntAct=EBI-715695, EBI-351007;
CC       O75874; O75874: IDH1; NbExp=4; IntAct=EBI-715695, EBI-715695;
CC       O75874; Q8TDX7: NEK7; NbExp=3; IntAct=EBI-715695, EBI-1055945;
CC       O75874; P16284: PECAM1; NbExp=3; IntAct=EBI-715695, EBI-716404;
CC       O75874; P17612: PRKACA; NbExp=3; IntAct=EBI-715695, EBI-476586;
CC       O75874; P50454: SERPINH1; NbExp=3; IntAct=EBI-715695, EBI-350723;
CC       O75874; P37173: TGFBR2; NbExp=3; IntAct=EBI-715695, EBI-296151;
CC       O75874; Q05086-3: UBE3A; NbExp=3; IntAct=EBI-715695, EBI-11026619;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:10521434}.
CC       Peroxisome {ECO:0000269|PubMed:10521434}.
CC   -!- PTM: Acetylation at Lys-374 dramatically reduces catalytic activity.
CC       {ECO:0000250}.
CC   -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant
CC       central nervous system neoplasms derived from glial cells. They
CC       comprise astrocytomas and glioblastoma multiforme that are derived from
CC       astrocytes, oligodendrogliomas derived from oligodendrocytes and
CC       ependymomas derived from ependymocytes. {ECO:0000269|PubMed:19117336,
CC       ECO:0000269|PubMed:19935646}. Note=The gene represented in this entry
CC       is involved in disease pathogenesis. Mutations affecting Arg-132 are
CC       tissue-specific, and suggest that this residue plays a unique role in
CC       the development of high-grade gliomas. Mutations of Arg-132 to Cys,
CC       His, Leu or Ser abolish magnesium binding and abolish the conversion of
CC       isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is
CC       converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2-
CC       hydroxyglutarate are correlated with an elevated risk of malignant
CC       brain tumors. {ECO:0000269|PubMed:19935646}.
CC   -!- DISEASE: Note=Genetic variations are associated with cartilaginous
CC       tumors such as enchondroma or chondrosarcoma. Mutations of Arg-132 to
CC       Cys, Gly or His abolish the conversion of isocitrate to alpha-
CC       ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-
CC       hydroxyglutarate. {ECO:0000269|PubMed:26161668}.
CC   -!- SIMILARITY: Belongs to the isocitrate and isopropylmalate
CC       dehydrogenases family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Isocitrate dehydrogenase entry;
CC       URL="https://en.wikipedia.org/wiki/Isocitrate_dehydrogenase";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF020038; AAD02918.1; -; mRNA.
DR   EMBL; AF113917; AAD29284.1; -; mRNA.
DR   EMBL; AL136702; CAB66637.1; -; mRNA.
DR   EMBL; CR541695; CAG46496.1; -; mRNA.
DR   EMBL; BX537411; CAD97653.1; -; mRNA.
DR   EMBL; AC016697; AAX93221.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70439.1; -; Genomic_DNA.
DR   EMBL; BC012846; AAH12846.1; -; mRNA.
DR   EMBL; BC093020; AAH93020.1; -; mRNA.
DR   EMBL; U62389; AAB17375.1; -; mRNA.
DR   CCDS; CCDS2381.1; -.
DR   PIR; T46280; T46280.
DR   RefSeq; NP_001269315.1; NM_001282386.1.
DR   RefSeq; NP_001269316.1; NM_001282387.1.
DR   RefSeq; NP_005887.2; NM_005896.3.
DR   PDB; 1T09; X-ray; 2.70 A; A/B=1-414.
DR   PDB; 1T0L; X-ray; 2.41 A; A/B/C/D=1-414.
DR   PDB; 3INM; X-ray; 2.10 A; A/B/C=1-414.
DR   PDB; 3MAP; X-ray; 2.80 A; A/B=1-414.
DR   PDB; 3MAR; X-ray; 3.41 A; A/B=1-414.
DR   PDB; 3MAS; X-ray; 3.20 A; A/B=1-414.
DR   PDB; 4I3K; X-ray; 3.31 A; A/B=1-414.
DR   PDB; 4I3L; X-ray; 3.29 A; A/B=1-414.
DR   PDB; 4KZO; X-ray; 2.20 A; A/B/C=1-414.
DR   PDB; 4L03; X-ray; 2.10 A; A/B/C=1-414.
DR   PDB; 4L04; X-ray; 2.87 A; A/B/C/D/E/F=1-414.
DR   PDB; 4L06; X-ray; 2.28 A; A/B/C/D/E/F=1-414.
DR   PDB; 4UMX; X-ray; 1.88 A; A/B=1-414.
DR   PDB; 4UMY; X-ray; 2.07 A; A/B=1-414.
DR   PDB; 4XRX; X-ray; 3.20 A; A/B=1-414.
DR   PDB; 4XS3; X-ray; 3.29 A; A/B=1-414.
DR   PDB; 5DE1; X-ray; 2.25 A; A/B=2-414.
DR   PDB; 5GIR; X-ray; 1.93 A; C/D=126-137.
DR   PDB; 5K10; EM; 3.80 A; A/B=3-413.
DR   PDB; 5K11; EM; 3.80 A; A/B=3-413.
DR   PDB; 5L57; X-ray; 2.69 A; A=1-414.
DR   PDB; 5L58; X-ray; 3.04 A; A=1-414.
DR   PDB; 5LGE; X-ray; 2.70 A; A/B/C/D=1-414.
DR   PDB; 5SUN; X-ray; 2.48 A; A/B=1-414.
DR   PDB; 5SVF; X-ray; 2.34 A; A/B/C/D=1-414.
DR   PDB; 5TQH; X-ray; 2.20 A; A/B/C/D=1-414.
DR   PDB; 5YFM; X-ray; 2.40 A; A/B/C=1-414.
DR   PDB; 5YFN; X-ray; 2.50 A; A/B=1-414.
DR   PDB; 6ADG; X-ray; 3.00 A; A/B/C=1-414.
DR   PDB; 6B0Z; X-ray; 2.33 A; A/B/C/D=1-414.
DR   PDB; 6BKX; X-ray; 1.65 A; A/B/C=1-414.
DR   PDB; 6BKY; X-ray; 2.17 A; A/B/C/D/E/F=1-414.
DR   PDB; 6BKZ; X-ray; 2.01 A; A/B=1-414.
DR   PDB; 6BL0; X-ray; 2.17 A; A/B/C=1-414.
DR   PDB; 6BL1; X-ray; 2.02 A; A/B/C=1-414.
DR   PDB; 6BL2; X-ray; 1.92 A; A/B/C=1-414.
DR   PDB; 6IO0; X-ray; 2.20 A; A/B=1-414.
DR   PDB; 6O2Y; X-ray; 2.80 A; A/B/C=1-414.
DR   PDB; 6O2Z; X-ray; 2.50 A; A/B=1-414.
DR   PDB; 6PAY; X-ray; 2.20 A; A/B/C/D=1-414.
DR   PDB; 6Q6F; X-ray; 3.30 A; A/B=1-414.
DR   PDB; 6U4J; X-ray; 2.11 A; A/B=1-414.
DR   PDB; 6VEI; X-ray; 2.10 A; A/B=1-414.
DR   PDB; 6VG0; X-ray; 2.66 A; A/B/C=1-414.
DR   PDB; 7PJM; X-ray; 2.10 A; A/B/C=1-414.
DR   PDB; 7PJN; X-ray; 2.45 A; A/B/C/D=1-414.
DR   PDB; 8BAY; X-ray; 2.35 A; A/B/C=1-414.
DR   PDB; 8HB9; X-ray; 2.80 A; AAA/BBB/CCC/DDD=1-414.
DR   PDBsum; 1T09; -.
DR   PDBsum; 1T0L; -.
DR   PDBsum; 3INM; -.
DR   PDBsum; 3MAP; -.
DR   PDBsum; 3MAR; -.
DR   PDBsum; 3MAS; -.
DR   PDBsum; 4I3K; -.
DR   PDBsum; 4I3L; -.
DR   PDBsum; 4KZO; -.
DR   PDBsum; 4L03; -.
DR   PDBsum; 4L04; -.
DR   PDBsum; 4L06; -.
DR   PDBsum; 4UMX; -.
DR   PDBsum; 4UMY; -.
DR   PDBsum; 4XRX; -.
DR   PDBsum; 4XS3; -.
DR   PDBsum; 5DE1; -.
DR   PDBsum; 5GIR; -.
DR   PDBsum; 5K10; -.
DR   PDBsum; 5K11; -.
DR   PDBsum; 5L57; -.
DR   PDBsum; 5L58; -.
DR   PDBsum; 5LGE; -.
DR   PDBsum; 5SUN; -.
DR   PDBsum; 5SVF; -.
DR   PDBsum; 5TQH; -.
DR   PDBsum; 5YFM; -.
DR   PDBsum; 5YFN; -.
DR   PDBsum; 6ADG; -.
DR   PDBsum; 6B0Z; -.
DR   PDBsum; 6BKX; -.
DR   PDBsum; 6BKY; -.
DR   PDBsum; 6BKZ; -.
DR   PDBsum; 6BL0; -.
DR   PDBsum; 6BL1; -.
DR   PDBsum; 6BL2; -.
DR   PDBsum; 6IO0; -.
DR   PDBsum; 6O2Y; -.
DR   PDBsum; 6O2Z; -.
DR   PDBsum; 6PAY; -.
DR   PDBsum; 6Q6F; -.
DR   PDBsum; 6U4J; -.
DR   PDBsum; 6VEI; -.
DR   PDBsum; 6VG0; -.
DR   PDBsum; 7PJM; -.
DR   PDBsum; 7PJN; -.
DR   PDBsum; 8BAY; -.
DR   PDBsum; 8HB9; -.
DR   AlphaFoldDB; O75874; -.
DR   EMDB; EMD-8192; -.
DR   EMDB; EMD-8193; -.
DR   SMR; O75874; -.
DR   BioGRID; 109643; 113.
DR   CORUM; O75874; -.
DR   DIP; DIP-59311N; -.
DR   IntAct; O75874; 33.
DR   MINT; O75874; -.
DR   STRING; 9606.ENSP00000390265; -.
DR   BindingDB; O75874; -.
DR   ChEMBL; CHEMBL2007625; -.
DR   DrugBank; DB09374; Indocyanine green acid form.
DR   DrugBank; DB01727; Isocitric Acid.
DR   DrugBank; DB14568; Ivosidenib.
DR   DrugBank; DB03461; Nicotinamide adenine dinucleotide phosphate.
DR   DrugBank; DB16267; Olutasidenib.
DR   DrugCentral; O75874; -.
DR   GuidetoPHARMACOLOGY; 2884; -.
DR   GlyGen; O75874; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; O75874; -.
DR   MetOSite; O75874; -.
DR   PhosphoSitePlus; O75874; -.
DR   SwissPalm; O75874; -.
DR   BioMuta; IDH1; -.
DR   OGP; O75874; -.
DR   REPRODUCTION-2DPAGE; IPI00027223; -.
DR   UCD-2DPAGE; O75874; -.
DR   CPTAC; CPTAC-2741; -.
DR   EPD; O75874; -.
DR   jPOST; O75874; -.
DR   MassIVE; O75874; -.
DR   PaxDb; 9606-ENSP00000390265; -.
DR   PeptideAtlas; O75874; -.
DR   PRIDE; O75874; -.
DR   ProteomicsDB; 50234; -.
DR   Pumba; O75874; -.
DR   ABCD; O75874; 4 sequenced antibodies.
DR   Antibodypedia; 34198; 1117 antibodies from 47 providers.
DR   DNASU; 3417; -.
DR   Ensembl; ENST00000345146.7; ENSP00000260985.2; ENSG00000138413.14.
DR   Ensembl; ENST00000415913.5; ENSP00000390265.1; ENSG00000138413.14.
DR   Ensembl; ENST00000446179.5; ENSP00000410513.1; ENSG00000138413.14.
DR   GeneID; 3417; -.
DR   KEGG; hsa:3417; -.
DR   MANE-Select; ENST00000345146.7; ENSP00000260985.2; NM_005896.4; NP_005887.2.
DR   AGR; HGNC:5382; -.
DR   CTD; 3417; -.
DR   DisGeNET; 3417; -.
DR   GeneCards; IDH1; -.
DR   HGNC; HGNC:5382; IDH1.
DR   HPA; ENSG00000138413; Tissue enhanced (liver).
DR   MalaCards; IDH1; -.
DR   MIM; 137800; phenotype.
DR   MIM; 147700; gene.
DR   neXtProt; NX_O75874; -.
DR   OpenTargets; ENSG00000138413; -.
DR   Orphanet; 86845; Acute myeloid leukaemia with myelodysplasia-related features.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 163634; Maffucci syndrome.
DR   Orphanet; 99646; Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.
DR   Orphanet; 296; Ollier disease.
DR   PharmGKB; PA29630; -.
DR   VEuPathDB; HostDB:ENSG00000138413; -.
DR   eggNOG; KOG1526; Eukaryota.
DR   GeneTree; ENSGT00390000012547; -.
DR   HOGENOM; CLU_023296_1_1_1; -.
DR   InParanoid; O75874; -.
DR   OMA; HGTVQRH; -.
DR   OrthoDB; 423at2759; -.
DR   PhylomeDB; O75874; -.
DR   TreeFam; TF300428; -.
DR   BioCyc; MetaCyc:HS06502-MONOMER; -.
DR   BRENDA; 1.1.1.42; 2681.
DR   PathwayCommons; O75874; -.
DR   Reactome; R-HSA-2978092; Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate.
DR   Reactome; R-HSA-389542; NADPH regeneration.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-9033241; Peroxisomal protein import.
DR   Reactome; R-HSA-9818025; NFE2L2 regulating TCA cycle genes.
DR   SABIO-RK; O75874; -.
DR   SignaLink; O75874; -.
DR   SIGNOR; O75874; -.
DR   BioGRID-ORCS; 3417; 19 hits in 1157 CRISPR screens.
DR   ChiTaRS; IDH1; human.
DR   EvolutionaryTrace; O75874; -.
DR   GeneWiki; IDH1; -.
DR   GenomeRNAi; 3417; -.
DR   Pharos; O75874; Tclin.
DR   PRO; PR:O75874; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O75874; Protein.
DR   Bgee; ENSG00000138413; Expressed in corpus epididymis and 212 other cell types or tissues.
DR   ExpressionAtlas; O75874; baseline and differential.
DR   Genevisible; O75874; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005782; C:peroxisomal matrix; TAS:Reactome.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004450; F:isocitrate dehydrogenase (NADP+) activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IEA:InterPro.
DR   GO; GO:0050661; F:NADP binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; IDA:UniProtKB.
DR   GO; GO:0008585; P:female gonad development; IEA:Ensembl.
DR   GO; GO:0006749; P:glutathione metabolic process; IEA:Ensembl.
DR   GO; GO:0006097; P:glyoxylate cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006102; P:isocitrate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006739; P:NADP metabolic process; IBA:GO_Central.
DR   GO; GO:0071071; P:regulation of phospholipid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0060696; P:regulation of phospholipid catabolic process; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0048545; P:response to steroid hormone; IEA:Ensembl.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.718.10; Isopropylmalate Dehydrogenase; 1.
DR   InterPro; IPR019818; IsoCit/isopropylmalate_DH_CS.
DR   InterPro; IPR004790; Isocitrate_DH_NADP.
DR   InterPro; IPR024084; IsoPropMal-DH-like_dom.
DR   NCBIfam; TIGR00127; nadp_idh_euk; 1.
DR   PANTHER; PTHR11822:SF28; ISOCITRATE DEHYDROGENASE [NADP] CYTOPLASMIC; 1.
DR   PANTHER; PTHR11822; NADP-SPECIFIC ISOCITRATE DEHYDROGENASE; 1.
DR   Pfam; PF00180; Iso_dh; 1.
DR   PIRSF; PIRSF000108; IDH_NADP; 1.
DR   SMART; SM01329; Iso_dh; 1.
DR   SUPFAM; SSF53659; Isocitrate/Isopropylmalate dehydrogenase-like; 1.
DR   PROSITE; PS00470; IDH_IMDH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Direct protein sequencing;
KW   Glyoxylate bypass; Magnesium; Manganese; Metal-binding; NADP;
KW   Oxidoreductase; Peroxisome; Phosphoprotein; Reference proteome;
KW   Tricarboxylic acid cycle.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..414
FT                   /note="Isocitrate dehydrogenase [NADP] cytoplasmic"
FT                   /id="PRO_0000083575"
FT   BINDING         75..77
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0000269|PubMed:19935646, ECO:0007744|PDB:1T09,
FT                   ECO:0007744|PDB:1T0L, ECO:0007744|PDB:3INM,
FT                   ECO:0007744|PDB:3MAP, ECO:0007744|PDB:3MAR,
FT                   ECO:0007744|PDB:3MAS, ECO:0007744|PDB:4I3K,
FT                   ECO:0007744|PDB:4I3L, ECO:0007744|PDB:4KZO,
FT                   ECO:0007744|PDB:4L03, ECO:0007744|PDB:4L04,
FT                   ECO:0007744|PDB:4L06, ECO:0007744|PDB:4UMX,
FT                   ECO:0007744|PDB:4UMY, ECO:0007744|PDB:4XRX,
FT                   ECO:0007744|PDB:4XS3, ECO:0007744|PDB:5DE1,
FT                   ECO:0007744|PDB:5L57, ECO:0007744|PDB:5L58,
FT                   ECO:0007744|PDB:5LGE, ECO:0007744|PDB:5SUN,
FT                   ECO:0007744|PDB:5SVF, ECO:0007744|PDB:5TQH"
FT   BINDING         77
FT                   /ligand="substrate"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0007744|PDB:1T0L"
FT   BINDING         82
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0000269|PubMed:19935646, ECO:0007744|PDB:1T09,
FT                   ECO:0007744|PDB:1T0L, ECO:0007744|PDB:3INM,
FT                   ECO:0007744|PDB:3MAP, ECO:0007744|PDB:3MAR,
FT                   ECO:0007744|PDB:3MAS, ECO:0007744|PDB:4I3K,
FT                   ECO:0007744|PDB:4I3L, ECO:0007744|PDB:4KZO,
FT                   ECO:0007744|PDB:4L03, ECO:0007744|PDB:4L04,
FT                   ECO:0007744|PDB:4L06, ECO:0007744|PDB:4UMX,
FT                   ECO:0007744|PDB:4UMY, ECO:0007744|PDB:4XRX,
FT                   ECO:0007744|PDB:4XS3, ECO:0007744|PDB:5DE1,
FT                   ECO:0007744|PDB:5L57, ECO:0007744|PDB:5LGE,
FT                   ECO:0007744|PDB:5SUN, ECO:0007744|PDB:5SVF,
FT                   ECO:0007744|PDB:5TQH"
FT   BINDING         94..100
FT                   /ligand="substrate"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0007744|PDB:1T0L"
FT   BINDING         109
FT                   /ligand="substrate"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0007744|PDB:1T0L"
FT   BINDING         132
FT                   /ligand="substrate"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0007744|PDB:1T0L"
FT   BINDING         212
FT                   /ligand="substrate"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0007744|PDB:1T0L"
FT   BINDING         252
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /evidence="ECO:0000305|PubMed:15173171,
FT                   ECO:0000305|PubMed:19935646, ECO:0007744|PDB:1T0L,
FT                   ECO:0007744|PDB:3INM"
FT   BINDING         260
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0000269|PubMed:19935646, ECO:0007744|PDB:1T0L,
FT                   ECO:0007744|PDB:3INM"
FT   BINDING         275
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000305|PubMed:15173171,
FT                   ECO:0000305|PubMed:19935646, ECO:0007744|PDB:1T0L,
FT                   ECO:0007744|PDB:3INM"
FT   BINDING         279
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /ligand_note="ligand shared between two neighboring
FT                   subunits"
FT                   /note="in other chain"
FT                   /evidence="ECO:0000305|PubMed:15173171,
FT                   ECO:0000305|PubMed:19935646, ECO:0007744|PDB:1T0L,
FT                   ECO:0007744|PDB:3INM"
FT   BINDING         310..315
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0000269|PubMed:19935646, ECO:0007744|PDB:1T09,
FT                   ECO:0007744|PDB:1T0L, ECO:0007744|PDB:3INM,
FT                   ECO:0007744|PDB:3MAP, ECO:0007744|PDB:3MAR,
FT                   ECO:0007744|PDB:3MAS, ECO:0007744|PDB:4I3K,
FT                   ECO:0007744|PDB:4I3L, ECO:0007744|PDB:4KZO,
FT                   ECO:0007744|PDB:4L03, ECO:0007744|PDB:4L04,
FT                   ECO:0007744|PDB:4L06, ECO:0007744|PDB:4UMX,
FT                   ECO:0007744|PDB:4UMY, ECO:0007744|PDB:4XRX,
FT                   ECO:0007744|PDB:4XS3, ECO:0007744|PDB:5DE1,
FT                   ECO:0007744|PDB:5L57, ECO:0007744|PDB:5L58,
FT                   ECO:0007744|PDB:5LGE, ECO:0007744|PDB:5SUN,
FT                   ECO:0007744|PDB:5SVF, ECO:0007744|PDB:5TQH"
FT   BINDING         328
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:15173171,
FT                   ECO:0000269|PubMed:19935646, ECO:0007744|PDB:1T09,
FT                   ECO:0007744|PDB:1T0L, ECO:0007744|PDB:3INM,
FT                   ECO:0007744|PDB:3MAP, ECO:0007744|PDB:3MAR,
FT                   ECO:0007744|PDB:3MAS, ECO:0007744|PDB:4I3K,
FT                   ECO:0007744|PDB:4I3L, ECO:0007744|PDB:4KZO,
FT                   ECO:0007744|PDB:4L03, ECO:0007744|PDB:4L04,
FT                   ECO:0007744|PDB:4L06, ECO:0007744|PDB:4UMX,
FT                   ECO:0007744|PDB:4UMY, ECO:0007744|PDB:4XRX,
FT                   ECO:0007744|PDB:4XS3, ECO:0007744|PDB:5DE1,
FT                   ECO:0007744|PDB:5L57, ECO:0007744|PDB:5L58,
FT                   ECO:0007744|PDB:5LGE, ECO:0007744|PDB:5SUN,
FT                   ECO:0007744|PDB:5SVF, ECO:0007744|PDB:5TQH"
FT   SITE            139
FT                   /note="Critical for catalysis"
FT   SITE            212
FT                   /note="Critical for catalysis"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         42
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         81
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O88844"
FT   MOD_RES         126
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O88844"
FT   MOD_RES         224
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O88844"
FT   MOD_RES         233
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O88844"
FT   MOD_RES         243
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O88844"
FT   MOD_RES         321
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         389
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88844"
FT   MOD_RES         400
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O88844"
FT   VARIANT         132
FT                   /note="R -> C (in colorectal cancer and glioma samples;
FT                   glioblastoma multiforme; somatic mutation; found in
FT                   patients with cartilaginous tumors; abolishes magnesium
FT                   binding and alters enzyme activity so that isocitrate is no
FT                   longer converted to alpha-ketoglutarate but instead
FT                   alpha-ketoglutarate is converted to
FT                   R(-)-2-hydroxyglutarate; induces histone methylation;
FT                   enhances expression of chondrocyte-related genes; disturbs
FT                   the formation of cartilaginous matrix; inhibits osteogenic
FT                   differentiation; dbSNP:rs121913499)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:19117336, ECO:0000269|PubMed:19935646,
FT                   ECO:0000269|PubMed:26161668"
FT                   /id="VAR_036013"
FT   VARIANT         132
FT                   /note="R -> G (in a glioma sample; glioblastoma multiforme;
FT                   somatic mutation; found in patients with cartilaginous
FT                   tumors; dbSNP:rs121913499)"
FT                   /evidence="ECO:0000269|PubMed:19117336,
FT                   ECO:0000269|PubMed:26161668"
FT                   /id="VAR_055454"
FT   VARIANT         132
FT                   /note="R -> H (in a glioma sample; glioblastoma multiforme;
FT                   somatic mutation; found in patients with cartilaginous
FT                   tumors; abolishes magnesium binding and alters enzyme
FT                   activity so that isocitrate is no longer converted to
FT                   alpha-ketoglutarate but instead alpha-ketoglutarate is
FT                   converted to R(-)-2-hydroxyglutarate; dbSNP:rs121913500)"
FT                   /evidence="ECO:0000269|PubMed:18772396,
FT                   ECO:0000269|PubMed:19935646, ECO:0000269|PubMed:26161668"
FT                   /id="VAR_055455"
FT   VARIANT         132
FT                   /note="R -> L (in a glioma sample; glioblastoma multiforme;
FT                   somatic mutation; abolishes magnesium binding and alters
FT                   enzyme activity so that isocitrate is no longer converted
FT                   to alpha-ketoglutarate but instead alpha-ketoglutarate is
FT                   converted to R(-)-2-hydroxyglutarate; dbSNP:rs121913500)"
FT                   /evidence="ECO:0000269|PubMed:19117336,
FT                   ECO:0000269|PubMed:19935646"
FT                   /id="VAR_055456"
FT   VARIANT         132
FT                   /note="R -> S (in a glioma sample; glioblastoma multiforme;
FT                   somatic mutation; abolishes magnesium binding and alters
FT                   enzyme activity so that isocitrate is no longer converted
FT                   to alpha-ketoglutarate but instead alpha-ketoglutarate is
FT                   converted to R(-)-2-hydroxyglutarate; dbSNP:rs121913499)"
FT                   /evidence="ECO:0000269|PubMed:18772396,
FT                   ECO:0000269|PubMed:19935646"
FT                   /id="VAR_055457"
FT   VARIANT         178
FT                   /note="V -> I (in dbSNP:rs34218846)"
FT                   /id="VAR_049780"
FT   CONFLICT        32
FT                   /note="F -> I (in Ref. 3; CAB66637)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        126
FT                   /note="K -> E (in Ref. 3; CAB66637)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        172
FT                   /note="F -> S (in Ref. 5; CAD97653)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        174
FT                   /note="E -> G (in Ref. 5; CAD97653)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        218
FT                   /note="K -> I (in Ref. 1; AAD02918)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        307
FT                   /note="A -> S (in Ref. 6; AAH93020)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="P -> L (in Ref. 1; AAD02918)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        381
FT                   /note="K -> R (in Ref. 1; AAD02918)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..14
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           17..30
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   TURN            31..34
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          35..43
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           46..51
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   TURN            52..54
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           55..67
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          68..72
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           80..86
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           95..103
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          106..111
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          115..117
FT                   /evidence="ECO:0007829|PDB:6ADG"
FT   STRAND          120..123
FT                   /evidence="ECO:0007829|PDB:6PAY"
FT   STRAND          128..133
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           137..140
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          142..146
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          148..156
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          165..172
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          173..175
FT                   /evidence="ECO:0007829|PDB:6ADG"
FT   STRAND          177..181
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          182..184
FT                   /evidence="ECO:0007829|PDB:3MAR"
FT   HELIX           186..203
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          207..211
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   TURN            213..215
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          216..218
FT                   /evidence="ECO:0007829|PDB:6Q6F"
FT   HELIX           219..234
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           236..241
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          246..250
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           251..260
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          265..269
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           271..285
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           288..290
FT                   /evidence="ECO:0007829|PDB:4UMX"
FT   STRAND          291..296
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   STRAND          303..306
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           313..320
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           330..347
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           350..368
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           374..381
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           383..385
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           388..390
FT                   /evidence="ECO:0007829|PDB:6BKX"
FT   HELIX           394..414
FT                   /evidence="ECO:0007829|PDB:6BKX"
SQ   SEQUENCE   414 AA;  46659 MW;  60428B0B6E5851DC CRC64;
     MSKKISGGSV VEMQGDEMTR IIWELIKEKL IFPYVELDLH SYDLGIENRD ATNDQVTKDA
     AEAIKKHNVG VKCATITPDE KRVEEFKLKQ MWKSPNGTIR NILGGTVFRE AIICKNIPRL
     VSGWVKPIII GRHAYGDQYR ATDFVVPGPG KVEITYTPSD GTQKVTYLVH NFEEGGGVAM
     GMYNQDKSIE DFAHSSFQMA LSKGWPLYLS TKNTILKKYD GRFKDIFQEI YDKQYKSQFE
     AQKIWYEHRL IDDMVAQAMK SEGGFIWACK NYDGDVQSDS VAQGYGSLGM MTSVLVCPDG
     KTVEAEAAHG TVTRHYRMYQ KGQETSTNPI ASIFAWTRGL AHRAKLDNNK ELAFFANALE
     EVSIETIEAG FMTKDLAACI KGLPNVQRSD YLNTFEFMDK LGENLKIKLA QAKL
//
ID   IDHP_HUMAN              Reviewed;         452 AA.
AC   P48735; B2R6L6; B4DFL2; Q96GT3;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2002, sequence version 2.
DT   24-JAN-2024, entry version 218.
DE   RecName: Full=Isocitrate dehydrogenase [NADP], mitochondrial;
DE            Short=IDH;
DE            EC=1.1.1.42 {ECO:0000269|PubMed:22416140, ECO:0000305|PubMed:19228619};
DE   AltName: Full=ICD-M;
DE   AltName: Full=IDP;
DE   AltName: Full=NADP(+)-specific ICDH;
DE   AltName: Full=Oxalosuccinate decarboxylase;
DE   Flags: Precursor;
GN   Name=IDH2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RA   Huh T.-L., Oh I.-U., Kim Y.O., Huh J.-W., Song B.J.;
RL   Submitted (NOV-1992) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain cortex, Heart, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-67; LYS-106; LYS-155; LYS-166;
RP   LYS-180; LYS-256; LYS-263; LYS-272; LYS-275; LYS-282 AND LYS-442, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, ACETYLATION AT LYS-413, MUTAGENESIS OF
RP   LYS-413, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=22416140; DOI=10.1074/jbc.m112.355206;
RA   Yu W., Dittenhafer-Reed K.E., Denu J.M.;
RT   "SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates
RT   mitochondrial redox status.";
RL   J. Biol. Chem. 287:14078-14086(2012).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [11]
RP   VARIANTS GLM GLY-172; LYS-172 AND MET-172, FUNCTION, CATALYTIC ACTIVITY,
RP   AND CHARACTERIZATION OF VARIANTS GLM GLY-172; LYS-172 AND MET-172.
RX   PubMed=19228619; DOI=10.1056/nejmoa0808710;
RA   Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I.,
RA   Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A.,
RA   Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B.,
RA   Bigner D.D.;
RT   "IDH1 and IDH2 mutations in gliomas.";
RL   N. Engl. J. Med. 360:765-773(2009).
RN   [12]
RP   VARIANTS D2HGA2 GLN-140 AND GLY-140.
RX   PubMed=20847235; DOI=10.1126/science.1192632;
RA   Kranendijk M., Struys E.A., van Schaftingen E., Gibson K.M., Kanhai W.A.,
RA   van der Knaap M.S., Amiel J., Buist N.R., Das A.M., de Klerk J.B.,
RA   Feigenbaum A.S., Grange D.K., Hofstede F.C., Holme E., Kirk E.P.,
RA   Korman S.H., Morava E., Morris A., Smeitink J., Sukhai R.N., Vallance H.,
RA   Jakobs C., Salomons G.S.;
RT   "IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.";
RL   Science 330:336-336(2010).
RN   [13]
RP   VARIANTS GLM LEU-158; SER-162 AND LYS-172.
RX   PubMed=25495392; DOI=10.1111/neup.12187;
RA   Koh J., Cho H., Kim H., Kim S.I., Yun S., Park C.K., Lee S.H., Choi S.H.,
RA   Park S.H.;
RT   "IDH2 mutation in gliomas including novel mutation.";
RL   Neuropathology 35:236-244(2015).
RN   [14]
RP   VARIANTS SER-172; THR-172 AND TRP-172, AND INVOLVEMENT IN DISEASE.
RX   PubMed=26161668; DOI=10.1371/journal.pone.0131998;
RA   Jin Y., Elalaf H., Watanabe M., Tamaki S., Hineno S., Matsunaga K.,
RA   Woltjen K., Kobayashi Y., Nagata S., Ikeya M., Kato T. Jr., Okamoto T.,
RA   Matsuda S., Toguchida J.;
RT   "Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in
RT   Association with Gene-Specific Histone Modifications to Cartilage- and
RT   Bone-Related Genes.";
RL   PLoS ONE 10:E0131998-E0131998(2015).
CC   -!- FUNCTION: Plays a role in intermediary metabolism and energy production
CC       (PubMed:22416140, PubMed:19228619). It may tightly associate or
CC       interact with the pyruvate dehydrogenase complex (PubMed:22416140,
CC       PubMed:19228619). {ECO:0000269|PubMed:19228619,
CC       ECO:0000269|PubMed:22416140}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-threo-isocitrate + NADP(+) = 2-oxoglutarate + CO2 + NADPH;
CC         Xref=Rhea:RHEA:19629, ChEBI:CHEBI:15562, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:16810, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.42;
CC         Evidence={ECO:0000269|PubMed:22416140, ECO:0000305|PubMed:19228619};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P33198};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000250|UniProtKB:P33198};
CC       Note=Binds 1 Mg(2+) or Mn(2+) ion per subunit.
CC       {ECO:0000250|UniProtKB:P33198};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.1 uM for NADP {ECO:0000269|PubMed:22416140};
CC         KM=6 uM for isocitrate {ECO:0000269|PubMed:22416140};
CC         Vmax=42.1 umol/min/mg enzyme for NADP {ECO:0000269|PubMed:22416140};
CC         Vmax=43.4 umol/min/mg enzyme for isocitrate
CC         {ECO:0000269|PubMed:22416140};
CC   -!- SUBUNIT: Homodimer. {ECO:0000250|UniProtKB:P33198}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000250|UniProtKB:P33198}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P48735-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48735-2; Sequence=VSP_056278;
CC   -!- PTM: Acetylation at Lys-413 dramatically reduces catalytic activity.
CC       Deacetylated by SIRT3. {ECO:0000269|PubMed:22416140}.
CC   -!- DISEASE: D-2-hydroxyglutaric aciduria 2 (D2HGA2) [MIM:613657]: A
CC       neurometabolic disorder causing developmental delay, epilepsy,
CC       hypotonia, and dysmorphic features. Both a mild and a severe phenotype
CC       exist. The severe phenotype is homogeneous and is characterized by
CC       early infantile-onset epileptic encephalopathy and cardiomyopathy. The
CC       mild phenotype has a more variable clinical presentation. Diagnosis is
CC       based on the presence of an excess of D-2-hydroxyglutaric acid in the
CC       urine. {ECO:0000269|PubMed:20847235}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant
CC       central nervous system neoplasms derived from glial cells. They
CC       comprise astrocytomas and glioblastoma multiforme that are derived from
CC       astrocytes, oligodendrogliomas derived from oligodendrocytes and
CC       ependymomas derived from ependymocytes. {ECO:0000269|PubMed:19228619,
CC       ECO:0000269|PubMed:25495392}. Note=The gene represented in this entry
CC       is involved in disease pathogenesis.
CC   -!- DISEASE: Note=enetic variations are associated with cartilaginous
CC       tumors such as enchondroma or chondrosarcoma.
CC       {ECO:0000269|PubMed:26161668}.
CC   -!- SIMILARITY: Belongs to the isocitrate and isopropylmalate
CC       dehydrogenases family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X69433; CAA49208.1; -; mRNA.
DR   EMBL; AK294148; BAG57473.1; -; mRNA.
DR   EMBL; AK312627; BAG35513.1; -; mRNA.
DR   EMBL; AK316388; BAH14759.1; -; mRNA.
DR   EMBL; AC087284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092769; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471101; EAX02082.1; -; Genomic_DNA.
DR   EMBL; BC009244; AAH09244.1; -; mRNA.
DR   EMBL; BC071828; AAH71828.1; -; mRNA.
DR   CCDS; CCDS10359.1; -. [P48735-1]
DR   CCDS; CCDS76792.1; -. [P48735-2]
DR   PIR; S57499; S57499.
DR   RefSeq; NP_001276839.1; NM_001289910.1. [P48735-2]
DR   RefSeq; NP_001277043.1; NM_001290114.1.
DR   RefSeq; NP_002159.2; NM_002168.3. [P48735-1]
DR   PDB; 4JA8; X-ray; 1.55 A; A/B=41-452.
DR   PDB; 5GIS; X-ray; 1.93 A; C=165-180.
DR   PDB; 5I95; X-ray; 1.54 A; A=40-452.
DR   PDB; 5I96; X-ray; 1.55 A; A/B=1-452.
DR   PDB; 5SVN; X-ray; 2.10 A; A/B=40-452.
DR   PDB; 5SVO; X-ray; 1.87 A; A/B=40-452.
DR   PDB; 6ADI; X-ray; 1.97 A; A/B=41-452.
DR   PDB; 6UJ7; X-ray; 1.90 A; C/F=134-143.
DR   PDB; 6UJ8; X-ray; 2.25 A; C/F=134-143.
DR   PDB; 6UJ9; X-ray; 2.90 A; C=134-143.
DR   PDB; 6VFZ; X-ray; 1.99 A; A/B=1-452.
DR   PDBsum; 4JA8; -.
DR   PDBsum; 5GIS; -.
DR   PDBsum; 5I95; -.
DR   PDBsum; 5I96; -.
DR   PDBsum; 5SVN; -.
DR   PDBsum; 5SVO; -.
DR   PDBsum; 6ADI; -.
DR   PDBsum; 6UJ7; -.
DR   PDBsum; 6UJ8; -.
DR   PDBsum; 6UJ9; -.
DR   PDBsum; 6VFZ; -.
DR   AlphaFoldDB; P48735; -.
DR   SMR; P48735; -.
DR   BioGRID; 109644; 259.
DR   CORUM; P48735; -.
DR   DIP; DIP-61416N; -.
DR   IntAct; P48735; 29.
DR   MINT; P48735; -.
DR   STRING; 9606.ENSP00000331897; -.
DR   BindingDB; P48735; -.
DR   ChEMBL; CHEMBL3991501; -.
DR   DrugBank; DB13874; Enasidenib.
DR   DrugBank; DB01727; Isocitric Acid.
DR   DrugCentral; P48735; -.
DR   GuidetoPHARMACOLOGY; 2885; -.
DR   CarbonylDB; P48735; -.
DR   GlyGen; P48735; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P48735; -.
DR   MetOSite; P48735; -.
DR   PhosphoSitePlus; P48735; -.
DR   SwissPalm; P48735; -.
DR   BioMuta; IDH2; -.
DR   DMDM; 20141568; -.
DR   OGP; P48735; -.
DR   UCD-2DPAGE; P48735; -.
DR   CPTAC; CPTAC-221; -.
DR   CPTAC; CPTAC-222; -.
DR   CPTAC; CPTAC-2742; -.
DR   CPTAC; CPTAC-2743; -.
DR   EPD; P48735; -.
DR   jPOST; P48735; -.
DR   MassIVE; P48735; -.
DR   MaxQB; P48735; -.
DR   PaxDb; 9606-ENSP00000331897; -.
DR   PeptideAtlas; P48735; -.
DR   ProteomicsDB; 4054; -.
DR   ProteomicsDB; 55932; -. [P48735-1]
DR   Pumba; P48735; -.
DR   ABCD; P48735; 1 sequenced antibody.
DR   Antibodypedia; 15858; 542 antibodies from 44 providers.
DR   DNASU; 3418; -.
DR   Ensembl; ENST00000330062.8; ENSP00000331897.4; ENSG00000182054.10. [P48735-1]
DR   Ensembl; ENST00000540499.2; ENSP00000446147.2; ENSG00000182054.10. [P48735-2]
DR   GeneID; 3418; -.
DR   KEGG; hsa:3418; -.
DR   MANE-Select; ENST00000330062.8; ENSP00000331897.4; NM_002168.4; NP_002159.2.
DR   UCSC; uc002box.4; human. [P48735-1]
DR   AGR; HGNC:5383; -.
DR   CTD; 3418; -.
DR   DisGeNET; 3418; -.
DR   GeneCards; IDH2; -.
DR   HGNC; HGNC:5383; IDH2.
DR   HPA; ENSG00000182054; Group enriched (heart muscle, skeletal muscle, tongue).
DR   MalaCards; IDH2; -.
DR   MIM; 137800; phenotype.
DR   MIM; 147650; gene.
DR   MIM; 613657; phenotype.
DR   neXtProt; NX_P48735; -.
DR   OpenTargets; ENSG00000182054; -.
DR   Orphanet; 86845; Acute myeloid leukaemia with myelodysplasia-related features.
DR   Orphanet; 251589; Anaplastic astrocytoma.
DR   Orphanet; 251663; Anaplastic oligoastrocytoma.
DR   Orphanet; 251630; Anaplastic oligodendroglioma.
DR   Orphanet; 79315; D-2-hydroxyglutaric aciduria.
DR   Orphanet; 251601; Fibrillary astrocytoma.
DR   Orphanet; 251604; Gemistocytic astrocytoma.
DR   Orphanet; 163634; Maffucci syndrome.
DR   Orphanet; 251656; Oligoastrocytoma.
DR   Orphanet; 251627; Oligodendroglioma.
DR   Orphanet; 296; Ollier disease.
DR   Orphanet; 251598; Protoplasmic astrocytoma.
DR   PharmGKB; PA29631; -.
DR   VEuPathDB; HostDB:ENSG00000182054; -.
DR   eggNOG; KOG1526; Eukaryota.
DR   GeneTree; ENSGT00390000012547; -.
DR   HOGENOM; CLU_023296_1_1_1; -.
DR   InParanoid; P48735; -.
DR   OMA; CIKRQQQ; -.
DR   OrthoDB; 423at2759; -.
DR   PhylomeDB; P48735; -.
DR   TreeFam; TF300428; -.
DR   BioCyc; MetaCyc:HS00021-MONOMER; -.
DR   BRENDA; 1.1.1.42; 2681.
DR   PathwayCommons; P48735; -.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-71403; Citric acid cycle (TCA cycle).
DR   SABIO-RK; P48735; -.
DR   SignaLink; P48735; -.
DR   SIGNOR; P48735; -.
DR   BioGRID-ORCS; 3418; 13 hits in 1171 CRISPR screens.
DR   ChiTaRS; IDH2; human.
DR   GeneWiki; IDH2; -.
DR   GenomeRNAi; 3418; -.
DR   Pharos; P48735; Tclin.
DR   PRO; PR:P48735; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P48735; Protein.
DR   Bgee; ENSG00000182054; Expressed in apex of heart and 210 other cell types or tissues.
DR   ExpressionAtlas; P48735; baseline and differential.
DR   Genevisible; P48735; HS.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005777; C:peroxisome; IEA:Ensembl.
DR   GO; GO:0004450; F:isocitrate dehydrogenase (NADP+) activity; IDA:CACAO.
DR   GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IEA:InterPro.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; ISS:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; NAS:ProtInc.
DR   GO; GO:0006097; P:glyoxylate cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006102; P:isocitrate metabolic process; ISS:UniProtKB.
DR   GO; GO:0006739; P:NADP metabolic process; IBA:GO_Central.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.718.10; Isopropylmalate Dehydrogenase; 1.
DR   InterPro; IPR019818; IsoCit/isopropylmalate_DH_CS.
DR   InterPro; IPR004790; Isocitrate_DH_NADP.
DR   InterPro; IPR024084; IsoPropMal-DH-like_dom.
DR   NCBIfam; TIGR00127; nadp_idh_euk; 1.
DR   PANTHER; PTHR11822:SF42; ISOCITRATE DEHYDROGENASE [NADP], MITOCHONDRIAL; 1.
DR   PANTHER; PTHR11822; NADP-SPECIFIC ISOCITRATE DEHYDROGENASE; 1.
DR   Pfam; PF00180; Iso_dh; 1.
DR   PIRSF; PIRSF000108; IDH_NADP; 1.
DR   SMART; SM01329; Iso_dh; 1.
DR   SUPFAM; SSF53659; Isocitrate/Isopropylmalate dehydrogenase-like; 1.
DR   PROSITE; PS00470; IDH_IMDH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Disease variant;
KW   Glyoxylate bypass; Magnesium; Manganese; Metal-binding; Mitochondrion;
KW   NADP; Oxidoreductase; Reference proteome; Transit peptide;
KW   Tricarboxylic acid cycle.
FT   TRANSIT         1..39
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000250|UniProtKB:P56574"
FT   CHAIN           40..452
FT                   /note="Isocitrate dehydrogenase [NADP], mitochondrial"
FT                   /id="PRO_0000014420"
FT   BINDING         115..117
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O75874"
FT   BINDING         117
FT                   /ligand="D-threo-isocitrate"
FT                   /ligand_id="ChEBI:CHEBI:15562"
FT                   /evidence="ECO:0000250|UniProtKB:P33198"
FT   BINDING         122
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O75874"
FT   BINDING         134..140
FT                   /ligand="D-threo-isocitrate"
FT                   /ligand_id="ChEBI:CHEBI:15562"
FT                   /evidence="ECO:0000250|UniProtKB:P33198"
FT   BINDING         149
FT                   /ligand="D-threo-isocitrate"
FT                   /ligand_id="ChEBI:CHEBI:15562"
FT                   /evidence="ECO:0000250|UniProtKB:P33198"
FT   BINDING         172
FT                   /ligand="D-threo-isocitrate"
FT                   /ligand_id="ChEBI:CHEBI:15562"
FT                   /evidence="ECO:0000250|UniProtKB:P33198"
FT   BINDING         291
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000250|UniProtKB:P33198"
FT   BINDING         299
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O75874"
FT   BINDING         314
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000250|UniProtKB:P33198"
FT   BINDING         349..354
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O75874"
FT   BINDING         367
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O75874"
FT   SITE            179
FT                   /note="Critical for catalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P33198"
FT   SITE            251
FT                   /note="Critical for catalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P33198"
FT   MOD_RES         45
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         48
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         67
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         69
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         80
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         80
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         106
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         106
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         155
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         166
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         166
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         180
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         180
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         193
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         193
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         199
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         256
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         256
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         263
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         272
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         275
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         280
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         282
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         282
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         384
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         384
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         400
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P54071"
FT   MOD_RES         413
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22416140"
FT   MOD_RES         442
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   VAR_SEQ         1..52
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056278"
FT   VARIANT         140
FT                   /note="R -> G (in D2HGA2; dbSNP:rs267606870)"
FT                   /evidence="ECO:0000269|PubMed:20847235"
FT                   /id="VAR_065174"
FT   VARIANT         140
FT                   /note="R -> Q (in D2HGA2; dbSNP:rs121913502)"
FT                   /evidence="ECO:0000269|PubMed:20847235"
FT                   /id="VAR_065175"
FT   VARIANT         158
FT                   /note="P -> L (in GLM; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:25495392"
FT                   /id="VAR_073181"
FT   VARIANT         162
FT                   /note="P -> S (in GLM; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:25495392"
FT                   /id="VAR_073182"
FT   VARIANT         172
FT                   /note="R -> G (in GLM; somatic mutation; reduces enzymatic
FT                   activity; dbSNP:rs1057519906)"
FT                   /evidence="ECO:0000269|PubMed:19228619"
FT                   /id="VAR_073183"
FT   VARIANT         172
FT                   /note="R -> K (in GLM; somatic mutation; reduces enzymatic
FT                   activity; dbSNP:rs121913503)"
FT                   /evidence="ECO:0000269|PubMed:19228619,
FT                   ECO:0000269|PubMed:25495392"
FT                   /id="VAR_073184"
FT   VARIANT         172
FT                   /note="R -> M (in GLM; somatic mutation; reduces enzymatic
FT                   activity; dbSNP:rs121913503)"
FT                   /evidence="ECO:0000269|PubMed:19228619"
FT                   /id="VAR_073185"
FT   VARIANT         172
FT                   /note="R -> S (found in patients with cartilagenous tumors;
FT                   dbSNP:rs1057519736)"
FT                   /evidence="ECO:0000269|PubMed:26161668"
FT                   /id="VAR_076512"
FT   VARIANT         172
FT                   /note="R -> T (found in patients with cartilagenous
FT                   tumors)"
FT                   /evidence="ECO:0000269|PubMed:26161668"
FT                   /id="VAR_076513"
FT   VARIANT         172
FT                   /note="R -> W (found in patients with cartilagenous tumors;
FT                   dbSNP:rs1057519906)"
FT                   /evidence="ECO:0000269|PubMed:26161668"
FT                   /id="VAR_076514"
FT   MUTAGEN         413
FT                   /note="K->A: 44-fold loss in activity."
FT                   /evidence="ECO:0000269|PubMed:22416140"
FT   MUTAGEN         413
FT                   /note="K->Q: 20-fold decrease in Vmax."
FT                   /evidence="ECO:0000269|PubMed:22416140"
FT   MUTAGEN         413
FT                   /note="K->R: No appreciable difference in Km for isocitrate
FT                   and NADP."
FT                   /evidence="ECO:0000269|PubMed:22416140"
FT   CONFLICT        34
FT                   /note="Q -> H (in Ref. 1; CAA49208)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        435
FT                   /note="T -> M (in Ref. 1; CAA49208)"
FT                   /evidence="ECO:0000305"
FT   STRAND          50..54
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           57..69
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   TURN            70..74
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          79..83
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           86..91
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   TURN            92..94
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           95..107
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          108..112
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           120..126
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           135..143
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          146..151
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          169..173
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           177..180
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          182..186
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          190..196
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          205..214
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          216..220
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           225..242
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          246..250
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   TURN            252..254
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           258..273
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           275..280
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          285..289
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           290..299
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          304..308
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           310..324
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          329..335
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   STRAND          342..345
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           352..359
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           369..386
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           389..407
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           413..420
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           422..424
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   TURN            427..429
FT                   /evidence="ECO:0007829|PDB:5I95"
FT   HELIX           434..449
FT                   /evidence="ECO:0007829|PDB:5I95"
SQ   SEQUENCE   452 AA;  50909 MW;  4DDC830AFC06AB52 CRC64;
     MAGYLRVVRS LCRASGSRPA WAPAALTAPT SQEQPRRHYA DKRIKVAKPV VEMDGDEMTR
     IIWQFIKEKL ILPHVDIQLK YFDLGLPNRD QTDDQVTIDS ALATQKYSVA VKCATITPDE
     ARVEEFKLKK MWKSPNGTIR NILGGTVFRE PIICKNIPRL VPGWTKPITI GRHAHGDQYK
     ATDFVADRAG TFKMVFTPKD GSGVKEWEVY NFPAGGVGMG MYNTDESISG FAHSCFQYAI
     QKKWPLYMST KNTILKAYDG RFKDIFQEIF DKHYKTDFDK NKIWYEHRLI DDMVAQVLKS
     SGGFVWACKN YDGDVQSDIL AQGFGSLGLM TSVLVCPDGK TIEAEAAHGT VTRHYREHQK
     GRPTSTNPIA SIFAWTRGLE HRGKLDGNQD LIRFAQMLEK VCVETVESGA MTKDLAGCIH
     GLSNVKLNEH FLNTTDFLDT IKSNLDRALG RQ
//
